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Abstract
Previous work in this group has shown 4,5-dihydroimidazolium ylides, formed by N- 
alkylation of 4,5-dihydroimidazoles, to undergo 1,3-dipolar cycloadditions with a range of 
dipolarophiles in a highly regio- and stereoselective fashion.
We have investigated two further aspects of this chemistry: (1) the synthesis of 4,5- 
dihydroimidazoles substituted with a heteroatom at C-2 and the subsequent N-alkylation of 
those templates followed by deprotonation to potentially access novel azomethine ylides; 
and (2) an intramolecular variant of the 1,3-dipolar cycloaddition, synthesising for this 
purpose a series of bromomethyl(co-l)-oxoalkenoates as dipolarophiles and subsequently 
reacting these with some 4,5-dihydroimidazole templates.
The synthesis of 4,5-dihydroimidazoles substituted with a heteroatom at C-2 was 
developed from 1 -benzyltetrahydroimidazol-2-thione 131. Méthylation of this with either 
iodomethane or methyl trifluoromethanesulfonate provided a key methylthioimidazolium 
iodide intermediate 135 from which 2-alkanethio- (136), 2-alkoxy (137) and 2- 
dialkylamino- (138) 4,5-dihydroimidazoles could be prepared by deprotonation, reaction 
with an alkoxide or reaction with a dialkylamine, respectively. N-Alkylation of the 
heterocycles was found to be unsuccessful. An alternative strategy, involving the synthesis 
of l-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-one 143a and -2-thione 143b, 
was developed. The oxygen-containing compound 143a was transformed into its 
corresponding 0-substituted salts by treatment with triethyloxonium tetrafluoroborate, 
trimethylsilyl trifluoromethanesulfonate or trifluoromethanesulfonic anhydride. The sulfur 
analogue 143b was ^-methylated using methyl trifluoromethanesulfonate. However,
neither of the salts was found to undergo a 1,3-dipolar cycloaddition reaction upon 
treatment with DBU followed by methyl acrylate.
Intramolecular 1,3-dipolar cycloaddition reactions of a variety of a-bromoketones with 1- 
benzyl4,5-dihydroimidazoles proved successful. Thus, reaction of 1-benzyl-4,5- 
dihydroimidazole 29 with methyl £’-8-bromo-7-oxooct-2-enoate 196a, followed by 
treatment with DBU afforded the tricyclic pyrroloquinoxaline adducts methyl 1-benzyl- 
2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-<fe]quinoxaline-6-carboxylate 217. This arises 
from the primary cycloadduct undergoing a cascade involving an eliminative ring-opening, 
recyclisation, loss of water and prototropic shift cascade. Seven other examples of this 
reaction, involving 2- and 4-phenyl-4,5-dihydroimidazoles, and ethyl and terf-butyl £-8- 
bromo-7-oxooct-2-endates are reported. However, the reaction fails with the corresponding 
£-10-bromo-9-oxodec-2-enoate, as well as with 2- and 3-methyl substituted octenoates (i.e 
trisubstituted double bonds). In these cases no cycloaddition reaction involving the double 
bond occurs. In one instance, the reaction of (£)-4-phenyl-4,5-dihydroimidazole 112 with 
terr-butyl iT-8-bromo-7-oxooct-2-enoate 278, we were able to isolate the primary 
cycloadduct, terf-butyl (3/?,4a/?,8aS,9S,9a£)-l-benzyl-5-oxo-3-phenyldecahydro-l/f- 
imidazo[l,2-a]indole-9-carboxylate 283. It would appear that the combination of sterically 
demanding phenyl and tert-butyl groups precludes eliminative ring-opening.
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Chapter 1 
Introduction
1.1 General Introduction
Of the vast array of structures which organic compounds adopt, many contain ring 
systems as a component. When the ring is made up of carbon and at least one other 
element, the compound can be classified as heterocyclic. Many nitrogen-containing 
heterocyclic compounds occur naturally and their functions are often of fundamental 
importance to living systems: it is striking how often a nitrogen-heterocyclic compound is 
found as a key component in biological processes. We can, for example, identify the 
nucleic acid bases, which are derivatives of the pyrimidine (Figure 1) and purine (Figure 2) 
ring systems, as being crucial to the mechanism of replication. Others, such as levamisole 
(Figure 3), have found their use as potential anti-cancer agents.1
Many modem pharmaceuticals are totally synthetic compounds and a large proportion of 
these are heterocychc. In other areas in which organic compounds are widely used, such as 
the pesticides and dyestuffs industries, heterocyclic compounds are also predominant. In 
laboratory synthesis, heterocyclic compounds are frequently a source of latent 
functionality.2 The ring systems can be carried through many stages of a synthetic
Figure 1 Figure 2 Figure 3
2
sequence and then cleaved to produce delicate functional groups, often in a highly selective 
manner.
For many of the common heterocychc ring systems there is a wide range of practicable 
synthetic routes available. These can vary in complexity from one-step syntheses using a 
single reaction component, to multicomponent procedures with a large number of steps. 
Heterocychc ring-forming reactions are recognised as being in general the most useful 
synthetic tools towards the synthesis of nitrogen-heterocyclic rings.3 Cychzation reactions 
involving the formation of one bond in the ring-forming step, illustrated by the well known 
Paal-Knorr synthesis of pyrroles 2 from 1,4-dicarbonyl compounds 1 (Scheme 1) are 
amongst some of the most widely used approaches towards the synthesis of nitrogen- 
heterocychc ring systems.
Scheme 1
The cychzation step is a nucleophihc attack on the carbonyl group, probably involving an 
intermediate species such as that shown in Scheme 1. The 1,4-diketone acts as an 
electrophile in both the initial step of the reaction of the amine and in the cychzation step. 
Many other heterocychc syntheses of the cychzation type are analogous, in that an initial
electrophile-nucleophile interaction between two reagents is followed by a second such 
interaction in the cychzation step. In contrast, cycloaddition reactions4 are those in which 
two bonds of the new ring are formed in the cychzation step. These can provide routes to 
nitrogen-heteroeyeles with well-defined substitution patterns, and in many cases, with 
great stereochemical control. Undoubtedly, the synthetically most important types of 
cycloadditions are the Diels-Alder and the 1,3-dipolar cycloaddition (1,3-DC) reactions. 
The former reaction, discovered nearly half a century ago, is the prototypical thermal 
cycloaddition. Because six-membered rings are generated with remarkable 
stereoselectivity and regioselectivity, the reaction is of great synthetic utihty. In addition, 
heteroatoms can be incorporated into the skeleton of the nucleophihc diene (electron-rich 
component) or of the electrophihc dienophile (electron-deficient component) to provide 
important routes to several six-membered heterocycles. For example, the Diels-Alder 
reaction of cyclopentadiene 3 with diethyl azodicarboxylate 4 to afford the pyridazine 5 is 
just one of the many synthetic examples (Scheme 2).
Scheme 2
The 1,3-DC reaction provides an excellent method for the construction of five-membered 
rings because a wide variety of 1,3-dipoles (a three-atom component) are available which 
can undergo addition to multiply-bonded systems that are defined as dipolarophiles ([the
4
two-atom component).5 Its utility is such that it has acquired a prominent place in synthetic 
strategy for a variety of targets, including natural products such as sugars and alkaloids.6,7 
Since our project has focused on the use of the 1,3-DC reaction, we shall discuss it in 
more detail.
1.2 The 1,3-dipolar cycloaddition reaction
The work of Huisgen and co-workers8 in the early 1960s led to the general concept 
of the 1,3-DC reaction and over the years this reaction has been widely explored in 
syntheses since many of the 1,3-dipolar species are readily available (or easily formed in 
situ) and are able to react with a wide variety of dipolarophiles.
1,3-Dipolar cycloadditions are bimolecular and involve the addition of a three-atom 1,3- 
dipolar component (a*-b+-c) to a two-atom multiply-bonded system (d=e or d^e), the 
dipolarophile, leading to five-membered heterocycles (Figure 4).
- A
}  c - 0
e = d
Figure 4: 1,3-Dipolar cycloaddition
The versatility of 1,3-dipolar cycloadditions arises from: (i) the wide array of available 
dipoles and dipolarophiles; (2) the concerted, that is stereoconservative, mechanism of the 
cycloaddition; (3) the latent functionalities within most cycloadducts, which can allow for
subsequent transformations, including ring-opening. The ever-increasing volume of 1,3- 
DC literature testifies to its growing importance and use in modem synthetic 
chemistry.9,10,11
1.2.1 The 1,3-dipole
The first molecule to act as a 1,3-dipole, diazoacetic ester, was discovered some 70 
years ago by Curtius.12 However, general application of 1,3-dipoles in organic chemistry 
was established by the systematic studies of Huisgen and co-workers in the 1960s.13 Since 
then, a variety of dipolarophiles have been discovered14 but only a few dipoles have found 
general application in synthesis.
The 1,3-dipole is a 3-atom species represented by ground state zwitterionic resonance 
structures, one of which has the formal charges at the termini (Figure 5a).
+ +
/X  — -------- ► octet structures
+/ b\ -  . -------- ► > x ^ \ + sextet structuresa c a c
Figure 5a: Resonance structures of allyl anion-type 1,3-dipoles
A feature shared by all 1,3-dipoles is an allyl anion-type 7i-system, i.e. four electrons in 
three parallel atomic p-orbitals. In contrast to the allyl anion, where the middle atom has no
formal charge, 1,3-dipoles feature an “onium” centre b (Figure 5a). In addition, two of the 
four allylic 7i-electrons of the 1,3-dipole can be envisaged localised at the central atom b, 
therefore cancelling the onium charge. As a consequence, resonance structures can be 
drawn in which electron sextets are created at atoms a or c. Whereas the terminal centres 
of the allyl anion are always nucleophihc, those of 1,3-dipoles have both nucleophihc and 
electrophihc character. This ambivalence is shown by the sextet canonical forms (Figure 
5a) and this is essential towards understanding the reactivity in these systems.
A second, and smaller, class of 1,3-dipoles is the propargyl/allenyl-type which arise from 
the incorporation of an additional Tt-bond in the 1,3-dipole system in the plane 
perpendicular to the allyl anion molecular orbital (MO) (Figure 5b). One of its resonance 
forms will thus contain a triple bond and dipoles of this type are linear (Figure 5b) in 
contrast to the bent allyl anion-type 1,3-dipoles (Figure 5b). Occasionally, the two classes 
of 1,3-dipole described thus far, are drawn as hypervalent resonance forms (Figure 5c), but 
these require the central atom to possess appropriate atomic orbitals to accommodate the 
additional electron density at that atom that these structures imply.
+ — +
octet structures aF^b— c -*-------------- a = b = c
Figure 5b: Propargyl/allenyl-type 1,3-dipoles.
Zs
Figure 5c: Hypervalent representations.
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Restricting the permutation of the three atoms of the 1,3-dipole to the second period 
elements C, N and O, and bearing in mind that for atom b in 1,3-dipoles of the 
propargyl/allenyl-type the choice is limited to an atom of the group XV elements (since 
only the latter can bear a positive charge on its tetravalent state), Huisgen proposed six 1,3- 
dipoles of the propargyl/allenyl-type and twelve of the allyl-type (Table I).15
Table 1: Classification of heteroatom 1,3-dipoles
Allyl-type 1,3-dipoles
> = 5o—o
Azomethine ylides 
Azomethine imines
Nitrones 
Azi mines
Azoxy compounds 
O—lst=o Nitro compounds
Carbonyl ylides
C— Carbonyl imines 
Carbonyl oxides
N—lji= 0
^ c - o = c
8
 +  — — +
N=0—N  ----------------- N—0=N>. Nitrosimines
+ — N. — +
—O---- -^--------------- ► N—0 = 0  Nitrosoxides
+  -  -  +
0 = 0 —0 -^-------------- ---  0—0 = 0  Ozone
Propargyl/allenyl-type 1,3-dipoles
— C=N-------------------------- - — G=N=cC^ Nitrile ylides
— C=N—  --------------- ». — C = N = N ^ Nitrile imines
+  — — +
C=N—O  ----------------» — G=N=0 Nitrile oxides
N=N—cC^ -^--------------   N=N=CC^ Diazoalkanes
+ -
N^N—N <i--------------- * N=N=N Azides
+  — — +
N=N—O  --------------- ► N=^N=0 Nitrous oxide
1.2.2 The dipolarophile
It is easy to envisage a vast number of multiply-bonded compounds which can act 
as dipolarophiles but by far the most useful and commonly employed are alkenes. Other
dipolarophiles widely used are alkynes (R02C=C02R), isocyanates (RNCO), conjugated
carbonyls (CH2=C(H)C0R) and thiocarbonyls (CH2=C(H)CSR).
9
The nature of the dipolarophile (functionality, reactivity, shape, size and propensity 
towards non-covalent interactions with the 1,3-dipole) is important since in most cases it 
influences the regio- and stereochemistry of the cycloaddition.
1.2.3 Mechanistic Issues
Given the importance of the 1,3-dipolar cycloaddition reaction, the elucidation of 
its mechanism is crucial to understanding the variables that determine its regio- and 
stereocontrol. Based on kinetic measurements, stereochemical results, and solvent and 
substituent effects16,17 Huisgen and co-workers developed a detailed rationale for the 
concerted mechanism of the 1,3-dipolar cycloaddition. The proposed model for the 
transition state of these reactions was of a concerted nature, in which the ^-electron 
system interacts with the Tt-bond of the dipolarophile (Figure 6a). Firestone, on the other 
hand,18 presented a variety of challenges to the concerted mechanism postulating that these 
reactions take place via a singlet diradical intermediate (Figure 6b).
a) The Huisgen mechanism
rX
b f
e = d
Figure 6a: The Huisgen postulated concerted mechanism
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b) The Firestone mechanism
; d'
Figure 6b: The Firestone postulated diradical mechanism
In the 1,3-DC reaction between benzonitrile N-oxide 6 and E-1,2-dideuterioethene 7 
(Scheme 3), where a diradical intermediate would allow a 180° rotation of the terminal 
bond and would thus be expected to yield a mixture of the cis and trans isomers, the 4,5- 
trans product was formed in > 98% stereospecificity.19 Taken together with the work of 
Houk, who showed that analysis of the concerted mechanism in terms of frontier molecular 
orbital theory20 could rationalise the regioselectivity of the reaction, this ultimately settled 
the dispute in favour of the concerted mechanism.
Ph—C=N—0 + ------
- f
X ^ D
6 7 Ph D
Scheme 3
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Ab initio calculations carried out by Komomicki et al. on the 1,3-DC of the prototypical 
nitrile oxide 8 and ethyne 9 (Scheme 4) verified the concerted nature of the reaction.21
H—C ^N —O + HC^CH
+
8 9
Scheme 4
1.2.4 Stereochemistry
The high regio- and stereoselectivity of these reactions strongly suggests that the 
addition of both intervening components takes place via a highly ordered transition state. 
Two possible transition state geometries arise for the reaction between, for example, an 
azomethine ylide 1,3-dipole and a dipolarophile (Figure 7).
dipolarophile
1,3-dipole
a suprafacial b antarafacial
Figure 7: Possible approaches of the dipole and dipolarophile in a 1,3-DC
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Theoretical studies support the contention that the 1,3-dipole and the dipolarophile will 
preferentially approach each other in a suprafacial manner,22 where the two new bonds 
form on the same surface of either particular reactant (Figure 7a). It is evident that this 
transition state is favourable since overlap of the relevant molecular orbitals is maximised. 
Naturally, the same degree of orbital overlap is achieved in the situation wherein the 1,3- 
dipole approaches the dipolarophile from either face.
If, in contrast, one bond is formed on one surface of a reactant and the other bond is 
formed on the other surface, then the reaction is described as being antarafacial (Figure 
7b). In this case, effective orbital overlap is much more difficult to achieve and in most 
cases the 1,3-dipole would have to spatially arrange itself in such a manner that would 
compromise its n  system and hence the allylic resonance. Such reactions are therefore 
considered to be rare and in 1,3-dipolar cyloadditions the formation of the major product 
occurs via the suprafacial approach.
A suprafacial approach involving a dipolarophile that contains substituents raises other 
issues that need to be addressed. First, the dipolarophile may approach the 1,3-dipole with 
its substituent directly underneath the plane of the latter; this constitutes the endo transition 
state (Figure 8). This transition state may lie on the most energetically favourable pathway 
if it involves a secondary non-covalent orbital interaction between the 1,3-dipole and the 
substituent Z that provides extra stabilisation in the transition state. Second, where Z is 
bulky, steric hindrance constitutes an obstacle to bond formation and therefore the 
dipolarophile may prefer to approach the 1,3-dipole with its substituent pointing away 
from the latter; this is called the exo transition state (Figure 8). Exo and endo transition 
states give rise to products that are diastereomeric (Figure 8).
endo- exo-
Figure 8: Suprafacial transition states for a 1,3-DC reaction
By introducing reagents which are facially discriminated, one can control the way in which 
the dipolarophile approaches the 1,3-dipole (above or below), or vice versa, hence giving 
rise to a specific stereochemistry in the adducts. Introduction of a substituted R at the 1,3- 
dipole blocking the approach of the dipolarophile from lower plane of the latter (Figure 9a) 
leads to a single diastereoisomer 10 due to the approach of the dipolarophile from the non­
hindered upper face of the 1,3-dipole. An approach of the dipolarophile from the lower 
plane is hindered by the substituent, thus compromising the formation of the alternative 
adduct (Figure 9b).
14
Figure 9: Facially discriminated 1,3-dipoles and stereochemistry of 1,3-DC reaction 
adducts ( *C is a chiral C atom).
1.2.5 Regiochemistry
Frontier molecular orbital theory (FMO) and the principle of conservation of orbital 
symmetry23 together offer a coherent mechanistic picture for the 1,3-DC reaction based on 
a concerted process.
The fundamental assumption of these concepts is that a majority o f chemical reactions 
should take place at the position o f and in the direction of, maximum overlap o f the 
HOMO (highest occupied molecular orbital) and the LUMO (lowest unoccupied molecular 
orbital) of the reactant species.24 The transition state of the concerted 1,3-DC reaction is 
thus governed by the FMOs (HOMO, LUMO) of the substrates. Thus, either the HOMO of 
the dipole interacting with the LUMO of the dipolarophile or the LUMO of the dipole with 
the HOMO of the dipolarophile should control the course of the reaction. Fukui24 reasoned 
that maximum orbital overlap takes place between orbitals which are separated by the
15
narrowest energy gap; the narrower the gap the faster the reaction. By calculating the 
relative energies of these FMOs25,26,27 one can predict the dominant FMO interaction and 
thus often directly predict the preferred regiochemistry of the reaction. Bearing in mind the 
relative FMO energies between the 1,3-dipole and the dipolarophile, Sustman has 
classified 1,3-DC reactions into three types (Figure 10)28.
Type IIType I Type m
LUMOLUMO
LUMOLUMQ LUMOLUMO
HOMOHOMO
HOMOHOMO
t  HOMO
dipole dipolarophiledipolarophiledipolarophile dipoledipole
strong interaction
weak interaction
Figure 10: Different types of HOMO-LUMO interaction between 1,3-dipole and 
dipolarophile.
In type I 1,3-DC reactions the dominant FMO interaction is that of the HOMO of the 
dipole with the LUMO of the dipolarophile (Figure 10). Azomethine ylides are typical 
substrates for this type of 1,3-DC reactions. For type H, the similarity of the FMO energies 
of the 1,3-dipole and dipolarophile implies that both HOMO-LUMO interactions are
16
significant and thus there is no dominant interaction. Typical substrates for this type of 1,3- 
DC reaction are nitrones. Finally, for type HI we have the case where the dominant FMO 
interaction is that between the LUMO of the dipole and the HOMO of the dipolarophile. 
Substrates for this type of 1,3-DC reaction are ozone and nitrous oxide.
Two directions of cycloaddition are conceivable if both the 1,3-dipole and the 
dipolarophile contain non-identical termini. Consequently, the formation of regioisomeric 
products is possible (Figure 11).
B
2 3
H k
v v
' 4  ;P'
4-substituted adduct 5-substituted adduct
Figure 11: Regiochemistry of the 1,3-DC reaction
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The ratio of regioisomers mirrors the ratio of the respective rate constants for the two 
orientations of cycloaddition; thus regioselectivity becomes an issue associated with 
reactivity. To determine reactivity and therefore account for the regioselectivity of the 1,3- 
DC reaction one must assess which type of orbital interaction is dominant; HOMO (dipole) 
and LUMO (dipolarophile), or LUMO (dipole) and HOMO (dipolarophile) (Figure 10). 
Having determined which interaction is of primary importance, focus shifts to the 
coefficients of the relevant orbitals. Consider a reaction that is dipole-HOMO controlled, 
i.e. type I (Figure 11). The relevant orbitals coefficients are then those of the dipole- 
HOMO and the dipolarophile-LUMO. The regioselectivity of the reaction is then expected 
to be that which maximises the size of the wave functions of the overlapping orbitals 
during bond formation. Maximum overlap of the relevant molecular orbitals and matching 
of the magnitude of the orbital coefficients, i.e large (dipole) with large (dipolarophile) and 
small (dipole) with small (dipolarophile), is achieved in example A (Figure 11), giving rise 
to the ^-substituted adduct. The alternative case B, however, despite the fact that the 
molecular orbitals are appropriately phased for overlap, the magnitudes of the orbital 
coefficients involved do not match and this represents the formation of the less favourable 
^-substituted regioisomer, which would constitute a minor product.
18
1.3 Azomethine ylides as 1,3-dipoles
Within the frame-work of 1,3-dipoles as defined by Huisgen, 14 azomethine ylides 
belong to the class of azomethinium betaines, and there are acyclic and cyclic examples of 
these (Figure 12).
iTBDMDSiTBDMDS
Figure 12: Acyclic an cyclic azomethine ylides.
It has been shown experimentally that azomethine ylides show low reactivity with simple 
alkene dipolarophiles. However, cycloadditions involving such yhdes are accelerated both 
by electron-donating or conjugating groups within the dipole, as these raise the energy of 
its HOMO, and by electron-withdrawing or conjugating groups in the dipolarophile, as 
these lower the LUMO of the latter.28,29
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1.3.1 Generation of azomethine ylides
Azomethine ylides are unstable species, so they are prepared in situ in low 
c o n c e n t r a t io n  a n d  trapped directly by added dipolarophiles.14 There are several methods 
for the generation of azomethine ylides; only a selection will be discussed here, arranged 
according to precursor functional group.
Conrotatory thermolysis and disrotatory photolysis
M eQM eQ
H"H"
cis-ll At ** trans-l\
> 100°C
'C 0 2M e MeCty
A r At
cis-12
Scheme 5
In 1967 Huisgen and co-workers reported the electrocyclic ring-opening by 
thermolysis and photolysis of the stereoisomeric aziridines, c is-ll and trans-W, to afford 
stereochemically distinct azomethine ylides, trans-Vl and cis-12, which were then trapped 
in situ by dipolarophiles.30 Thermal conrotatory ring opening of cis-ll afforded trans-Vl 
whereas thermal conrotatory ring opening of trans-11 afforded cis-12 (Scheme 5).
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Disrotatory photolytic ring opening of cis-ll afforded cis-12 whereas disrotatory 
photolytic ring opening of trans-11 afforded trans-12. Although the yields of the direct 
disrotatory photolysis were not as high as those obtained during thermolysis (81-84%), 
very reasonable yields (69%) of the adduct were obtained using this process. A limitation 
of this methodology is that ring-opening of aziridines only works well when the substituent 
groups are capable of stabilising the dipole centres, failing completely when simple alkyl 
substituents are used.
Imines
a) Isomérisation
Scheme 6 : Thermal isomérisation of an imine to form an azomethine ylide
This method involves isomérisation of an imine derivative of an a-aminoester 
containing an enolisable hydrogen, to yield the azomethine ylide (Scheme 6 ) which can 
then be trapped by reaction with the appropriate dipolarophile.31
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b) N-metalation
„r  M+X~ / Base
Scheme 7: Generation of azomethine ylides through N-metalation
An imine derivative of an a-aminoester containing an enolisable hydrogen can also 
be readily transformed into the N-metalated azomethine ylide by an appropriate metal salt 
(Mn+ = Ag, Tl, Li, Mg, Mn) in the presence of base (Scheme 7) .32'34 This kind of reaction 
has proved to be remarkably efficient in its possible asymmetric versions35 and in addition 
the reaction tolerates a wide range of substituents and is therefore well suited for 
combinatorial synthesis.36
c) Desilylation
CHJ
SPhSPh
CsF
SPh
Scheme 8: Desilylation of imines as a method for generation of
azomethine ylides
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Vedejs and co-workers have pioneered this approach37 and it has proved to be an 
efficient and widely used methodology for generation of azomethine ylides. Treatment of 
13, for example, with one equivalent of iodomethane (CH3CN, 25 C, 16 hours) affords the 
N-alkylated intermediate 14, which, upon addition of caesium fluoride, generates the 
azomethine ylide 15 (Scheme 8 ) .38
Pyridinium and similar salts
CHCOR
^CHCORCH2COR 
20 fir"
Scheme 9: Imonium and pyridinium salts as azomethine ylide precursors
A general route based on this approach is the deprotonation of isoquinolinium salts 
16,18 and the pyridinium salt 20. The azomethine ylides 17,19 and 21 retain the ability to 
undergo addition even though the C=N bond is an integral part of the heteroaromatic ring.
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cc-Amino acids
-CO
Scheme 10: Generation of azomethine ylide using a-amino acids
Aldehydes and ketones react with a-amino acids, or more generally with primary 
amines, to form imines (Schiff bases). Condensation of the 2,2/-bipyridyl ketone 22 with 
a-amino acids such as 23 yields an imine that upon decarboxylation gives rise to the 
azomethine ylide 24 (Scheme 10) .39 This chemistry has been successfully extended to TV- 
substituted acyclic and cyclic amino acids, 25 and 27 respectively, which afford the acyclic 
26 and cyclic 28 azomethine yhdes, respectively (Scheme l l) .40®
M eNHCH2CO O H  + RCOR'
M e CB
COOH
Scheme 11: Azomethine ylides from TV-substituted acyclic and cyclic amino acids.
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Amidines
-Ph-Ph
DBUTHF, A
-N+'N+
Br"
RO
Scheme 12: Amidines as azomethine ylide precursors
The use of amidines as a source of azomethine ylides has developed enormously 
over the past 20 years.38,4015 Previous researchers in our group have developed a very 
elegant and efficient methodology to access azomethine ylides generated from heterocyclic 
amidines, such as 1-benzyl-4,5-dihydroimidazole 29 41 This cyclic amidine is N-alkylated 
using a bromoacetate ester to afford the salt 30 that, upon deprotonation with an 
appropriate base (diazabicyclo[5.4.0]undec-7-ene, DBU), generates the azomethine ylide 
31 (Scheme 12) which can be trapped with a suitable dipolarophile to afford 
hexahydropyrrolo [ 1 ,2 -a] imidazoles.42
1.3.2 Generation of chiral azomethine ylides
Despite there being a variety of routes to form azomethine ylides, methods for the 
generation of chiral azomethine yhdes are continually sought. For instance, although 
azomethine ylides can be accessed from a-amino acids and their condensation with
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aldehydes or ketones (Section 1.2.1), the chirality at the a-centre is necessarily lost in the 
process of ylide generation. Consequently, Harwood and co-workers proposed the use of a 
chiral template en route to chiral azomethine yhdes from a-amino acid precursors (Scheme 
13)/"
2 prochiral auxiliary^
H R1 ttA ,
* = induced chiral centre
Scheme 13: The use of a prochiral auxiliary in the generation of chiral azomethine 
ylides
The chirality of the amino acid 32 is used to set up a new chiral centre in 
intermediate 33. Upon reaction with an appropriate aldehyde, followed by loss of water, 
this intermediate affords a chiral azomethine ylide 34 despite the loss of chirality at the 
original amino acid centre. Development of this concept was supported by earlier workers, 
such as Williams who described the use of (5/?, 6 S)-diphenylmorphohne as an azomethine 
ylide precursor,44 and also by Caplar who demonstrated that hydrogenation of the cyclic 
condensation products derived from a-bromoacetophenone 35 and a-amino acids 36 
occurs stereospecifically to form homochiral 3-substituted-5-phenylmorpholinones with a 
total transfer of chirality from the a-amino acid centre to the newly formed benzylic centre 
in the product 37 (Scheme 14)45
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Scheme 14: Chiral phenylmorpholinones as potential chiral azomethine ylide precursors
Harwood was then able to demonstrate that reaction of (Æ)-5-phenylmorpholinone 40, 
synthesised from (/?)-2-phenylglycinol 38 and phenyl bromoacetate 39, with an appropriate 
aldehyde afforded the desired chiral azomethine ylide 41 that could be trapped in szfw with
a variety of alkene dipolarophiles (Scheme 15).43
Ph
CHoOH
Ph
Scheme 15: Chiral azomethine ylides based on chiral morpholinone templates.
Using a different approach, Padwa and co-workers accessed chiral azomethine ylides by 
reaction of chiral W-cyanomethyl-N-trimethylsilylmethylamines 42 with silver fluoride
(Scheme 16).46
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Using a different approach, Padwa and co-workers accessed chiral azomethine ylides by 
reaction of chiral 7V-cyanomethyl-//-trimethylsilylmethylamines 42 ' with silver fluoride 
(Scheme 16).46
NCCH2x  /C H 2Si (CH3)3
Scheme 16: Chiral azomethine ylides from A^-cyanomethyl-A^trimethylsilylmethylamines.
A somewhat different, yet interesting and efficient, approach towards the generation of 
chiral azomethine ylides was adopted by Husson and co-workers47 who used the chiral 
oxazoline 44 as a chiral azomethine ylide precursor (Scheme 17).
TMSOTf
OTMS
Scheme 17: Chiral oxazolines as precursors to chiral azomethine ylides
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1.3.3 1,3-Dipolar cycloaddition of azomethine ylides
The 1,3-DC reactions of azomethine ylides are very well documented and widely 
studied.4,5 In particular, the assembly of biologically relevant heterocycles such as pyrroles, 
pyrrolidines and pyrrolizidines has been well recognised. 11,48,49
An earlier report of a 1,3-DC reaction of an azomethine ylide to afford a pyrrolidine ring 
was by Vedejs and co-workers in 1979.37 Since then a tremendous amount of work has 
been reported on this area,50 perhaps not so surprising since the pyrrolidine ring is a 
frequently encountered structural unit of many synthetically challenging alkaloids.51 
Annunziata et cd. reported the 1,3-DC reaction of azomethine ylides 46 with (E)-y-alkoxy- 
cc, |3-unsaturated esters 47 and 49 to afford substituted pyrrolidine rings (Scheme 18).35 
In each case, the 1,3-DC reaction afforded a single regioisomer as a diastereomeric pair, 
48a/48b and 50a/50b, respectively.
•Ar•At
-NH-NH
MeO-MeOoC
48a 48b
50a 50b
Scheme 18: Tetrasubstituted pyrrolidines from a 1,3-DC reaction of an azomethine ylide
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The synthesis of polyfunctionalised pyrrolidine ring derivatives using the 1,3-DC 
reaction of azomethine ylides constitutes a very active and rich research area. Reported 
examples, of such reactions are very numerous, therefore only one interesting example will 
be discussed  here. Using the common knowledge that azomethine ylides can be generated 
from the condensation of a-amino acids with aldehydes (Scheme 10), Risch and co- 
workers devised a route to tetrakis(alkoxycarbonyl) substituted pyrrolidines (Scheme 19).52
Ph
-NH
EtOjCHC^^CHCOîEt
-Ph
€ 0 2Et
MeO-
54b54a
PhPh
:o2EtEtO;EtO
M e02C
54a' 54b'
Scheme 19: Polyfunctionalised pyrrolidines by 1,3-DC reaction of azomethine ylides
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Reaction of ethyl N-(l-phenylethyl)aminoacetate 51 with ethyl glyoxalate 52 led to the 
generation in situ of the chiral azomethine ylide 53 which, upon reaction with dimethyl 
fumarate, afforded the exocycloadducts 54a and 54az and the ezido-cycloadducts 54b and 
54b'. These pyrrolidine adducts showed potential as precursors for new chiral auxiliaries 
due to their C2 axis of symmetry. Reduction of the pyrrolidine rac-54a by lithium 
aluminium hydride, followed by débenzylation with Ha-Pd/C (10%) in ethanol afforded the 
2,3,4,5-tetrahydroxymethylpyrrolidine rac- 5 5  in good yield (Scheme 20).
OH
rac-55
Scheme 20: Tetrahydroxymethylpyrrolidine rac-55
Five membered cyclic azomethine ylides are a powerful synthetic tool in the synthesis of 
tricyclic heterocycles rings such as pyrrolizidines.53,54 A classic example of this type of
1,3-DC reaction is the synthesis of racemic retronecine 56 (Scheme 21) by Vedejs and co- 
workers,55 using the desilylation methodology discussed earlier. Conversion of the salt 57 
to the cyclic azomethine ylide 58 was achieved by treating the former with anhydrous CsF. 
Addition of methyl acrylate to the azomethine ylide generated in situ afforded the 
pyrrolizidine derivative 59. Reduction of 59 with diisobutylaluminium hydride (DIBAL-H) 
was followed by trapping the aluminium enolate using PhSeCl to afford 60. Oxidation (m-
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CPBA) and thermal elimination of PhSeOH afforded 61 which was subsequently reduced 
using Dibal and deprotected to afford racemic retronecine 56.
NBzliNBzll
-OMe
CsF
NBzll NBzll
NBzll
Scheme 21: Synthesis of retronecine 56 using 1,3-DC of an azomethine ylide
The 1,3-DC reactions of azomethine ylides with dipolarophiles bearing heteroatoms such 
as sulfur as substituents have also proved to be of great synthetic utility, for example en 
route to imidazolidine derivatives (Scheme 22). In most cases these reactions appear to be 
highly diastereoselective producing adducts with a degree of enantiopurity since the 
sulfinimine substrates display an excellent facial selectivity upon reaction with various 
dipoles. For example, 64a and 64b are formed as a 95:5 mixture of diastereoisomers. Thus,
32
they constitute potential precursors to chiral imidazolidines, as reported by Viso and co­
workers (Scheme 22) .56
>Me
P h
p-Toh
-NH-NH
PhH2C C 02Me
64b
M e02C CH2Ph 
64a
Scheme 22: 1,3-DC reaction of sulfinimines with azomethine ylides
En route to pyroglutamates, Ibarra and co-workers have used Sm(III)-azomethine ylides as
1,3-dipoles.57 Due to the high coordination number of this cation,58 which should favour 
tightly coordinated reaction intermediates, high diastereolectivities in the cyclisation 
process could be expected (Scheme 23). Treatment of of ketone 65 with SmI^ leads to the 
formation of ylide 6 6  through a reductive deacetylation. Cycloaddition of the latter with 
ester 67 leads to 6 8  which affords pyroglutamate 69 in a de (diastereomeric excess) of 80% 
upon acid hydrolysis.
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•SMe
6 6  CH3 SMe
'OMe
MeOMeO
CH, CH-
Scheme 23:1,3-DC reaction of Sm (HQ-azomethine ylides
The application of 1,3-DC reactions of azomethine ylides in natural product chemistry is 
significant. For example, marine natural products known as lamellarins, and in particular 
lamellarin K 70 (Figure 13), have unusually high potency in the treatment of multi-drug 
resistant tumours. Not surprisingly, the total synthesis of these natural products has been 
attempted.59
Me<
Me<
OH
Figure 13: Lamellarin K
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The pivotal step adopted by Banwell and co-workers in their approach to the lamellarin 
ring system involves the construction of the central pyrrole moiety via an intramolecular
1,3-DC reaction of an isoquinoline-based azomethine ylide to a suitable tethered tolane 
(Scheme 24).60
Mel ►Me
71X = CHO
72 X = OCHO—
73 X = OH —  
74X = OCOCH2I
Me< ►Me
= C
Me<
Mei
base
Mel►Me
Mel
Mel
OlY 76
Scheme 24: Synthesis of Lamellarin K by 1,3-DC reaction of azomethine ylides
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Thus iodoacetate 74 was reacted with 3,4-dihydro-6,7-dimethoxy-5- 
isopropoxyisoquinoline to afford the salt 75. This was not isolated but immediately treated 
with Hunig’s base to afford the corresponding azomethine ylide. Intramolecular 
cycloaddition followed by in situ aromatisation took place to give lamellarin K triisopropyl 
ether 76, which upon three-fold deprotection with an excess of AlClg afforded lamellarin K 
70.
Solid-phase synthesis of polyfunctional heterocyclic targets has also proved to be yet 
another area of synthetic chemistry wherein the use of the 1,3-DC reaction of azomethine 
ylides plays a major role. En route to the synthesis of hydantoin-containing 
heterocycles,61;62 Kurth and co-workers have reported the solid-phase synthesis of 
hexahydro- l/Z-pyrrolo[ 1,2-c]imidazoles 82 using the 1,3-DC reaction approach (Scheme 
25).36 Triethyl orthoformate-mediated condensation of solid-supported amino ester 77 with 
aldehyde species 78 afforded 79 as the azomethine ylide precursor. Intramolecular 1,3-DC 
reaction of the latter gave the solid-phase bound proline derivative 80. Treatment of the 
latter with phenyl isocyanate afforded carbanilide 81. Hydantoin formation and 
concomitant release of product from the resin afforded pyrroloimidazole 82 in 13 % 
overall yield (Scheme 25).
36
CHO
H-
PhHN
Ph
Scheme 25: Solid-phase synthesis using the 1,3-DC reaction of azomethine yhdes
1.3.4 Chiral induction by the 1,3-dipole
The availability of chiral azomethine ylides constitutes an important tool in 
asymmetric synthesis due to their potential to induce enantio- and diastereoselectivity in
1.3-DC reactions. In 1985, Padwa et cd. published the first report of diastereoselectivity in
1.3-DC reactions of chiral azomethine ylides with a range of dipolarophiles leading to
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optically active adducts.46 Reaction of the azomethine ylide precursor 83a with the P- 
nitrostyrene 84 afforded the adduct 85a in 20% de, whereas precursor 83b afforded the 
adduct 85b with a de of 60% (Scheme 26).46
NCCH2X X H 2SiMe: m
83a R = H 
83b R = OCH
AgF
85a R = H
85b R = OCH
Scheme 26: 1,3-DC reaction using a chiral azomethine ylide template
To account for the observed diastereoselectivity two different conformations of the 
azomethine ylide were considered, 8 6 a and 8 6 b. The approach of the dipolarophile toward 
conformation 8 6 a is to the face anti to the phenyl group, for the obvious steric reasons, 
while anti attack of the dipolarophile to 8 6 b arises from the approach of the latter to the 
opposite face of the 1,3-dipole (Figure 14).
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CH-
8 6 a 8 6 b
Figure 14: Possible conformations of the azomethine ylide derived from 83b.
In a series of papers, Husson et al, have investigated the 1,3-DC reaction of electron- 
deficient dipolarophiles with chiral azomethine ylides 87 (Scheme 27).47,63,64
OTMS
/  \  :— n + cOTMS
EWGEWG
8 8 a
Scheme 27: 1,3-DC reaction of chiral azomethine ylides with electron-deficient alkenes
In the reaction of 87 (W = CN) with N-phenylmaleimide, four adducts were isolated (the 
major diastereoisomer in 41% yield), whereas 87 (W = CC^Et) gave two isomers in nearly 
equal amounts. This reaction was further investigated by introducing a menthyl ester as the 
W substituent in 87. Using this chiral azomethine ylide, only the exo product 8 8 b (Figure 
15) was obtained with a.de> 95%.
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Ph-
OTMS
EWGEWG
8 8 b
Figure 15: Exo adduct for reaction depicted in Scheme 27 (W = menthyl ester)
Chiral azomethine ylides 90 have been used in 1,3-DC with dimethyl maleate (Scheme 
28) 48
Ph
Ph Ph-
RCHO
HN.
endo-91
Ho/Pd-C
MeO-
Schcme 28: Chiral azumelhine ylides from OAaziii-2-ones and tlieir 1,3-DC reaction
In the case when higher aliphatic and aromatic aldehydes were employed in ylide 
formation, the endo selectivity in the 1,3-DC reaction was excellent but the 
stereoselectivity at the C-6 position of 91, i.e. the carbon atom arising from the aldehyde
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carbonyl carbon atom, was generally low due to syn-anti interconversion of the R 
substituent in 90. However, as an exception, 2-methylpropanal gave selectively a single 
diastereoisomer 91 (R = i-Pr) in the reaction. The 1,3-DC reaction products 91 could be 
converted into the corresponding pyrrolidines 92 in high ee (enantiomeric excess) .48
1.3.5 Chiral induction by the dipolarophile
An extensive study was accomplished by Grigg and co-workers, who reacted a 
series of metalloazomethine ylides, 93, with electron-deficient dipolarophiles, e.g. menthyl 
acrylate 94, to afford 1,3-DC product 95 in good yield, with high endo and diastereofacial 
selectivity induction and with ck up to > 95% (Scheme 29).32,65-72
MenthyK
'OMenthyl
M = Ag (I), Li (I), T1(I), Ti (IV)
Scheme 29: 1,3-DC reaction of metalloazomethine ylides with chiral dipolarophiles
The reaction of azomethine ylides with menthyl acrylate is significantly slower compared 
with the analogous reaction of methyl acrylate, often leading to lower yields due to a slow 
metal ion-induced hydrolysis of the imine in the presence of traces of water. However, this
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can be overcome by the addition of a base, and the stronger the base the faster the 
reaction.66,67 The mechanism of the 1,3-DC reaction of these metalloazomethine ylides has 
been studied extensively. X-Ray diffraction studies of representative cycloadducts has 
revealed that the absolute configuration of the pyrrolidine stereocentres is independent 
both of the metal salt and the size of the C-2 substituent. Related work, involving reaction 
of the metalloazomethine ylides 93 with chiral dipolarophiles such as 2,5-dihydro-5- 
oxymenthylfuran-2-one 96 (R3 = menthyl) afforded 1,3-DC adduct 97 with complete 
regioselectivity and endo selectivity and with > 95% de via the syn dipoles, i.e. R1 is on the 
same face of the imine functionality in 93, (Scheme 30).66,73 The preferred base proved to 
be 2 -ferf-butyl-l ,1,3,3-tetramethylguanine > DBU > EtgN.
R = menthyl: endo:exo = 100:0 
de > 9 5 %
—H
Scheme 30: 1,3-DC of metalloazomethine ylides with chiral furanones.
Meyers et al. have studied the addition of azomethine ylides 98 to chiral unsaturated 
bicyclic lactams 99.74-77 The diastereoselectivities are dependent on the various 
substituents R^R4; for R1 = Me, Ph, the major stereoisomer obtained is 100, whereas for 
R1 = H the epimer at C-8 b is formed (Scheme 31).77
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100
Scheme 31: 1,3-DC of azomethine ylides with chiral bicyclic lactams
In addition, it was found that for R3 = H, the Tt-facial selectivity is insensitive to chiral 
substituents in the 1,3-dipole (R4 = chiral group), whereas when R3 is an electron- 
withdrawing substituents lower selectivities were observed. The 1,3-DC reaction of these 
azomethine ylides with chiral unsaturated bicyclic lactams was used for the synthesis of 
the (+)-conessine precursor (+)-benzohydrindan 101 (Figure 16).76
Me
Mel
101
Figure 16: (+)-benzohydiindan
1.3.6 Chiral catalysis of 1,3-DC reactions
Grigg et al. have found that chiral Ag(I), Co(II) and Mn(II) complexes are excellent 
catalysts for the 1,3-DC reaction of azomethine ylides derived from arylidene imines of 
glycine.78,79 Reaction of azomethine ylides 102 with methyl acrylate 103 in the presence of
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a stoichiometric amount of Co(II) and the chiral ephedrine ligand 104 gave the best yield 
(84%) and ee (96%) of the 1,3-DC reaction product 105 (Scheme 32).
M eO
OMe + < ^ ^ C O ?Me Cat.
102 105103
104
Scheme 32: 1,3-DC reaction catalysed by Co (Q) complexes
The presence of Ag(I) salts in combination with chiral ligands can catalyse similar 1,3-DC 
with ee of about 70%.65 The postulated working model for the asymmetric induction is 
based on 106 (Figure 17).65
Me
PHAr
106
Figure 17: Postulated asymmetric induction model for formation of 105.
The cis arrangement of the methyl group and phenyl group of the ligand result in a 
pseudoequatorial conformation of the phenyl group and provides an effective blockage of 
one of the faces of the dipole.
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Silver acetate is also an efficient catalyst for the cycloaddition of the azomethine ylide 
precursor methyl isocyanoacetate 107 with a range of olefins bearing conjugated activating 
groups 108. The reactions proceed smoothly at ambient temperature with 0.2-2 mol % of 
the catalyst to give, depending on the nature of the olefin used, either pyrroline 109 or 
pyrroline 110 in good yields (Scheme 33)7*
EWi EWi
EWG MeCN, r. t.
or
AgOAc (cat.)
107 108 109 110
Scheme 33: Silver acetate as catalyst in 1,3-DC reactions of azomethine ylides
Throughout this introductory Chapter we have endeavoured to provide the reader with the 
relevant background information on 1,3-DC reactions, as well as on the generation of 
azomethine ylides as specific 1,3-dipole components of these reactions. The synthetic 
utility of the latter in 1,3-DC chemistry has also been outlined.
Our project concerns the synthesis of novel imidazolinium ylides as azomethine ylides and 
their subsequent 1,3-DC chemistry with a range of dipolarophiles in both an inter- and 
intramolecular sense. The chemistry and results involved in this project follow.
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Chapter 2 
Results and Discussion
46
2.1 Intermolecular approach
This section describes approaches to the synthesis of dihydroimidazoles substituted 
with a heteroatom at C-2, their conversion into azomethine ylides, and our attempts to 
perform 1,3-DC reactions between the latter and a variety of dipolarophiles.
2.1.1 C-2 substituted dihydroimidazoles and imidazolinium ylides in 1,3- 
dipolar cycloaddition reactions
Previous researchers in our group have developed methodologies whereby 
azomethine ylides such as 19 are generated from the N-alkylation of 4,5-dihydroimidazoles 
29 and subsequent deprotonation of the salts so-formed. These ylides undergo 1,3-DC 
reactions with a wide variety of dipolarophiles, to afford functionalised pyrroloimidazoles, 
for example 111 (Scheme 34), and hence pyrrolidines and pyrroles. 41,80,42
-Ph -Ph-Ph
CH2=C(Me)CQ2Me
THF, A 
DBU
111a R = Me
111b R = Et 
111c R = tezt-butyl
19a R = Me 
19b R = Et 
19c R = tezt-butyl
Scheme 34
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In these reactions endo adducts predominate and only traces of the exo diastereoisomers 
are formed. The dipole appears to have an anti geometry in which the H atom is on the 
opposite face of the imine functionality of the dipole. The proposed transition state (Figure 
18) is consistent with other results involving azomethine ylides generated from iminium 
salts.81-83
X =C02Me, C02 Et, C02lBu 
Y = C02Me
Figure 18: Proposed transition state for 1,3-DC reaction described in Scheme 34
The relative stereochemistry of the cycloadducts was secured by nuclear Overhauser 
enhancement (n.O.e.) spectroscopy and by X-ray crystallographic analysis in the chiral 
series (see later). For adduct 111b, enhancement of the signal for the C-7a bridgehead 
proton on irradiation of the C-7 methyl group protons confirms that these two substituents 
are on the same face of the molecule, consistent with an endo approach of the dipolarophile 
to the azomethine ylide dipole (Figure 19).
2.5%
EtO
1 1 1 b
Figure 19: Relative stereochemistry of adduct 111b according to n.O.e. studies
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The observed regiochemistry of cycloaddition is as expected for the addition of an 
electron-deficient dipolarophile to a stabilised azomethine ylide {i.e. one carrying an 
electron-withdrawing group attached to the formally negatively charged end of the dipole) 
with an electron-deficient dipolarophile; orbital control involves HOMO-dipole / LUMO- 
dipolarophile interactions. This work was extended to optically active azomethine ylides 
generated from the homochiral dihydroimidazole 1 1 2  that can be synthesised from the 
commercially available optically active amino acid phenylglycine 113 (Scheme 35) .84
-Ph
NH-
Ph" NBNHCbz
115114113
-Ph
-PhPh
or
Ph" NH-PtfPh
(S)- 112(R)-112 116
Reagents: i, PhCH2OCOCl, aq. NaOH; ii, N-methylmorpholine, EtOCOCl, BnNH2; iii, H2, Pd-C; . 
iv, BH3.THF; v, HC(OEt)3, p-TsOH
Scheme 35
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The chiral azomethine ylides 117 were found to exhibit complete facial discrimination in 
their 1,3-DC reactions with a variety of dipolarophiles, affording, for example, the 
pyrroloimidazole 118 with methyl methacrylate (Scheme 37) .85
-PhMe
'MeDBU "N + Ptf
(S)-112 (S)-117 118
Scheme 37
Again, stereochemistry was confirmed by n.O.e. and X-ray studies. The stereochemical 
outcome of the cycloaddition is consistent both with an endo approach of the dipole and 
the dipolarophile and with the dipole having the anti geometry; facial selectivity is 
provided by the 4-phenyl substituent in the dipole. This is summarised in Figure 20.
■Me
Figure 20: Endo transition state for 118
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The cycloadduct 118 could be elaborated by a simple yet highly efficient two-step template 
removal protocol to yield optically active substituted pyrrolidines 120 (Scheme 38).86
HN
Me
Me BuO
BuO
120119
Scheme 38
In summary, cycloaddition using azomethine ylides generated from achiral and chiral 
dihydroimidazoles constitutes a powerful synthetic tool that affords access to 
polyfunctionalised pyrroloimidazole and pyrrolidine systems.
2.1.2 Strategy
Bearing in mind the azomethine ylide methodology described above, we proposed 
to prepare dihydroimidazoles substituted at C-2 with a heteroatom (O, S and N) that would 
constitute the precursors for a new generation of azomethine ylides. We anticipated that 
1,3-DC reaction conditions involving such ylides 122 would afford hexahydropyrrolo[l,2- 
^imidazoles 123 possessing additional heteroatom functionality at the bridgehead carbon 
(C-7a) (Scheme 39). Our strategy was to introduce sulfur functionality (SR) to the C-2 
position of dihydroimidazole 29.87 Dihydroimidazoles substituted with sulfur at C-2 would 
have a two-fold significance. In addition to acting as precursors for new sulfur-containing
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azomethine ylides such as 1 2 2 , they could be intermediates from which to synthesise the 
dihydroimidazoles substituted with O- and N- at C-2. This latter property arises from the 
inherent leaving group ability of the SR species; i.e. treatment of dihydroimidazoles 
carrying SPh or SBu at C-2 with an oxygen or nitrogen nucleophile, e.g. an alkoxides or a 
secondary amine, would afford the desired O- and N- substituted dihydroimidazoles 121 
via substitution and concomitant loss of the thiol or thiolate.
-Ph-Ph
-ZR-ZR
THF, DBU m
-122121
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Z = O, S, NR
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-EWG-EWG
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124 123
Scheme 39
The C-2 substituted dihydroimidazoles 121 would be N-alkylated using an activated 
haloalkane such as methyl bromoacetate to afford the azomethine ylides 1 2 2  after 
deprotonation. Application of the standard 1,3-DC reaction conditions, i.e. treatment of 
122 with excess dipolarophile followed by addition of DBU, would then follow. Our 
expectation was that removal of the dihydroimidazole template would furnish the
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pyrrolidones 124. We proposed to explore the methodology in the achiral series shown in 
Scheme 39 before applying it to chiral systems.
2,1,3 Synthesis of dihydroimidazoles substituted at C-2 with 
heteroatoms and attempted 1,3-dipolar cycloaddition reactions
We took as the starting point the synthesis of sulfur-substituted dihydroimidazoles 
since previous researchers in our group had reported a protocol for the introduction of the 
SPh group onto the C-2 position of dihydroimidazole 29.87 Thus, we treated an anhydrous 
THF solution of the dihydromidazole 29, synthesised from commercial 1,2-diaminoethane 
125 by N-alkylation with benzyl chloride to afford 126 followed by ring closure using 
triethyl orthoformate,42 with n-butyllithium at -78°C under a nitrogen atmosphere to obtain 
the C-2 deprotonated dihydroimidazole, which was then treated with diphenyldisulfide to 
afford the phenylthio-substituted dihydroimidazole 127a in 36 % yield (Scheme 40).
-Ph -Ph-Ph
-NH'
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i) n- BuLi
ii) (SR)2'NH NH'
127a R = Ph 
127b R = Bu125 126 R -  Ph, Bu
Scheme 40
Although this methodology allowed us to access the butylthio analogue 127b (using 
dibutyldisulfide as electrophile) in 21% yield, the yield for both reactions was low. Indeed, 
in both cases, the major product (40%) of the reaction was 1-benzyl-4,5-dihydroimidazol-
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2-one 128. We suspect this arises from the presence of adventitious water during work-up; 
a route involving hydrolysis is shown in Scheme 41.
-Ph-Ph
H* transferSR
SR
127 R = Ph, Bu 128
Scheme 41
Despite these unsatisfactory results, we decided to investigate whether these sulfur- 
substituted dihydroimidazoles could be used successfully as precursors to their oxygen 
counterparts. We envisaged using a fairly straightforward methodology, i.e. treatment of 
the sulfur substituted dihydroimidazole 127a with an appropriate alcohol (Scheme 42).
excess MeOH
Scheme 42
However, this approach proved unsuccessful despite using reflux conditions and the use of 
alkoxide nucleophiles {e.g. Na+ "OEt; 2.5 equiv.) in ethanol as solvent. We therefore 
adopted a different approach based on the parent tetrahydroimidazol-2 -one 128 and thione 
131 (Scheme 43). These were available in high yield (>90%) by treating a THF solution of
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N-benzyl-1,2-diaminoethane 126 with a THF solution of either commercial 1,1'- 
carbonyldiimidazole 130a or 1,1 '-thiocarbonyldiimidazole 130b (Scheme 43).
-Ph -Ph
-NH
•NH-
128 x  = O 99% 
131 X = S 94%
126 130a x = o 
130b x = s
Scheme 43
To the best of our knowledge, for cyclic urea 128 there have been only two other reported 
syntheses. The first, reported by McKay and co-workers,90 involved hydrolysis of 1- 
benzyl-2-nitroamino-2-imidazoline 132 using 10% aqueous sodium hydroxide to afford 
128 in 91% yield (Scheme 44).
-Ph
10% NaOH 1 2 8
132
Scheme 44
The second, published by previous researchers in our group,87 involved isolation of 128 in 
25% as a hydrolysis by-product from the synthesis of 1 -benzyl-2-phenylthio-2-imidazoline 
127a (see Scheme 41), as we also reported above.
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With the heteroatom-substituted dihydroimidazoles 128 and 131 to hand, we attempted 
their alkylation. To introduce alkyl functionality at the oxygen atom of the 
tetrahydroimidazol-2-one 128, we chose to follow methodology developed by Kohn and
QQ
co-workers, where O-alkyl-N-acylimidazolines 134 were prepared by reaction of 
trialkyloxonium tetrafluoroborates (Meerwein salts) 90 with the N-acylimidazolidone 133 
(Scheme 45).
aq. NaHCO;
134133
Scheme 45
In our hands this methodology failed to produce the desired O-alkylated dihydroimidazole, 
the starting materials invariably being recovered in quantitative yield. The use of other 
alkylating agents such as methyl trifluoromethanesulfonate, or an increase in thé 
equivalents of alkylating agent used, also proved unsuccessful. Indeed, reaction of 
tetrahydroimidazol-2-one 128 with excess methyl trifluoromethanesulfonate for 72h at RT 
afforded only traces of the desired O-alkylated product according to spectroscopic analysis. 
In contrast, introduction of an alkyl functionality into sulfur-substituted dihydroimidazole 
131 proved facile. Treatment of 131 with either excess iodomethane or methyl 
trifluoromethanesulfonate afforded the methylthioimidazolinium salt 135 which, upon 
treatment with excess K2CO3 gave the desired free base l-benzyl-2-methylthio-4,5- 
dihydroimidazole 136 in 8 6 % yield (Scheme 46).
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In fact, the methylthioimidazolinium salt 135 proved central to the synthesis of several 
related derivatives. For example, reaction of the salt 135 with a freshly prepared solution of 
NaOEt in ethanol under reflux for 24 h afforded upon work-up the desired l-benzyl-2- 
ethoxy-4,5-dihydroimidazole 137 in 6 6 % yield (Scheme 47). Further, the salt 135 could be 
used to synthesise N-substituted derivatives 138 and 139 by reaction with either a 2M THF 
solution of EtNH2 under reflux for 20 h to afford l-benzyl-2-ethylamino-4,5- 
dihydroimidazole 138 in 75% yield or with pyrrolidine under reflux for 20 h to afford 1- 
benzyl-2-(pyrrolidin-l-yl)-4,5-dihydroimidazole 139 in 47% yield (Scheme 47).
Scheme 47
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Unfortunately, the use of the bulkier primary amine terf-butylamine and the aromatic 
amine aniline failed to produce the corresponding nitrogen-substituted dihydroimidazoles; 
invariably starting material was recovered quantitatively. We also attempted the synthesis 
of a nitrogen-substituted dihydroimidazole using a similar approach to the one developed 
for the oxygen and sulfur species depicted in Scheme 43. We anticipated that coupling the 
phosgene iminium chloride 140 with 1-benzyl-1,2-diaminoethane 126 would lead to the 1- 
benzyl-2-dimethylamino-4,5-dihydroimidazole 141. This approach proved unsuccessful 
with only starting material 126 being recovered (Scheme 48).
-Ph
126 + \= N M <
C1 cr
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Scheme 48
Attempts to oxidise l-benzyl-2-methylthio-4,5-dihydroimidazole 136 to its sulfone 
derivative 142 (Scheme 49) failed in our hands. Oxidising agents such as oxone® and m- 
chloroperbenzoic acid (m-CPBA) were used, as well as different reaction conditions 
(temperature, solvents, increase of equivalents of oxidising agent), but in all cases we did 
not observe the formation of a new product by thin layer chromatography.
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However, since we had at this stage achieved the synthesis of heteroatom substituted 
dihydroimidazoles such as 136, 137, 138 and 139, we proceed to investigate the N- 
alkylation of these substrates, as would be required en route to azomethine ylides.
We used l-benzyl-2-methylthio-4,5-dihydroimidazole 136 as the model substrate and thus 
reacted a solution of the latter in THF with methyl bromoacetate under refluxing 
conditions for 5 h. After the removal of solvent under reduced pressure the crude residue 
was analysed by !H NMR spectroscopy. Unexpectedly, the crude residue was characterised 
as the starting material 136, implying no reaction with the alkylating agent. In order to 
tackle this low reactivity,91 we decided to use more reactive alkylating agents such as 
iodoacetonitrile as well as those bearing mesylate leaving groups such as ethyl 
methylsulfonyloxyacetate, synthesised from ethyl glycolate with methanesulfonyl chloride. 
However, none of these proved successful and invariably the substrate 136 was the only 
isolated material from these reactions that could be characterised. Applying the same 
methodology to the oxygen and nitrogen substituted dihydroimidazole species 137 and 
138, respectively, produced identical results.
In the light of these results, we modified our strategy by reversing the elaboration of 
substituents and attempting first the synthesis of tetrahydroimidazol-2 -ones and - 2 -thiones 
already bearing an N-methoxycarbonylmethyl substituent, e.g. 143a and 143b, respectively
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(Scheme 50). We envisaged that subsequent alkylation at the X heteroatom would generate 
imidazolinium salts from which the desired ylides could be formed by deprotonation. Thus, 
l-benzyltetrahydroimidazol-2-one 128 was reacted in anhydrous THF under nitrogen at - 
78°C with sec-BuLi to form the corresponding anion. The resulting solution was treated 
with methyl bromoacetate and subsequently heated at reflux for 24 h to afford the desired 
l-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-one 143a in 41% (Scheme 50). 
Attempts to improve the yield by the use of other bases such as n-BuLi, IDA, NaH and 
terf-butyllithium proved unsuccessful, with the highest yield of these being for tert- 
butyllithium (15%). Thus, sec-BuLi became the base of choice for the reaction.
-Ph-Ph
C02Me
143a, X = 0  
143b, X = S
128, x = 0  
131, X = S
X alkylation
-Ph -Ph
DBU-XR - -XR
(deprotonation)-N+
Scheme 50
Unexpectedly, this methodology failed to produce the desired results when applied to 1- 
benzyltetrahydroimidazol-2-thione 131. When either sec-BuLi or NaH were employed as 
the base, starting material was recovered in virtually quantitative yield (Scheme 51, 
method A). We also envisaged that the use of the Mitsunobu reaction would generate the
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desired l-benzyl-3-methoxycarbonylmethyl-4,5-dihydroimidazol-2-thione 143b. Thus 
tetrahydroimidazole 131, triphenylphosphine and ethyl glycolate were dissolved in 
dioxane, before diethyl azodicarboxylate (DEAD) was added (Scheme 51, method B). 
After 8  h work-up afforded unreacted starting material 131 (contaminated with traces of 
triphenylphosphine) in approximately 80%, and triphenylphosphine itself. Perhaps naively, 
we also attempted the synthesis of 143b by simply treating a solution of 131 in dry THF 
with methyl bromoacetate and heating the resulting solution at reflux for 18 h. Silica gel 
column chromatography of the crude residue using a basic eluant afforded l-benzyl-2 - 
(methoxycarbonylmethylthio)-4,5-dihydroimidazole 144 in 87% yield (Scheme 51, method 
C). Since alkylation not surprisingly occurs at sulfur89 rather than nitrogen, this approach 
to 143b was unsuitable.
-Ph-Ph
143b
method Amethod B
143b131
method C
-Ph
144
A: (i) THF, -78°C, -sec-BuLi, (ii) BrCHgCOzMe, A, 18 h. 
B: Ph3P, HOCHzCOgEt, dioxane, DEAD.
C: THF, BrCHzCOzMe, A, 18 h.
Scheme 51
61
A successful synthesis of 143b was finally developed by simple treatment of a solution of 
1-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-one 143a in dry ozt/io-xylene 
under nitrogen with the thionating agent 2,4-bis-(4-methoxyphenyl)-l ,3- 
dithiadiphosphetane-2,4-disulfide92 (Lawesson’s Reagent) and heating the resulting 
solution at reflux for 26 h. Column chromatography of the crude residue afforded 143b in 
6 6 % (Scheme 52). The use of dry THF or anhydrous toluene instead of ozt/zo-xylene as 
solvent resulted in decreased yields, 33% and 49%, respectively.
-Ph
Lawesson's Reagent 
orf/io-xylene, A
143b143a
Mel
Lawesson's Reagent =
OMe
Scheme 52
Having developed syntheses of 143a and 143b, we turned our attention to the introduction 
of a substituent onto the C-2 heteroatom in both of these molecules.
In the case of the sulfur analogue 143b, méthylation at sulfur was easily achieved by 
reaction with methyl trifluoromethanesulfonate in anhydrous dichloromethane under 
nitrogen for 1 h. This afforded l-benzyl-3-methoxycarbonylmethyl-2-methylthio-4,5- 
dihydroimidazolium trifluoromethanesulfonate 145 in 97% yield (Scheme 53).
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Unsurprisingly, alkylation at the oxygen atom of l-benzyl-3-methoxycarbonylmethyl 
tetrahydroimidazol-2-one 143a proved to be a more challenging task due to the lower 
reactivity of the parent compound89 and the known susceptibility of imidate salts to 
hydrolysis.93 Under standard reactions conditions using an atmosphere of nitrogen we were 
unable to isolate the desired salt using the methylating agent methyl 
trifluoromethanesulfonate at RT even after increasing the amount of alkylating agent up to 
10 equivalents. We decided to conduct a test reaction of the substrate 143a with 
triethyloxonium tetrafluoroborate (1M solution in dichloromethane; 1.2 equiv.) as 
ethylating agent in a meticulously dried NMR sample tube, using deuterated 
dichloromethane as solvent and making the addition of the alkylating agent (1 .2  equiv.) to 
143a via syringe inside a glove box. After 30 min the solution was analysed by NMR 
spectroscopy; no peaks corresponding to the starting material 143a were observed and the 
spectrum clearly showed the formation of a new product that had peaks consistent with it 
being l-benzyl-3-methoxycarbonylmethyl-2-ethoxy-4,5-dihydroimidazolium tetrafluoro­
borate 146 (Scheme 54).
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The patterns of the signals corresponding to the newly formed salt 146 were analogous to 
those of the substrate 143a, but there was a 8  0.5 downfield shift evident for each signal. 
This is consistent with the formation of the salt, the delocalised positive charge deshielding 
the protons in the molecule. In addition, the ethyl signals of the imidate ester salt 146 
(triplet integrating to three protons at 8  1.60 and quartet integrating to two protons at 8  
4.75) were observed, as were those of diethyl ether, the by-product of alkylation.
We also envisaged the use of other reagents that would introduce a substituent onto oxygen 
in 143a. Thus, compound 143a was treated with trifluoromethanesulfonic anhydride 
(TfaO) (1.2 equiv.) to afford the salt l-benzyl-3-methoxycarbonylmethyl-2- 
trifluoromethanesulfonyloxy-4,5-dihydroimidazolium thfluoromethanesulfonate 147 in 
80% yield according to NMR spectra (Scheme 55). Further, treatment with terf-butyl- 
dimethylsilyl trifluoromethanesulfonate afforded l-benzyl-3-methoxycarbonylmethyl-2- 
terr-butyldimethylsilyloxy-4,5-dihydroimidazolium trifluoromethanesulfonate 148 in 
quantitative yield as seen in the NMR spectra (Scheme 55). Again, both salts 147 and 148 
display NMR spectroscopic evidence of downfield shifts of the relevant product peaks 
by 8  0.5 in comparison to the substrate 143a. However, due to the hygroscopic nature of
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the salts 147 and 148, prolonged NMR spectroscopic monitoring of these reactions 
revealed a gradual conversion of the salts with time to the starting material 143a.
-Ph
(CFaSO^O, 
CD2CI2, 30 min,
OTf
143a
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TBDMSOTf, ^  
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" N + IfD
Scheme 55
We could now proceed to investigate a one-pot sequence whereby sulfur and oxygen 
derivatisation (alkylation, sulfonation or silylation) of the dihydroimidazoles 143a and 
143b could be followed by deprotonation of the so-formed salts 145, 146, 147, and 148, 
respectively, as a way to attempt 1,3-DC reactions (see Scheme 56). Methyl 
trifluoromethanesulfonate (1 .2  equiv.) was added to a solution of l-benzyl-3 - 
methoxycarbonylmethyltetrahydroimidazol-2-thione 143b in anhydrous THF under 
nitrogen to afford the crude salt, l-benzyl-3 methoxycarbonylmethyl 2 methylthio-4,5- 
dihydroimidazolium trifluoromethanesulfonate 145. This was treated without isolation 
with an excess of the dipolarophile methyl acrylate (3 equiv.) and the solution brought to 
reflux before the dropwise addition of DBU (1.2 equiv.). However, the 1,3-DC reaction 
product expected from the trapping of with the azomethine ylide 149 with methyl acrylate,
65
i.e. the hexahydropyrroloimidazole 150, was not isolated (Scheme 56). Instead, the major 
material isolated after column chromatography of the crude residue was l-benzyl-3- 
methoxycarbonylmethyltetrahydroimidazol-2-one 143a in 87% yield. The other material 
isolated from this reaction was baseline material containing DBU residues, which could 
not be adequately characterised. The same reaction was also attempted using higher boiling 
solvents, such as toluene, and more polar solvents, such as dimethylsulfoxide; again, the 
major isolated material was l-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-one, 
143a, in yields varying from 80-85 %.
-Ph-Ph
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145143b
DBU
-Ph
-Ph-Ph
SMe
SMe
MeO 149150 143a
Scheme 56
The formation of compound 143a suggests that either the salt 145 or the azomethine ylide 
149 was hydrolysed under the reaction conditions. Alternatively, though less likely, the salt 
145 could afford the product 143a by the route shown in Scheme 57, although the triflate
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ion is not known to be particularly nucleophilic. Moreover, we did not obtain any evidence 
for the S-methyl trifluoromethanethiosulfonate by-product.
SMe
SMe
SMe
-Ph
143a
Scheme 57
Despite this lack of success with the sulfur analogue, we adopted a similar synthetic 
approach with the oxygen-substituted dihydroimidazole 143a. Thus, O-alkylation of 143a 
with triethyloxonium tetrafluoroborate (1 .2  equiv.) followed by subjecting the so-formed 
salt 146 to DBU and methyl acrylate again resulted in isolation of the dihydroimidazol-2- 
one starting material 143a rather than the hexahydropyrroloimidazole 151a (Scheme 58). 
The use of more reactive dipolarophiles, such as methyl vinyl sulfone, afforded identical 
results and thus the hexahydropyrroloimidazole 151b was not isolated.
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Similarly, the dihydroimidazole salts 147 and 148 were generated by treating l-benzyl-3 - 
methoxycarbonylmethyltetrahydroimidazol-2-one 143a in anhydrous THF with Tf20  or 
TBDMSOTf, respectively, and subsequently treated with excess methyl acrylate followed 
by DBU. However, neither reaction afforded the desired hexahydropyrroloimidazole 152a 
or 152b, respectively (Scheme 59). As before, the major isolated material was the 1-
benzyl-3 -methoxycarbonylmethyltetrahydroimidazol-2 -one substrate 143a in 8 5 % and
89% yield, respectively. Use of toluene or acetonitrile as solvent afforded identical results.
r-Ph
O
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CH2=CHC02Me
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152a Z = Tf 
152b Z = TBDMS
Scheme 59
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As an alternative approach to the formation of ylides from C-2 heteroatom-substituted 
dihydroimidazoles, we turned our attention to an approach based upon the desilylation 
methodology developed by Vedejs and co-workers for the synthesis of the pyrrolizidine 
alkaloid retronecine 56 (see Scheme 21 ) .55 This involved the fluoride ion-promoted 
desilylation of a silylalkyl substituent in an imidate salt 57 to afford the corresponding 
azomethine ylide, which subsequently underwent a 1,3-DC reaction with methyl acrylate 
to afford a bicyclic pyrrolizidine adduct.
To achieve this we needed first to introduce a silylmethyl substituent at the amide nitrogen 
of the tetrahydroimidazol-2-one 128 and the tetrahydroimidazol-2-thione 131. Subsequent 
derivatisation of the oxygen and sulfur heteroatoms by the protocols described above 
would then afford the corresponding imidazolinium salts, which upon desilylation would 
generate the desired azomethine ylides. Silylmethylation of 128 was easily achieved 
through adaptation of the N-alkylation of 128 and 131 using methyl bromoacetate. Thus, 
reaction of l-benzyltetrahydroimidazol-2-one 128 with NaH in anhydrous DMSO (use of 
THF as solvent led to lower yields) generated an imidazolone anion that was reacted with 
chloromethyltrimethylsilane to yield the desired l-benzyl-3-trimethylsilylmethyl 
tetrahydroimidazol-2-one 153a in 45% yield (Scheme 60). Also isolated was the 1-benzyl-
3-methyl-tetrahydroimidazol-2-one 154 in 27% yield. The use of iodomethyltrimethyl 
silane as silylating agent afforded identical results. In contrast to the previous attempts to 
N-alkylate 128, NaH afforded the best results in this reaction.
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The formation of 1-benzyl-3-methyl-tetrahydroimidazol-2-one 154 could be rationalised as 
shown in Scheme 61.
154
Scheme 61
The sulfur analogue 153b was obtained in 69% yield by treating 153a in anhydrous ortho- 
xylene with Lawesson’s Reagent (1 equiv.) under nitrogen (Scheme 62).
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Not surprisingly, it proved difficult to introduce a substituent at the oxygen atom of 153a. 
Reaction of 153a with methyl trifluoromethanesulfonate and triethyloxonium 
tetrafluoroborate was monitored using NMR spectroscopy. The best results were 
obtained using methyl trifluoromethanesulfonate (5 equiv.), with O-methylation of 153a 
proceeding to approximately 35% after 3 h (the conversion percentage was calculated from 
the integration of the methylene proton signal of 153a in the !H NMR spectrum, relative to 
the methylene proton signal of the product 155). Despite the low yield of the O-alkylation, 
we decided to attempt a one-pot reaction of 153a towards the synthesis of 
hexahydropyrroloimidazoles 157 (Scheme 63). This involved initial O-alkylation to afford 
the salt 155, followed by in situ fluoride-promoted desilylation using CsF and subsequent 
treatment of the so-formed ylide 156 with excess dipolarophile (Scheme 63). This required 
that all glassware was flame dried, and that solvents and caesium fluoride, were 
meticulously dried prior to the reaction, since any adventitious water would compromise 
the progress of the reaction. Thus, l-benzyl-3-trimethylsilylmethyltetrahydroimidazol-2- 
one 153a was treated with methyl trifluoromethanesulfonate (1 .2  equiv.) in anhydrous 
dichloromethane at RT under nitrogen and the solution stirred for 3 h. The 
dichloromethane solvent was removed and replaced by 2 -methoxyethyl ether, then methyl 
acrylate (3 equiv.) was added. The solution was transferred via syringe to a reaction flask
containing CsF (2.5 equiv.) under nitrogen. However, after subjection of the residue to 
silica gel column chromatography, the starting material 153a was recovered in 89% yield 
(Scheme 63).
CsF
.Ph
Me
157 156
Scheme 63
Recovery of the starting material from this reaction could either be due to low conversion ’ 
to the salt 155, or to hydrolysis of 155 due to adventitious moisture. In either case, it was 
clear that fluoride ion-promoted desilylation had not taken place. Consequently, as we had 
the sulfur analogue 153b to hand, and since we had developed a successful S-methylation 
of the sulfur atom in 153b (Scheme 64), we decided to attempt the same one-pot 
methodology with the latter. Once again, the glassware was flame dried and all solvents 
and reagents were anhydrous.
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Thus, 1-benzyl-3-trimethylsilylmethyltetrahydroimidazol-2-thione 153b was treated with 
methyl trifluoromethanesulfonate (1.2 equiv.) in anhydrous dichloromethane at RT under 
nitrogen for 3 h. The solvent was then removed and replaced by anhydrous diglyme, 
following which methyl acrylate (3 equiv.) was added. This solution was transferred via 
syringe to a reaction flask containing CsF (2.5 equiv.) under nitrogen and the subsequent 
mixture stirred at RT for 24 h. Unfortunately, purification of the crude residue by silica gel 
column chromatography did not afford the expected hexahydropyrroloimidazole 159; 
instead, l-benzyl-3-trimethylsilylmethyltetrahydroimidazol-2-one 153a was isolated in 
37% yield together with recovered starting material l-benzyl-3- 
trimethylsilylmethyltetrahydroimidazol-2-thione 153b in 60% yield (Scheme 65). The 
former presumably arises from hydrolysis of the intermediate salt 158, since 153b is 
relatively stable to hydrolysis. These results imply that desilylation does not occur in these 
systems, so we abandoned this synthetic approach.
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As a final approach to ylides from C-2 heteroatom substituted dihydroimidazoles we 
envisaged the use of the use of the dibenzylated species 161a and 161b (Scheme 66). We 
assumed that the heteroatom alkylation, silylation or sulfonation methodologies previously 
developed would be applicable to these dibenzylated species. Thus, the most relevant issue 
was whether or not the benzylic position of these species, after appropriate O- or S- 
substitution, would constitute the suitable deprotonation site essential for the formation of 
the desired azomethine ylides.
We were able to access 1,3-dibenzyltetrahydroimidazol-2-one 161a in 97% yield, and 1,3- 
dibenzyltetrahydroimidazol-2-thione 161b in 98% yield, by reacting a solution of 
commercial N, N'-dibenzyl-1,2-diaminoethane 160 in anhydrous THF with a THF solution 
of the appropriate coupling agent, 1, V-carbonyldiimidazole or 1,1'- 
thiocarbonyldiimidazole respectively, at RT for 18 h (Scheme 66).
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We then investigated the S-alkylation of 161b (Scheme 67), since the salts so-obtained are 
both potential azomethine ylide precursors and substrates for C-2 amination, the latter 
allowing us to access to 1,3-dibenzylated C-2 nitrogen-substituted dihydroimidazoles. As 
expected, quantitative méthylation at sulfur in the dihydroimidazol-2-thione 161b was 
achieved by treatment with methyl trifluoromethanesulfonate (1.2 equiv.) in anhydrous 
dichloromethane under nitrogen at RT (Scheme 67). The use of anhydrous THF as solvent 
produced identical results.
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SMe
‘N+
TfO
'Ph•Ph
162161b
Scheme 67
75
As planned, the dibenzylated salt 162 did afford access to dibenzylated C-2 nitrogen- 
substituted dihydroimidazoles. Thus, the 1,3-dibenzyltetrahydroimidazol-2-thione 161b 
was methylated as described above, following which methylamine (2M solution in THF; 
1.2 equiv.) was injected via syringe. After 18 h at reflux, the crude reaction residue was 
purified by silica gel column chromatography to give l,3-dibenzyl-2- 
methyliminotetrahydroimidazole 163 in 40% yield (Scheme 68). Replacing methylamine 
by pyrrolidine and excluding the chromatographic purification step, we were also able to 
access the crude salt l,3-dibenzyl-2-(tetramethyleneimino)tetrahydroimidazolium 
trifluoromethanesulfonate 164 in 77% yield. NMR spectroscopic analysis of 164 
showed the downfield shift of the corresponding proton signals of the amidine and 
pyrrolidine ring of 164 in comparison to the proton signals in the starting materials. As 
described above for similar systems such as 145, this implies formation of the salt due to 
the deshielding effect cause by the delocalised positive charge. However, using either 
diethyl iminodiacetate or proline methyl ester as the nitrogen nucleophile proved 
unsuccessful. Monitoring these reactions in a sealed NMR tube at reflux using deuterated 
dichloromethane provided conclusive evidence that no reaction was taking place between 
these latter amines and the salt 162. Replacement of deuterated dichloromethane by higher 
boiling solvents such as deuterated acetonitrile or toluene and using extended periods of 
reflux (72 h) or excess amine proved unfruitful (Scheme 68).
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Sulfonation or silylation at the oxygen atom of 1,3-dibenzyltetrahydroimidazol-2-one 161a 
was achieved using Tf^O and either trimethylsilyl trifluoromethanesulfonate or 
TBDMSOTf, respectively. Thus, addition of Tf^O (1.2 equiv.) to a CD2CI2 solution of 1,3- 
dibenzyltetrahydroimidazol-2-one 161a afforded the O-triflated salt 167 in quantitative 
yield after 1 h, according to spectroscopic analysis. In the same manner, addition of either 
TMSOTf (1.2 equiv.) or TBDMSOTf (1.2 equiv.) to a CD2CI2 solution of 1,3- 
dibenzyltetrahydroimidazol-2-one 161a afforded the O-silylated salts 168a and 168b,
77
respectively, in quantitative yield as observed spectroscopically (Scheme 69). Again, the 
observed downfield shift of the amidine ring protons in the NMR spectrum, implying 
the formation of the corresponding salts, together with the absence of proton signals 
corresponding to either TMSOTf or TBDMSOTf starting materials, provided conclusive 
evidence.
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Having accessed to the S- and O- substituted salts 162 and 167/168, respectively, we 
proceeded to investigate deprotonation at the benzylic site and subsequent 1,3-DC reaction 
with a suitable dipolarophile. We focused on the 1,3-dibenzyl-2-methylthio-4,5- 
dihydroimidazolium trifluoromethanesulfonate salt 162, due to the simplicity of its 
synthesis and also to its stability towards hydrolysis. Thus, a solution of the salt 162 in 
anhydrous THF was cooled to -78°C, then treated with the base sec-BuLi (1.2 equiv.). We 
chose this base rather than DBU as the benzylic sites in 162 will be less acidic than the
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methylene site (a- to the ester group) in salts carrying an electron-withdrawing group, e.g 
145. After addition of excess methyl acrylate (3 equiv.), the resulting solution was warmed 
to RT then heated at reflux for 12 h. After work-up of the reaction mixture, none of the 
desired product 170 was isolated (Scheme 70). The major isolated product (82% yield) was 
the l,3-dibenzyltetrahydroimidazol-2-one 161a, presumably derived from hydrolysis of the 
salt 162. The use of other bases, such as LDA, DBU and tert-BuLi, produced similar 
results with isolation of 161a varying from 67% to 80%. Moreover, the use of other 
solvents such as toluene and more polar solvents such as DMSO also proved unsuccessful; 
once again 161a was isolated as the major product.
-Ph-Ph
THF 161aSMe
TfO"
Ph
161b 162
-Ph
-Ph
,SMe
CH7=CHC02Me SMe
"N +
Ph 169Ph 170
Scheme 70
A comparable result was obtained when we subjected the nitrogen-substituted 
dihydroimidazole salt l,3-dibenzyl-2-(tetramethyleneimino)tetrahydroimidazolium 
trifluoromethanesulfonate 164 to this procedure. Thus, a THF solution of l,3-dibenzyl-2-
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(tetramethyleneimino)tetrahydroimidazolium trifluoromethanesulfonate 164 was treated 
with sec-BuLi (1.2 equiv.) at -78°C under nitrogen. The resulting solution was stirred for 
20 min at -78°C, then excess methyl acrylate (3 equiv.) was added and the solution heated 
at reflux for 8 h. However, purification of the crude reaction residue by silica gel column 
chromatography afforded, as was found for the sulfur analogue, the hydrolysis product 
161a in 79% yield (Scheme 71). Similarly, the use of LDA or DBU as alternative bases, as 
well as an alternative solvent, such as toluene, afforded identical results, i.e. the major 
isolated product being 161a.
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To determine the reason for this lack of reaction between methyl acrylate and the 
azomethine ylides that we assumed had been formed, we conducted a series of deuteration 
experiments to investigate the extent of deprotonation at the benzylic site. Thus, treatment 
of the parent compounds, 1,3-dibenzyltetrahydroimidazol-2-one 161a or 1,3-
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dibenzyltetrahydroimidazol-2-thione 161b, in anhydrous THF under nitrogen at -78°C 
with sec-BuLi (1.2 equiv.) followed by the addition of deuterated trifluoroacetic acid (1 
equiv.) resulted in the formation of the deuterated species 173a and 173b (Scheme 72). 
The incorporation of a deuterium atom in both substrates was supported by spectroscopic 
evidence. The benzylic signals in the NMR spectra of 161a or 161b are sharp singlets at 
Ô 4.32 or 8 4.92, respectively, each integrating to four protons. After deuterium 
incorporation, the pattern of these signals changes to two singlets 8 0.03 apart, one 
integrating to two protons, the other to one proton, as expected for the replacement of one 
of the protons by a deuterium atom.
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Scheme 72
This implies that it is possible to form the carbanion at the benzylic site from these 
compounds. We also screened other bases, such DBU and LDA, but we were unable to 
detect any deuterium incorporation.
We then turned our attention to examining deuteration of the sulfur-, nitrogen- and oxygen- 
substituted dihydroimidazole salts, 162, 164 and 168a, respectively, under analogous 
conditions (Scheme 73).
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Most surprisingly, attempted deuteration of the 1,3-dibenzyl-2-methylthio-4,5- 
dihydroimidazolium trifluoromethanesulfonate salt 162 failed to afford the deuterated 
dihydroimidazole 174; NMR analysis revealed both the pattern and integration ratio of 
the substrate 162 to be unchanged. Thus, it would appear that the failure of the 1,3-DC 
reactions involving 162 (Scheme 70) may be attributable to the non-formation of the 
desired azomethine ylide. Analogous results were obtained from attempts to deuterate 
either the benzylic position or the position a- to the nitrogen atom of the pyrrolidine ring 
of 1,3-dibenzyl-2-(tetramethyleneimino)tetrahydroimidazolium trifluoromethanesulfonate
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164. Thus, !H NMR spectroscopic analysis showed that both the pattern and integration 
ratio of the signals of substrate 164 were unchanged, again implying that formation of the 
desired azomethine ylide did not take place. The results obtained for the deuteration of the 
oxygen-silylated dihydroimidazole 168a were more encouraging. According to NMR 
spectroscopic evidence, deuterium insertion into the benzylic site takes place since the 
signal corresponding to the benzylic protons of 168a changes from a singlet integrating to 
four protons at 8 4.61 to two singlets separated by 8 0.03, one of which integrates to one 
proton and the other to two protons. Since the results were consistent with formation of 
the azomethine ylide from 168a, we decided to subject the oxygen-substituted 
dihydroimidazoles, 167, 168a and 168b, to the 1,3-DC reaction conditions. To minimize 
potential hydrolysis of these salts, we performed the reactions on 1,3- 
dibenzyltetrahydroimidazol-2-one 161a as starting material using a one-pot method. Thus, 
a solution of 161a in anhydrous THF at RT and under nitrogen was treated with TMSOTf 
(1.2 equiv.). After 1 h the solution was cooled to -78°C and sec-BuLi (1.2 equiv.) was 
added dropwise, and 30 min later excess methyl acrylate (3 equiv.) was added at -78°C 
(Scheme 74).
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Unfortunately, the only compounds isolated from this reaction were the starting material, 
161a, in 28 % yield and the C-silylated compound 179 in 13% yield (Scheme 75). Thus, 
from the formation of 179 it would appear either that the ylide 177 has formed and the 
trimethylsilyl group has migrated from the oxygen atom to the benzylic carbon, or that the 
substrate 161a is deprotonated and silylated directly.
Ph -Ph-Ph
THF, TMSOTf 
RT. Ih
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CH?=CHCO?Me
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Scheme 75
If 179 were the result of a silyl group migration in the azomethine ylide, we hoped that the 
use of a dihydroimidazole substrate O-silylated with a bulkier group such as in 168a would
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impede the rate of migration and allow the azomethine ylide to be trapped by the 
dipolarophile. Thus, a solution of 161a in anhydrous THF at RT and under nitrogen was 
treated with TBDMSOTf (1.2 equiv.) to form the salt 168a. The solution was cooled to 
-78°C and sec-BuLi (1.2 equiv.) was added dropwise to form the corresponding 
azomethine ylide 180. Addition of excess methyl acrylate (3 equiv.) followed by 
purification of the crude mixture by silica gel column chromatography afforded 161a in 
78% yield as recovered starting material (Scheme 76). The use of a lower polarity solvent 
(toluene) afforded similar results.
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Using the same reaction conditions, the O-trifluoromethylsulfonated salt 167 was 
generated (using TfzO as sulfonating agent), and treated with sec-BûLi (1.2 equiv.) 
followed by excess methyl acrylate (3 equiv.). Once again, the expected 1,3-DC reaction
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adduct 182 was not isolated, the major material recovered being the starting material 161a 
in 65% yield (Scheme 77).
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As a complement to the studies described above of 4,5-dihydroimidazoles substituted at C- 
2 with lone-pair donor heteroatoms, and their potential as azomethine ylide precursors, we 
initiated preliminary studies on the introduction of electron-withdrawing substituents at C- 
2. The application of the so-formed substituted 4,5-dihydroimidazoles, such as 183 would 
have potential application to [4+2] cycloaddition reactions. We anticipated these reactions 
would ultimately, after 4,5-dihydroimidazole template removal and appropriate reduction 
of the double bond in 184, allow access to piperidine adducts such as 185 (Scheme 78).
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Based on a reported protocol applied in benzimidazole systems,94 we anticipated that the 
dihydroimidazole 183 would be accessible from the reaction of N-benzyl-1,2- 
diaminoethane 126 with ethyl glyoxalate 186 (Scheme 79) followed by oxidation with 
iodine.
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N-Benzyl-1,2-diaminoethane 126 was accessible as described previously42 whereas ethyl 
glyoxalate 186 was synthesised in 89% yield by the reaction of commercial ethyl 
diethoxyacetate 187 with glyoxylic acid monohydrate 188 in the presence of p- 
toluenesulfonic acid (Scheme 80), as reported by Hook.95
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Scheme 80
However, in our hands, the reaction between a solution of ethyl glyoxalate 186 (1.2 equiv.) 
in toluene, and a solution of N-benzyl-1,2-diaininoethane 126 in ethanol in the presence of 
catalytic iodine (0.2 equiv.) did not afford the desired product. The major product of this 
reaction could not be adequately characterised but its lH NMR suggested the formation of 
an ethyl glyoxalate polymer such as 189 (Scheme 81). This result was unsurprising since 
the tendency of ethyl glyoxalate to polymerisation is well known.95,96
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We were, however, able to access the 2-formyl analogue of 183. This was achieved by 
reacting a solution of N-benzyl-l,2-diaminoethane 126 in diethyl ether with commercial 
ethyl diethoxyacetate 187 (1.2 equiv.) to afford, after purification by silica gel column 
chromatography, N-(2-benzylaminoethyl)-2,2-diethoxyethanamide 190 in 47% yield. A 
solution of the latter in ethanol was stirred at RT for 14 h and then quenched to afford, 
after purification by silica gel column chromatography, the 1 -benzyl-2-formyl-4,5- 
dihydroimidazole 191 in 60% yield (Scheme 82).
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Due to time restrictions we did not have the opportunity to subject 191 to [4+2] 
cycloaddition conditions and the preliminary studies described above remain to be 
exploited. At this point we decided to conclude the 1,3-DC reaction studies of heteroatom- 
substituted 4,5-dihydroimidazoles and concentrate our efforts on intramolecular 1,3-DC 
reactions using novel azomethine ylides. The results and discussion of this project follow.
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2,2 Intramolecular approach
This section describes the results obtained from an investigation involving the 
generation of novel azomethine ylides by the reaction of dihydroimidazole systems with N- 
alkylating agents that also contain remote alkene functionality. Since these also constitute 
suitable dipolarophiles they are expected to undergo intramolecular 1,3-dipolar 
cycloaddition reactions to afford heterotricyclic adducts.
2,2,1 Strategy
Previous researchers in our group had successfully developed a rapid and 
stereocontrolled intramolecular 1,3-DC approach to 2,3,4-trisubstituted pyrrolidines. This 
route employed the homochiral dihydroimidazole (S)-112 as the dipole precursor and a 
haloalkyl reagent £-192 carrying the dipolarophile (Scheme 83), that was synthesised from 
acrolein in four steps in moderate yield.97 Treatment of a solution of dihydroimidazole (Sty- 
I l l  in anhydrous THF under nitrogen at reflux with £-bromoacetate ester 192, followed by 
the dropwise addition of DBU as base afforded the tricyclic adduct 193 in 31% yield. The 
stereochemistry of the adduct is consistent with the transition state model previously 
postulated,85 i.e. endo approach of the dipolarophile to the anri-configured dipole, with 
facial selectivity controlled by the 4-phenyl substituted.
90
-Ph
DBU, A aq. HCI-THF OH
Ph
(S)-112 Ph-
194193
£-192= Bi
OHPh
195
Scheme 83
Removal of the chiral template in adduct 193 to reveal the trisubstituted pyrrolidine 195 
involved aminal reduction followed by hydrogenolysis of the spontaneously formed 
bicyclic lactam 194.
The aim of our project involved the extension of the intramolecular 1,3-DC methodology 
depicted in Scheme 83 to an all-carbon tethered dipolarophile 196, i.e. using an a- 
haloketone rather than an ot-haloester, which it was anticipated would lead to a tricyclic 
product such as 197 (Scheme 84).
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Removal of the dihydroimidazole template, perhaps using the conditions described in 
Scheme 83 for 193, should enable us to access reduced indole derivatives such as 199, 
from adducts such as 198 (Scheme 85), which share the original indole skeleton of marine 
natural products such as Aeruginosin 98-C 200 (Figure 21). Compounds such as 
Aeruginosin 200 constitute new protease inhibitors, which have recently become the focus 
for extensive research.98"100
COoR
Ph
199198
Scheme 85
92
NH
OH NH,
200
Figure 21: Aeruginosin 98-C
2.2.2 Syntheses of the cc-haloketone dipolarophiles and their 1,3-dipolar 
cycloaddition reactions.
It was anticipated that variation of the chain length of the oc-haloketone 196 would 
allow access to smaller and larger carbocyclic ring derivatives of 198. Investigation of 
different R groups in the ester would also be addressed. Since the synthesis of either 
enantiomer of 1 -benzyl-4-phenyl-2-imidazoline 112 had been successfully developed by 
previous researchers in our group,84 our efforts were focused both on the development of a 
suitable approach towards the synthesis of the a-haloketones N-alkylating agents 196 and 
also suitable 1,3-DC reaction conditions that would allow the formation of the adducts.
A few examples of synthetic approaches towards the synthesis of the oc-haloketone 
196 had been previously reported,101'104 but after consideration of yields, starting material 
availability and the length of the synthesis, we decided to adopt the methodology 
developed by Grigg et a/.105 According to these workers, treatment of a solution of ethyl 
acetoacetate 201 in anhydrous ethanol with sodium ethoxide (1.2 equiv.) to afford the
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intermediate enolate followed by the dropwise addition of commercial 2-(2-bromoethyl)-
1,3-dioxolane 202 at reflux is reported to afford 2-(3-ethoxycafbonyl-4- 
oxopentyl)dioxolane 203 (Scheme 86).
NaOEt/EtOH, A
201
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Scheme 86
However, in our hands the reaction conditions established by these workers did not afford 
the desired product. Instead, we isolated 2-(2-ethoxyethyl)-1,3-dioxolane 204 in 20% yield, 
derived from the nucleophilic substitution reaction of ethoxide anion with 2-(2- 
bromoethyl)-1,3-dioxolane 202 (Scheme 87).
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We did, however, overcome this problem by substituting sodium hydride for sodium 
ethoxide and using THF as solvent, obtaining the desired product 203 in 45% yield.
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Attempts to optimise the yield of this reaction by using higher boiling solvents such as 
tetrahydropyran (THP) and diglyme afforded identical results.
Since the proposed synthesis (Scheme 8 8 ) of the dipolarophile precursor 196 would need 
to include halogénation, to incorporate the oc-haloketone N-alkylating agent,
decarboxylation ^
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we envisaged the use of ethyl 4-chloroacetoacetate 208 as an alternative starting material 
(Scheme 89), thus resolving the issue of halogénation directly in the first step of our 
dipolarophile synthesis (Scheme 8 8 ). However, by thin layer chromatography we did not 
observe the formation of a new product from the reaction of 208 with 2 0 2 ; moreover, 
subjection of the crude residue to silica gel column chromatography afforded starting 
material 208 in 91% yield and not the expected 2-(5-chloro-3-ethoxycarbonyl-4- 
oxopentyl)dioxolane 209.
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Consequently, we resumed the synthesis of 196 by the route shown in Scheme 8 8 . Basic 
hydrolysis and decarboxylation of 2-(3-ethoxycarbonyl-4-oxopentyl)dioxolane 203 was 
achieved by heating in 5% aqueous sodium hydroxide solution at reflux for 16 h to afford 
the desired 2-(4-oxopentyl)dioxolane 205 in 89% after purification. Acid-mediated acetal 
cleavage was accomplished by treating an ice-cold solution of 205 in THF with 1M 
hydrochloric acid (3 equiv.), and heating the resulting solution to 50°C for 5 h, giving the 
desired aldehyde, 5-oxohexanal 206 in 79% yield. The latter was subjected to Wittig 
olefination in anhydrous dichloromethane with freshly prepared methyl 
(triphenylphosporanylidene)acetate106 210 in dichloromethane at RT for 18 h to afford 
methyl 7-oxooct-2-enoate in 90% yield as an 8:1 mixture of E- and Z- isomers (207a and 
207b, respectively) which were separable by silica gel column chromatography (Scheme 
90).
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By changing the solvent of the Wittig reaction from dichloromethane to ethanol we were 
also able to affect the ratio of the isomeric products 207a:207b from 8:1 in favour of the 
E- isomer to a 1:1 isomeric ratio, thus giving better access to the Z-isomer. Although the 
use of this approach allowed us ready access to our dipolarophile precursors 207a and 
207b, we decided to investigate an alternative route to these since the 2-(2-bromoethyl)-
1,3-dioxolane 202 starting material is expensive. We were able to achieve this by treating 
ethyl acetoacetate 201 with acrolein 211 (1 equiv.) at -10°C (ice-methanol bath) in the 
presence of activated alumina (AI2O3) for 10 min which gave the keto-aldehyde 212 in 
80% yield as the product of a Michael addition.107 Acid-catalysed acetal protection of the 
aldehyde moiety of 212 using ethylene glycol108 and Dean-Stark azeotropic removal of 
water afforded 2-(3-ethoxycarbonyl-4-oxopentyl)dioxolane 203 in 70% yield (Scheme 91). 
Unfortunately, attempts to scale-up the reaction using more than 1 g of starting material 
invariably resulted in a considerable decrease in the yields of both synthetic steps, 
rendering this approach impractical.
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We therefore employed the original approach, using commercial 2-(2-bromoethyl)-1,3- 
dioxolane 202, throughout the remainder of the project.
Having synthesised 207a and 207b we now needed to develop a protocol for the 
regioselective halogénation of these compounds at the methyl carbon a- to the ketone, i.e. 
the least hindered site. To that end, we envisaged the formation of the kinetic enolate 
followed by quenching with a mild electrophilic brominating agent such as N- 
bromosuccinimide. Thus, treatment of a solution of either 207a or 207b in anhydrous 
THF under nitrogen at -78°C with a solution of IDA in anhydrous THF, freshly prepared 
from n-BuLi and diisopropylamine (1.2 equiv.), also at -78°C generated the kinetic enolate 
anion. This anion was quenched by the addition of excess ehlorotrimethylsilane (5 equiv.) 
in anhydrous THF at -78°C to form the E- and Z- isomers silyl enol ethers 213a and 213b 
in 79% yield. When these were treated in anhydrous THF at -78°C under nitrogen with 
solid NaHCOs (1.4 equiv.) followed by portionwise addition of NBS (1.3 equiv.) as 
brominating agent and then heating the mixture to 80°C for 2 h, both methyl £-8-bromo-7-
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oxooct-2-enoate 196a (from 207a) and methyl Z-8-bromo-7-oxooct-2-enoate 196b (from 
207b) were afforded in 45% combined yield (Scheme 92). We found that it was absolutely 
crucial for the success of this reaction for all reagents and solvents to be meticulously dry 
as well as all glassware flame dried.
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Scheme 92
Having synthesised the required alkylating agents, viz. methyl E-8-bromo-7-oxooct-2- 
enoate 196a and methyl Z-8-bromo-7-oxooct-2-ehoate 196b we proceeded to investigate 
their intramolecular 1,3-DC reactions with dihydroimidazoles. Thus, adopting the 
intermolecular 1,3-DC reaction conditions discussed in Chapter 1, 1-benzyl-4,5- 
dihydroimidazole 29, synthesised from 1,2-diaminoethane 125 by N-alkylation with benzyl 
chloride followed by ring closure using triethyl orthoformate,42 was heated with methyl E- 
8-bromo-7-oxooct-2-enoate 196a in THF at reflux followed by dropwise addition of DBU 
over 4 h and reflux for a further 4 h, to afford a product that was not the expected 
cycloadduct 216 (Scheme 93).
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Firstly, the mass spectrum had a molecular ion at m/z 310 rather than the expected m/z 328 
for 216. Secondly, the NMR spectrum contained a 1H singlet at 8 7.12, reminiscent of 
an aromatic proton, and the anticipated doublets at 8 3.86 and 8 4.65 for the 4a-C# and 9a- 
CH protons97, respectively, for 216 were absent. Thirdly, the 13C NMR spectrum did not 
contain the expected ketone carbon signal at about 8 200-210. Furthermore, DEPT 13C 
NMR analysis showed the presence of only two CH carbon atoms at 8 59.7 and 8 124.3 in 
contrast to the expected four CH for 216. One other feature stands out in the NMR 
spectrum (Figure 22); namely, not only are the benzylic methylene protons diastereotopic 
(two separate doublets at 8 3.12 and 8 4.24) but also every other CHz proton is 
magnetically unique. This implies the molecule does contain at least one chiral centre. 
Finally, four signals in the I3C NMR spectrum at 8 113.8, 8 117.0, 8 124.3, 8 130.2 are 
consistent with the presence of an aromatic ring; that at 8 124.3 bears the hydrogen atom
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that gives rise to the 8 7.12 signal in the lK  NMR spectrum, the others are singlets 
observed in the region expected for a pyrrole ring.
'U
Figure 22: *H NMR of compound 217.
On the basis of these spectroscopic data we assigned the structure of this as product methyl 
l-benzyl-2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-tik]quinoxaline-6-carboxylate, 217. The 
compound was isolated in 31% yield (Scheme 93).
The formation of the unexpected pyrroloquinoxaline 217 can be rationalised rationalized as 
shown in Scheme 94.
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We propose initial formation of dipole 215 and 1,3-dipolar cycloaddition as expected to 
form 216. Eliminative ring-opening of the primary adduct 216 and closure of the liberated 
secondary amine onto the ketone carbonyl group42,97 with loss of water leads to the 
formation of the enamine 218 (or regioisomer). Subsequent prototropic shift leads to the 
aromatic pyrrole substructure and formation of 217.
In order to investigate whether the eliminative process shown in Scheme 94 was base 
catalysed, we performed the reaction under base deficiency conditions (0.7 equiv.). 
However, the same product 217 was nonetheless isolated. Given that acid catalysis was 
also a possible cause for this eliminative process, we repeated this reaction and analysed 
the crude mixture prior to silica gel column chromatography (since silica could provide the 
acidic environment that might catalyse the process). However, ^H NMR analysis of the 
crude mixture shows the presence of the pyrrolo proton signal at 8 7.12 and the absence of
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any signals anticipated for the cycloadduct 216, implying that the eliminative process must 
be structurally inherent in the primary cycloadduct 216.
In these reactions we found that it was essential to heat the solution containing 29 and E- 
196a at reflux for at least 2 h prior to the addition of DBU, presumably to enable the 
intermediate N-alkylated salt 214 (Scheme 93) to form. Addition of DBU before 2 h 
invariably led to the recovery of starting materials 29 and E 196a
As would be expected based on the mechanism of Scheme 94, the same pyrroloquinoxaline 
217 was also isolated (20% yield) when the diastereomeric Z-dipolarophile 196b was used 
in the reaction.
To block the eliminative ring-opening of the primary adduct 216, we envisaged 
incorporation of non-migrating methyl groups at strategic sites in the dipolarophile 
precursor molecules. The first example (Scheme 95), involves positioning a methyl group 
a- to the methoxycarbonyl group such that it would be attached to the C-9 carbon atom in 
216. This is the site from which the hydrogen is lost during initial eliminative ring-opening 
in 216. This strategy necessitates the dipolarophile 220, similar to 196a but possessing a 
methyl substituent on the alkene cc-to the ester group. We reasoned that this should be 
available from Wittig olefination of the previously synthesised 5-oxohexanal 206 (see 
Scheme 90) with an alkyl 2-(triphenylphosphoranylidene)propionate followed by 
regioselective a-bromination as described previously for the preparation of E 196a.
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Thus, our expectation was that dipolarophile 220 would react with 1-benzyl-4,5- 
dihydroimidazole 29 to afford adduct 219 (Scheme 96).
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Scheme 96
Reaction of 5-oxohexanal 206 in anhydrous dichloromethane under nitrogen at RT with 
commercial ethyl 2-(triphenylphosphoranylidene)propionate109 221 gave the Wittig 
product ethyl E-2-methyl-7-oxooct-2-enoate 222 in 32% yield (Scheme 97). Treatment of a 
solution of 222 in anhydrous THF under nitrogen at -78°C with a solution of LDA in 
anhydrous THF, freshly prepared from n-BuIi and diisopropylamine (1.2 equiv.)
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generated the appropriate kinetic enolate anion which was quenched by the addition of 
excess ehlorotrimethylsilane (5'equiv.) in anhydrous THF at -78°C to form the silyl enol 
ether 223. Treatment of the latter in anhydrous THF at -78°C under nitrogen with solid 
NaHCOg (1.4 equiv.) followed by the portionwise addition of NBS (1.3 equiv.) as the 
electrophilic brominating agent and subsequent heating of the solution to 80°C for 2 h 
allowed us to isolate ethyl Zs-8-bromo-2-methyl-7-oxooct-2-enoate 224 in 44% yield 
(Scheme 97).
Me
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THF, -78°C 
LDA, TMSC1
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Having accessed the modified dipolarophile E-224, we were now in position to attempt the 
cycloaddition reaction depicted in Scheme 96, and hopefully block the eliminative ring- 
opening process. In the event, treatment of 1-benzyl-4,5-dihydroimidazole 29 in anhydrous 
THF under nitrogen at reflux with ethyl £-8-bromo-2-methyl-7-oxooct-2-enoate 224 in 
anhydrous THF for 2 h before the dropwise addition of DBU over 4 h, and heating for a 
further 4 h at reflux did not afford the expected adduct 225 (Scheme 98).
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The NMR spectrum of the isolated product (Figure 23) showed the methylene benzylic 
peaks to be diastereotopic, appearing as two doublets integrating to one proton each at 5 
3.43 and 8  3.90; in the starting material 29, these appear as a singlet integrating to two 
protons at 8  4.29. This behaviour is consistent with the creation of a chiral centre in the 
molecule and, indeed, in agreement with the expected 225. However, two crucial pieces of 
evidence in the NMR spectrum indicate that the isolated product was not the expected 
cycloadduct 225. First, the expected doublet at 8  4-4.50 corresponding to the 9a-C/7 
bridgehead proton97 required in 225 was not observed. The second, and most surprising, 
piece of evidence was that both the alkene proton (8  6.70, tq) and the alkene methyl peak 
( 8  1.83, d) from the starting material were intact, therefore implying that the alkene 
functionality plays no part in the formation of this unexpected product. Further, the 
presence of a singlet intregrating to one proton at 8  9.46 in the NMR spectrum, is 
reminiscent of perhaps a formyl type proton (Figure 23). For 225, the only hydrogen 
expected to appear as a singlet would be that at C-9a, which as mentioned previously, we 
would expect to appear at97 8  4-4.50. Another curious feature of the NMR spectrum 
was a triplet integrating to one proton observed at 8  3.28 with a 5Hz coupling constant, i.e.
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characteristic of a 3J  coupling constant to two protons. The 2-D ^H-^H CÔSŸ NMR 
spectrum showed this signal to be coupled to protons in the alkene chain.
Figure 23: NMR of the product obtained from reaction of 29 with £'-224.
The 13C NMR spectrum of the product did not show the presence of a ketone carbon atom 
as expected for 225. Moreover, peaks observed at 5 141.2 and Ô 128.7, corresponding to 
the original dipolarophile alkene carbon atoms, confirmed the evidence observed in the 
NMR spectrum that the alkene functionality plays no part in the reaction. Two signals at Ô
163.3 and ô 65.4 can be observed, which, according to DEPT-90 NMR studies, correspond 
to two CH carbon atoms. The former is consistent with a formyl carbon atom; the latter is 
due either to a CH attached to a heteroatom or, possibly, to an alkene CH such as that 
shown in structure A for which chemical shifts of approximately Ô 55 have been 
reported.110
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AStructure A
Furthermore, a signal at 8  173.3 can also be observed (in addition to the ester at 8  168.1), 
which, according to DEPT-45 NMR studies, corresponds to a quaternary carbon. This 
could be due to the carbonyl carbon of a carboxylic acid derivative, or alternatively, to the 
alkene carbon atom in structure A that carries the two heteroatoms for which chemical 
shifts of approximately 8  165 have been reported.110 Low-resolution mass spectrometric 
analysis showed the molecular ion at m/z 344, corresponding to a twelve Dalton loss from 
the molecular ion expected for 225. Given that the 13C NMR spectrum contains signals that 
account for all the twenty-one carbon atoms in the two starting materials (allowing for two 
aromatic CH signals arising from two pairs of equivalent carbon atoms), this twelve mass 
unit deficit cannot be due to loss of a carbon atom. It more likely comes about by an 
incorporation of a molecule of water {i.e. expected mass 356, plus 18, giving 374) followed 
by loss of a 30 Dalton fragment {e.g. CH2O) to give the M*+ at 344.
At the time of writing we have been unable to assign a definitive structure to this product, 
although several have been considered/ For example, two obvious structures (although
The structure of this compound is described in the addendum on page 235
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neither incorporates a water molecule) are the products from cyclisation of the ylide 226 
(Scheme 99); vzz., 227 and 228 (Scheme 100).
-Ph -Ph -Ph
DBU
THF
226 R = (CH2)2CH==C(Me)C02Me29 £-224 R = (CH2)2CH=C(Me)C02Me
Scheme 99
226 R = (CH2)2CH=C(Me)C02Me
Scheme 100
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Both of these contain chiral centres that would account for the observed diastereotopicity. 
However, the aziridine hydrogen atoms in 227 should both be doublets (not observed) and 
neither would have the observed chemical shift values. Furthermore, the carbonyl carbon 
atom expected between 8  200-210 in 227 is absent from the 13C NMR spectrum. Similarly, 
the orthoformamide proton in 228 would be a singlet and it should resonate at 8  6-7.111 
Further, the alkene CH in 228 is unlikely to resonate at 8  3.30 and the observed 5 Hz 
coupling is too large to be due to a 4J interaction with the adjacent CH2 group.
Another structure that has been considered is 229.
-Ph
229
This would give a close fit to the NMR spectra: there is a formyl proton and its 
corresponding carbonyl carbon; the alkene would give appropriate 13C NMR signals at ca. 
8  60 and 8  170; the alkene proton would be at ca. 8  3.5-4.0 in the ^H NMR spectrum, 110 
and it would exhibit a triplet 3J coupling to the CH2 group adjacent to the double bond. 
However, the lack of a chiral centre means that none of the CH2 protons would be 
diastereotopic, a crucial feature of our isolated product.
Consequently, we decided to probe this reaction in more detail. We anticipated that the 
reaction of 1 -benzyl-4,5-dihydroimidazole 29 with an a-haloketone chain lacking the 
alkene functionality would afford a product with similar but simpler spectroscopic
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characteristics. In addition, by using an a-haloketone such as 2-bromo-4- 
nitroacetophenone 230 (Scheme 101) we hoped that a crystalline adduct would result in 
and hence provide us with a crystallographic analysis to settle the structural question.
-Ph
-NO
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Scheme 101
Thus, 1-benzyl-4,5-dihydroimidazole 29 in anhydrous THF at reflux was treated with 
commercial 2-bromo-4-nitroacetophenone 230 (1.2 equiv.) in anhydrous THF. Heating 
was continued for 2 h before the addition of DBU over a period of 4 h. Heating was 
continued for a further 4 h and the crude residue subjected to appropriate purification by 
silica gel column chromatography. The !H NMR spectrum of the isolated compound is 
shown in Figure 24. Interestingly, for this compound diastereotopicity of the benzylic 
methylene protons is not observed. Thus, it is unlikely that the product contains a chiral 
centre. However, the signal corresponding to these protons appears as two singlets at S 
3.81 and 8  3.84, of almost equal intensity and in all integrating to two protons. This type 
of “signal doubling” was also seen for multiplets at 8  3.06, 8  3.15, 8  3.30 and 8  3.42 
(Figure 24). The total for these signals integrates to four protons and the multiplets at 8
3.06 and 8  3.42 show correlation on the ^H-^H COSY spectrum. Similar correlation is 
observed between multiplets at 8  3.15 and 8  3.30. Two other pairs of singlets are apparent;
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the first at 8  6.48 and 8  6.98, the second at 8  7.90 and 8  8.27. Each integrates to one proton. 
This doubling of signals is strongly suggestive of the presence of a rotamer mixture.
Figure 24: NMR for compound 232.
Not surprisingly, the l3C NMR spectrum also displayed signal doubling. The signals 
observed at 8  159.3 and 8  159.9 were considered to be in the appropriate region for a 
formyl type carbon atom and, in addition, the pairs of signals at 8  108.6/8 1 1 2 .2  and 8  
143/8 147 were considered to belong to the CH and C carbon atoms, respectively, of an 
alkene system. Low-resolution mass spectrometry showed MH*+ at m/z 323, which is 
precisely the mass expected from the formation of an ylide such as 231 (Scheme 102).
On the basis of these data, we identified the product from this reaction as l-benzyl-4- 
formyl-2-(4-nitrophenyl)-1,4,5,6 -tetrahydropyrazine 232, isolated in 87% yield as a 
rotamer mixture (Scheme 102). Unfortunately, the compound is an oil, precluding X-ray 
crystallographic analysis.
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The multiplets observed at 8  3.06 and 8 3.42 in the NMR spectrum can be assigned to 
6 -CH2 and 5 -C//2, respectively, of one rotamer of 232. Similarly, the multiplets observed 
at 8 3,15 and 8 3.30, are assigned to the 6 -CH2 and 5 -CH2, respectively, of the other 
rotamer of 232. Presumably, the syn rotamer would bring about the greatest chemical shift 
difference between the 5 -CH2 and the 6 -CH2 protons, so we suggest the pair of signals at 8
3.06 and 8  3.42 correspond to this rotamer. The singlets at 8  3.81 and 8  3.84 are the 
methylene benzylic protons of each rotamer for 232. The singlets observed at 8  6.48 and 8
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6.98, integrating to one proton in total, are assigned to the 3-Œ/ alkene proton for 232; that 
at 5 6.98 is assigned to the anti rotamer because of the proximity of the adjacent 
deshielding formyl oxygen atom. Indeed, the relative intensities of the signals are 
consistent with this. Thus, the 8 6.98 signal is the smaller of the two alkene signals, and 
this corresponds with the 5 3.15/5 3.30 pair for the ring CH2 protons, which is the smaller 
of the two pairs in this region. Naturally, if the alkene proton in the anti rotamer is 
deshielded, then the ring CH2 protons are not. Finally the singlets at 5 7.90 and 5 8.27, 
integrating in total to one proton, can be assigned to the formyl proton NCJ/O for each 
rotamer of 232. The downfield signal corresponds to the syn rotamer based upon signal 
intensities and this is also consistent with the deshielding effect of the alkene functionality. 
The 13C NMR spectrum is consistent with 232 and its signal assignment followed. The 
signals at 8 159.3 and 8 159.9 are due to the formyl carbon atom NCHO for 232 in each 
rotamer, the signals at 5 108.6 and 5 112.2 to the alkene carbon atom 3-CH for 232 in each 
rotamer and the signals at 8 143 and 8 147 due to the C-2 in each rotamer. In addition, 
high-resolution mass spectrometry showed MH*+ 323.1268 in agreement with the expected 
MH"+ 323.1270 for 232.
We rationalize the formation of 232 through initial formation of the corresponding 
azomethine ylide 231 as shown in Scheme 103. Hydrolysis of this, or its cyclization 
product 233, by adventitious moisture will lead to the formation of ketone 237. However it 
is formed, the secondary amine moiety of 237 attacks the ketone carbonyl group affords 
pyrazine 238, which upon loss of water affords the tetrahydropyrazine 232.
114
Ph -Ph
Ph<
Ar Ar
234231 233
H* transfer
-Ph
Ar
Ar236 237 235
Ar
H+ transfer
OH
232238 Ph'
Scheme 103
Clearly, the reaction involving the aryl-substituted bromomethylketone has taken a 
different pathway to that described for compound 224. Certainly, the product from reaction 
of 224 does not have the features consistent with the general framework of 232. Thus, we 
decided to investigate the reaction of an alkyl-substituted bromomethylketone in which the 
alkyl group contained no functionality. We therefore turned our attention to the reaction of
l-bromoheptan-2-one 239 and 1 -benzyl-4,5-dihydroimidazole 29 (Scheme 104).
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Scheme 104.
We prepared l-bromoheptan-2-one 239 by bromination of commercial heptan-2-one 241
using the a-bromination methodology employed previously. Treatment of heptan-2-one
241 in anhydrous THF at -78°C with a freshly prepared solution of IDA (1.2 equiv.) in
anhydrous THF afforded the enolate which was quenched with excess TMSC1 to afford the
silyl enol ether 242 (Scheme 105). A solution of the latter in anhydrous THF at -78°C was
directly treated with solid NaHCOg (1.4 equiv.) followed by the addition of NBS (1 .3
equiv.) which, after heating at 80°C for 2 hours, afforded l-bromoheptan-2-one 239 in 
41% yield.
ITMS
THF, LDA -78°C
TMSC1
241 242
239
Scheme 105
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Subsequently, 1-benzyl-4,5-dihydroimidazole 29 in refluxing anhydrous THF under 
nitrogen was treated with 1 -bromoheptan-2-one 239 for 2 h before the addition of DBU 
and further heating of the resulting solution for 4 h. Upon work-up we isolated a compound 
that had the lH NMR spectrum shown in Figure 25. Clearly this bears no resemblance to 
the possible structure 240 (see Scheme 104). Indeed, it exhibits all of the features observed 
for the product from the reaction between 29 and £-224 (see Scheme 98). These are: (1) 
the diastereotopicity of the methylene benzylic peaks, observable in the !H NMR spectrum 
as two doublets at 8  3.88 and 8  3.37 each integrating to one proton; the triplet signal at 8  
3.21 integrating to one proton that has a 5 Hz coupling constant; and (3) the singlet at 8  
9.47. Clearly absent in this ^H NMR spectrum are any alkene signals in the region 8  6.0- 
7.0, that would correspond to the 3-CH in 240 or some similar structure.
Figure 25: H^ NMR spectrum for the product isolated from the reaction between 29 
and 239.
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Further congruence between the products from the reactions of 29 with 239 and 29 with 
224 comes from the 13C NMR spectrum. Once again, the spectrum reveals CH carbon 
signals at 5 65.5 and 5 162.3 and a quaternary C atom at 8  173.6. The remainder of the 
signals in the 13C NMR spectrum account for the presence of the benzylic CHz carbon 
atom as well as the signals for the carbon atoms belonging to the dihydroimidazole 29 
and the aliphatic CFfe signals for the carbon atoms of 1 -bromoheptan-2-one 239. Indeed all
13of the carbon atoms in the two starting materials are accounted for by the signals in the C 
NMR spectrum. Low-resolution El mass spectrometry shows a weak signal at m/z 260, 
and, in the Cl (NH3), signals at 261 and 289. As before, we have been unable to 
structurally identify the product obtained in this reaction/ although this result confirms that 
(a) the reaction is typical of bromomethyl alkyl ketones, and (b) the alkene functionality in 
224 plays no part in the reaction.
Next we focused our efforts into synthesising a dipolarophile that contained an 
a p p r o p r ia t e ly  p o s i t io n e d  m e th y l  g r o u p  th a t  w o u ld  b lo c k  th e  p r e s u m e d  p r o to t r o p ic  s h i f t  o f  
the proton in enamine 218. Our expectation was that this should allow access either to 
cycloadducts such as 243 or to a ring-opened and recyclized derivative such as 244. To this 
end we required the bromomethylketone 245 which bears a methyl group 0- to the ester 
functionality (Scheme 106).
t
The structure of this compound is described in the addendum on page 235
-Ph
243
245
244
Phf
Scheme 106
Michael addition of terf-butyl acetoacetate 246 and but-3-en-2-one 247 (1.1 equiv.) at RT, 
catalysed by a mixture of cerium (III) chloride heptahydrate (0.2 equiv.) and sodium iodide 
(0.1 equiv.), afforded terr-butyl 2-acetyl-5-oxohexanoate 248 in 97% yield. 112 Acid 
catalysed ester cleavage-decarboxylation of 2-acetyl-5-oxohexanoate 248 with excess 
trifluoroacetic acid at RT led to 2,6-heptanedione 249 in 98% yield. Wadsworth-Emmons 
olefination of diketone 249 with trimethyl phosphonacetate (1.2 equiv.) in the presence of 
sodium hydride as base (1.2 equiv.) afforded an inseparable 1:1 mixture of methyl E- and 
Z-3-methyl-7-oxooct-2-enoate 250 in 40% yield after 10 h at RT. Regioselective 
bromination of the isomeric mixture 250 proceeded in the usual way. The enolate was 
formed at -78°C using LDA as base, and this was quenched with excess TMSC1 to give the 
respective intermediate silyl enol ether. The latter, upon reaction with solid NaHCOg and
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NBS at -78°C and heating of the resulting solution to 80°C for 2 h, afforded the single 
isolated isomeric methyl £-8-bromo-3-methyl-7-oxooct-2-enoate 245 in 30% yield. 
(Scheme 107). Although isolation of Z-245 was expected we were not able to locate this 
during the purification of the crude mixture.
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Scheme 107
We then investigated whether the 1,3-DC reaction of the dipolarophile 245 with 1-benzyl-
4,5-dihydroimidazole 29 would in fact hinder the prototropic shift proposed for 218. Thus, 
29 in anhydrous THF under nitrogen at reflux was treated with methyl £-8-bromo-3- 
methyl-7-oxooct-2-enoate 245 and the resulting solution heated at reflux for 2 h before the 
dropwise addition of DBU. Further heating of the solution was continued for 4 h followed 
by silica gel column chromatography of the reaction residue. Surprisingly, the major 
isolated material was the dehalogenated derivative of 245, i.e. methyl E-3-methyl-7- 
oxooct-2-enoate 250 in 20% yield (Scheme 108), contaminated with traces of DBU. Given 
the results obtained thus far, it is not clear how this arises.
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We next decided to investigate the possibility of applying the intramolecular cycloaddition 
reaction to systems that involved longer and shorter alkyl chains between the ketone and 
alkene functionalities. This has the potential to allow access to larger and smaller 
carbocyclic derivatives related to the pyrroloquinoxalines 217.
In the case of a longer chain dipolarophile, we had access to a sample of the ethyl ester 251 
of the honeybee “queen substance”.113 Application of the regioselective a-bromination 
methodology employed thus far afforded ethyl £,-10-bromo-9-oxodec-2-enoate 253 in 36% 
yield (Scheme 109).
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With compound 253 to hand we reacted it with 1-benzyl-4,5-dihydroimidazole 29, hoping 
to access tricyclic species such as the primary cycloadduct 254 or the rearranged product 
255 (Scheme 110).
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Thus, dihydroimidazole 29 in anhydrous THF under nitrogen and heated at reflux was 
treated with ethyl E-10-bromo-9-oxodec-2-enoate 253 for 2 h before the dropwise addition 
of DBU over a period of 4 h. Heating was continued for a further 4 h, and after subjection 
of the residue to silica gel column chromatography, a compound was isolated whose ^H 
NMR spectrum is shown is Figure 26. Comparison of this with that in Figure 22 for 217 
reveals that the product is not the pyrrolo compound 255. For example, the unique pyrrolo 
proton at 5 7.12 in compound 217 is not present in Figure 26. However, the ^H NMR 
spectrum is similar to those shown in Figures 23 and 25 that were obtained from the 
products of the reaction of 29 with E-224 and 239, respectively. Thus, the lR  NMR 
spectrum of the product shows evidence of a chiral centre due to the diastereotopicity of 
the benzylic methylene protons, which appear as two doublets at Ô 3.42 and 8 3.94, each 
integrating to one proton. Again, we can observe a one-proton singlet at 8 9.47 that may be 
characteristic of a formyl NCHO signal. Moreover, the triplet signal observed at 8 3.27 
integrating to one proton and with a coupling constant of 5.0 Hz is again present (Figure 
26). Further, the original alkene protons signals of compound 253 are preserved in the 
product as revealed by the proton multiplets (both dt) at 8 5.80 and 8 6.94, respectively. 
Yet again, it is clear that the alkene functionality plays no part in the reaction.
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Figure 26: NMR spectrum of the product isolated from reaction of 29 and 253.
The similarity of the product from this reaction to those of £-224 and 239 is corroborated 
by the 13C NMR spectrum. This exhibits signals at 8 65.5 and 8 162.4 (CH carbon atoms 
according to DEPT studies) and 8 173.5 (quaternary carbon atom according to DEPT 
studies). The remainder of the observed 13C NMR signals was consistent with the carbon 
atoms of both starting materials 29 and 253. The presence of the alkene carbon atoms at 8
121.4 (CH) and 8 149.1 (CH) confirmed that the alkene moiety plays no part in the 
reaction.
Low-resolution El mass spectrometric analysis, indicated a molecular ion at 386 and Cl 
(NH3) MH* at m/z 387. Although we were unable to assign the structure of this product/ it 
is obvious that the cycloaddition that was observed for the shorter chain analogue £  196a
* The structure of this compound is described in the addendum on page 235
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does not occur in this case. Presumably, unfavourable transannular interactions in the 
transition state leading to the larger ring make its formation disfavoured.
Next, the synthesis of a shorter chain oc-haloketone was undertaken. Oxidation of 
commercial 5-hydroxypentan-2-one 256 with pyridinium chlorochromate (PCC) (1.5 
equiv.) afforded, after purification, the desired 4-oxopentanal 257 in rather poor 10% yield. 
Attempts to improve this low yielding step by employing the alternative Swem oxidation 
of 256 failed to produce any improvement, yielding products which that could not relate to 
the expected aldehyde 257 (Scheme 111). However, since starting material 256 was 
available cheaply the low yielding PCC oxidation step was accepted as adequate. Wittig 
olefination of aldehyde 257 using methyl (triphenylphosphoranylidene)acetate (1.2 equiv.) 
afforded, after purification, methyl E-6-oxo-hept-2-enoate 258 in 72% yield. 
Regioselective a-bromination of the latter using the bromination methodology employed 
for all the dipolarophile precursors synthesised thus far, i.e. via the silyl enol ether 259, 
afforded, after purification, methyl E -l-bromo-6-oxohept-2-enoate 260. in 34% yield 
(Scheme 111).
PCCOH COoMe
256 257 258
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Prior to embarking on the synthesis of 260 and its subsequent reaction with .29, we 
constructed a framework molecular model of the expected cycloadduct 261. Examination 
of this revealed that, although eliminative ring-opening to give 262 could still occur, 
closure of the liberated secondary amine onto the ketone carbonyl group and subsequent 
aromatisation to give a pyrrole ring would be disfavoured due to the angle strain that 
would ensue. Consequently, we expected that the two likely products of this reaction 
would be either the dipolar cycloadduct 261 or the ring-opened product 262 (Scheme 112).
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We were surprised to find, however, that after performing the reaction between 29 and 260 
under the standard conditions and subjecting the residue to silica gel column 
chromatography, the major isolated products of the reaction were the unchanged 
dipolarophile 260 in 30% yield (with some impurities) and 1-benzyl-4,5-dihydroimidazole 
29 in 67% yield.
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Thus, we returned to the original successful cycloaddition-rearrangement that led to the 
isolation of methyl l-benzyl-2,3,7,8,9,9a-hexahydro-li/-pyrrolo[l,2,3-tife]quinoxaline-6- 
carboxylate 217 (Scheme 113). We felt that this presented a valuable and novel synthetic 
methodology to access heterotricyclic compounds such as 217 derived from primary 
intramolecular 1,3-DC reaction. We decided to further explore this unexpected result and 
investigate the use of other alkyl esters of the dipolarophile E 196a, as well as the effect of 
substitution at C-2 and C-4 of 1-benzyl-4,5-dihydroimidazole 29 on the outcome of the 
reaction. Since we had already developed an adequate synthetic approach towards the 
synthesis of dipolarophile E 196a, we reacted the latter in anhydrous THF under nitrogen 
and at reflux with l-benzyl-2-phenyl-4,5-dihydroimidazole 263.114 The solution was 
heated for a further 2 h before the dropwise addition of DBU. Further reflux for 4 h 
followed by purification of the residue afforded, as expected, methyl 1 -benzyl-5-phenyl- 
2,3,7,8,9,9a-hexahydro-lH-pyrrolo[l,2,3-ck]quinoxaline-6-carboxylate 264a in 33% yield. 
In similar fashion, reaction of (/?)-l-benzyl-4-phenyl-4,5-dihydroimidazole 11263 with 
dipolarophile E 196a led to methyl (R)-l-benzyl-3-phenyl-2,3,7,8,9,9a-hexahydro-l//- 
pyrrolo[l,2,3-<fe]quinoxaline-6-carboxylate 264b in 30% yield (Scheme 113).
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The structures of both adducts 264a (Figure 27) and 264b (Figure 28) were supported by 
standard spectral data as well as X-ray crystal structure determinations.
Ph,
Figure 27: X-Ray crystal structure of pyrrolo[l,2-de]quinoxaline 264a
This latter technique enabled us to determine that the relative stereochemistry for adduct 
264b is as illustrated in Figure 28, i.e. that the phenyl 3-substituent and the bridgehead 
proton at C-9a are located on the same face of the molecule.
Ph,
Figure 28: X-Ray crystal structure of pyrrolo[l,2-rfe]quinoxaline 264b
From these results, it is possible to conclude that the ylide formed from reaction of a 4,5- 
dihydroimidazole and an a-bromoketone in the presence of base is able to undergo 
intramolecular 1,3-dipolar cycloaddition provided that the carbocyclic ring thus formed is 
six-membered.
We were interested to see if replacing the 4,5-dihydroimidazole ring by an oxazoline 
would produce similar results. Thus, commercial 2-phenyl-2-oxazoline 265 was reacted 
with methyl E-8-bromo-7-oxooct-2-enoate 196a (Scheme 114). However, after subjection 
of the crude residue to silica gel column chromatography the major compounds recovered 
were the dipolarophile 196a in 15% yield (contaminated with DBU traces) and unchanged
2-phenyl-2-oxazoline 265 in 86% yield. The reluctance of oxazolines to undergo N- 
alkylation has been previously reported by other workers perhaps making these results not 
so surprising.115
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Similarly, we were interested to discover if a differently functionalised alkene would 
undergo the 1,3-DC reaction. Thus, we envisaged the use of an a-bromoketone bearing a 
conjugated nitrile functionality that would hopefully allow access to cyano derivatives of 
the pyrroloquinoxalines. Wittig olefination of 5-oxohexanal 206 using 
cyanomethylenetriphenylphosphorane 267 (prepared from chloroacetonitrile and 
triphenylphosphine)106 afforded, after purification, the desired E -l-oxooct-2-enenitrile 268
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in 53% yield. However, regioselective a-bromination of 268 using the usual protocol, le  
via the corresponding silyl enol ether 269 and addition of NaHCOg and NBS did not afford 
the desired £-8-bromo-7-oxooct-2-enenitrile 270. Analysis of the spectral data for the 
isolated compound tentatively indicated bis-bromination of the starting material, i.e. 
bromine substitution at the a-carbon of the conjugated nitrile as well as a-bromination at 
the desired a-position of the ketone had taken place to afford £’-2,8-dibromo-7-oxooct-2- 
enenitrile 271 in 12% (Scheme 115).
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Scheme 115
Thus, the ^H NMR spectrum of the product revealed that the signal (5 5.40, dt) 
corresponding to the alkene proton a- to the nitrile group in 268, was clearly absent. In 
addition, the signal due to the (3-alkene proton (8 6.78, dt) in 268 is a simple triplet
130
integrating to one proton. Both observations support the proposal that bromine substitution 
of double bond a- to the nitrile group has occurred. The 13C NMR spectrum of the product 
accounted for the correct number of carbons expected for 271 and, in addition, further 
supported our structural assignment by showing the absence of the peak corresponding to 
the original a- carbon atom CH=CHCN at Ô 100.4 and the presence of new alkene signal at 
Ô 121.4 corresponding to the new vinylic carbon atom CH=C(Br)CN. Given that 271 
contains an a-bromoketone functionality, we attempted a 1,3-DC reaction between the 
presumed 271 and 1-benzyl-4,5-dihydroimidazole 29. Unfortunately, after purification, the 
expected product 272 was not isolated. Only unchanged starting material 29 was isolated in 
virtually quantitative yield (Scheme 116).
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Further examples of the dipolar cycloaddition-ring opening-recyclization cascade were 
observed. The ethyl ester variant ethyl E-8-bromo-7-oxooct-2-enoate 273 was synthesised 
from 5-oxohexanal 206 in a similar fashion to methyl 2s-8-bromo-7-oxooct-2-enoate 196a 
(see Scheme 92) but employing ethyl (triphenylphosphoranylidene)acetate 274 (freshly 
prepared from ethyl bromoacetate and triphenylphosphine)106 in the Wittig olefination step, 
Regioselective bromination of 275 via the silyl enol ether 276 afforded the ethyl ester 273 
in 41% yield (Scheme 117).
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Scheme 117
Treatment of 1-benzyl-4,5-dihydroimidazole 29 with ethyl 2s-8-bromo-7-oxooct-2-enoate 
273 in anhydrous THF at reflux and under nitrogen, followed by addition of DBU as usual 
afforded, after purification, ethyl 1-benzyl-2,3,7,8,9,9a-hexahydro-lH-pyrrolo[l,2,3- 
de]quinoxaline-6-carboxylate 277a in 30% yield. In similar fashion, the reaction of 1- 
benzyl-2-phenyl-4,5-dihydroimidazole 263 with ethyl 2s-8-bromo-7-oxooct-2-enoate 273 
afforded ethyl l-benzyl-5-phenyl-2,3,7,8,9,9a-hexahydro-lH-pyrrolo[l,2,3- 
tik]quinoxaline-6-carboxylate 277b in 31% yield, and the reaction of (/?)-l-benzyl-4- 
phenyl-4,5-dihydroimidazole 112 with 273 afforded ethyl (R)-1 -benzyl-3-phenyl- 
2,3,7,8,9,9a-hexahydro-lH-pyrrolo[l,2,3-<fe]quinoxaline-6-carboxylate 277c in 30% yield 
(Scheme 118).
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Scheme 118
The third ester variant, terf-butyl E-8-bromo-7-oxooct-2-enoate 278, was synthesised using 
the same synthetic methodology described for the synthesis of all the other dipolarophiles. 
Thus, Wittig olefination of 5-oxohexanal 206 with ferf-butyl 
(triphenylphosphoranylidene)acetate 279 (freshly prepared from terf-butyl acetate and 
triphenylphosphine)106 afforded, after purification, rerr-butyl E -l-oxooct-2-enoate 280 in 
58% yield. Regioselective a-bromination proceeded as usual through initial enolate 
generation and TMSC1 quenching to afford the silyl enol ether 281. Treatment of the latter 
with solid NaHCOg (1.4 equiv.) at -78°C and portionwise addition of NBS (1.3 equiv.) 
followed by heating afforded terf-butyl £-8-bromo-7-oxooct-2-enoate 278 in 40% yield 
(Scheme 119).
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We then reacted the terf-butyl ester dipolarophile 278 with 1-benzyl-4,5-dihydroimidazole 
29 under the standard cycloaddition conditions to afford, after purification, terf-butyl 1-
t
benzyl-2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-<ie]quinoxaline-6-carboxylate 282a in 
33% yield (Scheme 120). Likewise, changing the dihydroimidazole to l-benzyl-2-phenyl-
4,5-dihydroimidazole 263 afforded tezt-butyl l-benzyl-5-phenyl-2,3,7,8,9,9a-hexahydro- 
l//-pyrrolo[l,2,3-de]quinoxaline-6-carboxylate 282b in 34% yield. The success of the 
latter reaction demonstrated the robustness of this dipolar cycloaddition-ring opening- 
recyclization reaction since the introduction of bulky substituents at both dipole and 
dipolarophile is tolerated.
Of greater significance, when the procedure was applied to (/?)-4-phenyldihydroimidazole 
112 and the tezt-butyl ester dipolarophile 278, for the first time a primary cycloadduct tert- 
butyl (3/?,4aÆ,8aS,9S,9aÆ)-1 -benzyl-5-oxo-3-phenyldecahydro- l//-imidazo[ 1,2-a]indole- 
9-carboxylate 283 was isolated (Scheme 120) in 31% yield.
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Indeed, analysis of both and 13C NMR spectra of 283 did not reveal the usual features 
of the pyrroloquinoxalines obtained thus far: the characteristic 5-CH pyrrolo proton for 
compounds such as 282a at 6  7.12 was clearly absent, as was its corresponding carbon at Ô 
124.3. In addition, the 9a-C/f proton at 5 3.28 (also a common feature in the 
pyroloquinoxaline systems thus far obtained) was not observed. Furthermore, the 
remaining signals for the quaternary carbons of the pyrrole ring in, say 282a, i.e. 5 113, 5  
117 and 5 130 were also absent. The NMR spectrum of 283 (Figure 29) exhibited the 
expected main features for such a structure, namely: (1) the diastereotopicity of the 
methylene benzylic peaks at 5 3.22 and 8  4.11, suggesting the presence of at least one 
chiral centre; (2) the expected doublet signals97 integrating to one proton at 8  3.62 and 8
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4.58 corresponding to 4a-C# and 9a-C//; (3) the signal at Ô 2.83 integrating to one proton 
and corresponding to 9-CH in 283 is a triplet due to identically sized coupling to both 9a- 
CH and 8 a-C//. Similarly, in the 13C NMR spectrum the crucial carbonyl carbon atom 
corresponding to C-5 in 283 is present at 8  210.3.
Figure 29: !H NMR spectrum of 283.
An X-ray crystal structure (Figure 30) confirmed the structure and relative stereochemistry 
of the cycloadduct 283.
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Figure 30: X-Ray crystal structure of cycloadduct 283.
The stereochemistry of the adduct can be accounted for by the cycloaddition involving an 
fl/m-dipole adding to a dipolarophile via the face anti to the 4-phenyl substituent in an 
endo-fashion, as previous researchers in our group have consistently observed with 
dihydroimidazolium ylides (Figure 30).42,85,97 The isolation of 283 supports the suggested 
sequence for pyrroloquinoxaline 217 formation described in Scheme 94. It appears that the 
combination of these two particular substitutents at the dipole (/?-phenyl group) and 
dipolarophile (terf-butyl ester) disfavours the eliminative ring-opening process, perhaps for 
steric reasons.
Figure 31: Transition state for intramolecular 1,3-DC reaction of 112 with £-278.
P H
CH2Ph
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Summary
Throughout this discussion we have demonstrated that introduction of heteroatom 
substituent at the C-2 position of 1-benzyl-4,5-dihydroimidazole 29, followed by N- 
alkylation of the so-formed heterocycle to form novel azomethine ylides, is, according to 
our studies, synthetically non-viable thus rendering the application of intermolecular 1,3- 
DC chemistry to these systems not worth exploiting.
However, 4,5-dihydroimidazoles 29, (R)-1YI and 263 undergo N-alkylation and 
intramolecular 1,3 DC cascade reactions with a variety of uncaturated a  bromoketoncs as 
dipolarophiles. When both the dihydroimidazole and the dipolarophile contain bulky 
substituents ((/?)-! 12 and £-278), the primary imidazo[l ,2-<z]indole cycloadduct 283 is 
formed. However, in most cases, the initially formed cycloadduct undergoes subsequent 
eliminative ring-opening, recyclization and tautomerism to form the rarely reported 
hexahydropyrrolo[ 1,2,3-de]quinoxaline ring system.116,117 Previous syntheses have 
invariably involved annulation of a preformed bicycle (quinoxaline or indole), as 
examplified in Scheme 121 for the synthesis of tricycle 284,116f rendering the 
intramolecular 1,3-DC approach described herein as a novel approach to this system.
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In addition, these previous reports do not include the hexahydro oxidation level with a 
pyrrole sub-unit that is afforded by the work described in this thesis.
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2.3 Future Work
The methodology developed by previous researchers in our group towards template 
removal86 should be applicable to our novel terf-butyl l-benzyl-5-oxo-3-phenyldecahydro- 
l/f-imidazo[l,2-a]indole-9-carboxylate 283. Aminal cleavage of 283 by sodium 
cyanoborohydride would afford the N-substituted indole derivative 285. Débenzylation of 
285 by catalytic hydrogenolysis would then furnish the optically active perhydro-indole 
derivative 286 (Scheme 122).
-Ph •Ph
-NH
p r
285283
286
Scheme 122
A more challenging, yet perhaps more interesting, transformation would be the reduction 
of the carbonyl moiety of 286 to afford 287, followed by coupling with the amino acid 288 
to afford 289 (Scheme 123).
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Hydrolysis of the indole terf-butyl ester 289 to the corresponding acid 290 would then set 
up another potential amino-acid coupling between 290 and the suitably protected amino- 
acid tether 291 (Scheme 124) to afford, after de-protection, the product 292, which would 
constitute an important step en route to Aeruginosin 98-C (Figure 21) analogues.
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Chapter 3 
Experimental
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3.0 Experimental
Proton VH) and carbon (13C) NMR spectra were recorded in CDCI3 using either a JEOL 
EX400 (400MHz and 100MHz, respectively) or a JEOL LA300 spectrometer (300MHz 
and 75MHz, respectively). Chemical shifts are reported in parts per million (ppm) from 
tetramethylsilane (TMS) as the internal standard. Multiplicities are: s-singlet, d-doublet, t- 
triplet, q-quartet, quin-quintet, sext-sextet, m-multiplet, br-broad signal. Coupling 
constants (J) are expressed in Hz. Infrared spectra were recorded using a Perkin-Elmer 
1710 Fourier Transform Infrared spectrophotometer. Low resolution mass spectra were 
recorded using a VG Micromass VG-250 mass spectrometer by electron impact (El), 
chemical ionisation (Cl) or fast atom bombardment (FAB) methods, the latter employing a 
thioglycerol matrix in both positive and negative ion modes. Accurate mass measurements 
were performed by the EPSRC National Mass Spectrometry Service (University of Wales, 
Swansea). Elemental analyses were performed by MEDAC Ltd, Brunei Science Centre, 
Surrey, TW20 OJZ, UK. X-Ray crystallography was performed by the EPSRC X-Ray 
Crystallographic Service (University of Southampton). Optical rotations were measured on 
a JASCO DIP-1000 digital polarimeter. Melting points were measured on a Kofler hot- 
stage apparatus and are uncorrected. Column chromatography was carried out using Fluka 
Silica Gel 60 (220-440mesh) (Brockmann 2-3). TLC analysis was carried out using 
Machery-Nagel Polygram SEL G/UV254 plates on a plastic backing and visualised by 
ultraviolet light or aqueous potassium permanganate spray (KMnO^K^CO^water, 6:1:100, 
w/w/v).
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All chemicals were purified by distillation or recrystallisation where appropriate. THF, 
THF, diethyl ether, toluene, ethanol and glyme were dried over sodium or potassium and 
distilled. DCM and DMSO were dried over sodium or calcium hydride and distilled. 
Anhydrous reactions were carried out using flamed dried glassware with all transfers 
performed using oven-dried syringes and needles.
3.1 Intermolecular approach experimental
N-Benzyl-l^-diaminoethane118
H2N\ ^ n h 2 -----------------
£ H
125 126
Benzyl chloride (22.89 g; 179.0 mmol) was added dropwise to cooled (0-5°C), 
stirred 1, 2-diaminoethane (53.94 g; 897.0 mmol) and the resulting solution was heated at 
reflux for 8  h. After being allowed to cool to room temperature (RT) the solution was then 
extracted with ether (2 x 10 ml). The organic phase was dried (MgSCU) and evaporated 
under reduced pressure. The residue was fractionally distilled under vacuum to afford the 
title compound as a colourless oil (26.85 g; 62 %): bp 84-86° C / 0.12 mmHg ( lit . ,118 6 8 - 
75°C / 0.07 mmHg); Ôh (400MHz) 1.38 (s, 3H, NH2 and NH), 2.68 (m, 2H, 
NHCH2CH2N), 2.82 (m, 2H, NHCH2CH2N), 3.37 (s, 2H, CH2Ph), 7.20 (m, 5H, Ar-H); Sc 
(100MHz) 41.7 (CH2Ph), 51.9 (NH2CH2CH2NH), 53.8 (NH2CH2CH2NH), 126.8, 128.1, 
128.3 (3 x Ar-CH), 140.4 (Ar-Q.
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1 -Benzyl-4,5-dihydroimidazole42
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N-Benzyl-1 ,2-diaminoethane (8.00 g; 5.3 mmol), triethyl orthoformate (31.60 g; 
2 1 0 .0  mmol) and p-toluenesulphonic acid (0.18 g; 1 .0  mmol) were heated together at 
reflux for 23 h. After cooling the mixture to RT, aqueous sodium hydroxide (5 % w / v; 50 
ml) was added and the mixture was extracted with chloroform (2 x 100 ml). The organic 
phase was dried (MgS04) and evaporated under reduced pressure. The residue was 
fractionally distilled under vacuum to afford the title compound as a colourless amorphous 
solid (8.48 g; 51 %): b.p. 112-116°C / 0.15 mmHg (lit. ,42 120°C / 2.0 mmHg); 6 »
According to the literature procedure,87 to 1-benzyl-4,5-dihydroimidazole (1.00 g;
(400MHz), 3.15 (t, 2H, / =  9.9, NCH2CH2N), 3.83 (t, 2 H, /  = 9 .9 , NCH2Ctf2N), 4.29 (s,
2H, Ctf2Ph), 7.04 (s, 1H, N=CHN), 7.34 (m, 5H, Ar-H); ôc (100 MHz) 48.1 (CH2Ph), 51.7
(NCH2CH2N), 54.7 (NCH2CH2N), 127.6, 127.8, 128.7 (3 x Ar CH), 136.7 (Ar-Q, 157.5 
(N=CH-N).
l-BenzyI-2-phenylthio-4,5-dihydroimidazole87
29 127a
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6.25 mmol) in dry tetrahydrofiiran (THF) (62.5 ml) stirred at -78°C, under an atmosphere 
of nitrogen, was added n-butyl-lithium (2.50 M in hexanes ; 2.5 ml; 7.5 mmol). After 20 
min diphenyldisulphide (1.50g; 6.87 mmol) in dry THF (5 ml) was added dropwise and the 
mixture maintained at -78°C for 2 h. The liquor was allowed to warm to RT and stirred for 
a further 20 min. The reaction was quenched by the addition of H2O (2 ml). The organic 
phase was extracted with ether (2 x 50 ml), dried (MgS04) and concentrated under reduced 
pressure. The residue was purified by silica gel column chromatography using 
isopropylamine / chloroform (1 : 99 v/v) as eluant to afford the title compound as a yellow 
gum (0.60 g; 36 %): (film) / cm"1 3063, 2957, 2871, 1568, 1189, 1079, 788 and 700;
5h (400MHz) 3.21 (t, 2 H, J  = 6.4, NCH2CH2N), 3.68 (t, 2H,7 = 6.4, NCH2CH2N), 4.32 (s, 
2H, C #2Ph), 7.26 (m, 10H, Ar-fl); 5c (100MHz) 50.8 (CH2PI1) 51.7 (NCH2Œ 2N), 53.6 
(NCH2CH2N), 127.2, 127.4,127.8,128.7,128.8, 129.2 (6  x Ar-CH), 137.2 and 134.4 (Ar- 
Q , 163.92 (C-SPh); m/z (El) 268 (M*+, 48 %).
l-Benzyl-2-butylthio-4,5-dihydroimidazole
-Ph -Ph
IBu
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To 1 -benzyl-4,5-dihydroimidazole (0.62 g; 3.87 mmol) in dry THF (38 ml) stirred 
at -78°C under an atmosphere of nitrogen, was added n-butyllithium (2.50 M in hexanes; 
1.55 ml; 4.60 mmol). After 20 min dibutyldisulphide (0.76 g; 4.20 mmol) in dry THF (5
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ml) was added dropwise and the mixture maintained at -78°C for 2 h. The liquor was 
allowed to warm up to RT and stirred for a further 20 min. The reaction was quenched by 
the addition of H2O (2 ml). The organic phase was extracted with ether (2 x 50 ml), dried 
(MgSOj) and concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography using isopropylamine / chloroform (1 : 99 v/v) as eluant to afford 
the title compound as a yellow gum (0.20 g; 21 %): Vmax (film) / cm'1 3063, 2957, 2871, 
1568, 1189, 1079, 788; Ôh (400MHz) 0.97 (t, 3H, 7=7.0, SfCHzbC#;) 148 (sext, 2H, /  = 
7.0, SCH2CH2C7/2CH3), 1.70 (quin, 2H, J  = 7.0, SCHzCTfzCHzCHg), 3.14 (t, 2H, J  = 6 .2 , 
NCH2Œ 2N), 3.23 (t, 2H, J  = 6.2, NC//2CH2N), 3.78 (t, 2H, J = 7.0, SC//2CH2CH2CH3), 
4.29 (s, 2 H, C//2Ph), 7.28 (m, 5H, Ar-#); ôc (100MHz) 13.5 (CH3) 2 2 .2  (SCH2CH2CH2), 
30.9 (SCH2CH2CH2), 31.5 (S Œ 2CH2CH2), 50.8 (CH2Ph), 51.1 (NCH2CH2N), 53.2 
(NCH2CH2N), 127.6, 127.9, 128.4 (3 x Ar-CH), 137.3 (Ar-Q, 164.9 (NC-S); m/z (El) 248 
(NT, 8 %), 215 (14%), 2 0 1  (9%), 192 (1 0 0 %), 178 (6 %), 159 (2 0 %), 91 (76%), 89 (9%), 
65 (13%), 57 (17%), 44 (31%).
l-Benzyltetrahydroimidazol-2-one
JPh
JlH 
1^ n h 2 
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To a solution of N-benzyl-1,2-diaminoethane (5.00 g; 33.0 mmol) in dry THF (200
148
ml) under nitrogen was added a solution of l.V-carbonyldiimidazole (6.48 g; 39.6 mmol) 
in dry THF (25 ml). The resulting solution was stirred at RT for 18 h. The solvent was 
removed under reduced pressure and the mixture was washed with dilute hydrochloric acid 
(2 M; 50 ml) and extracted with dichloromethane (2 x 50 ml), The combined organic 
phases were dried (MgSO^O and the solvent removed under reduced pressure to afford the 
title compound as a white crystalline solid (5.79 g; 99%): m.p. 124-127°C (lit. , 119 127°C); 
Vmax. (nujol) / cm"1 1601, 1496, 1467, 1301 and 1116; 0H (400MHz) 3.38 (m, 2H,
(100MHz) 38.2 (CH2Ph) 44.5 (N Œ 2CH2N), 47.7 (NCH2CH2N), 127.5, 128.1, 128.6 (3 x 
Ar-CH) 136.9 (Ar-Q, 162.8 (NC=0); m/z (El) 176 (NT, 100%), 161 (2%), 147 (35%),
To a solution of N-benzyl-1,2-diaminoethane (0.50 g; 3.30 mmol) in dry THF (33 
ml) under nitrogen was added a solution of 1,T-thiocarbonyldiimidazole (0.71 g; 3.96 
mmol) in dry THF (5 ml). The resulting solution was stirred at RT for 18 h. The solvent 
was removed under reduced pressure and the mixture washed with dilute hydrochloric acid
HNCH2Œ 2N) 3.42 (m, 2H, HNCH2CH2N), 4.40 (s, 2H, Ctf2Ph), 7.29 (m, 5H, Ar-Q; ôc
132 (7%), 104 (43%), 99 (28%), 91 (91%), 85 (27%), 77(9%), 65 (21%), 56 (8 %); (Found:
(El): M*+ 176.0941; C10H12N2O requires M*+ 176.0949).
l-Benzyltetrahydroimidazol-2-thione
126 130b
H
131
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(2 M; 50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organic 
phases were dried (MgSO^ and the solvent removed under reduced pressure to afford the 
title compound as a white crystalline solid (0.60 g; 94%): m.p. 181-182°C (lit. , 120 177-
NC%C#2NH) 4.84 (s, 2H, Ctf2Ph), 7.38 (m, 5H, Ar-#); 6 c (100MHz) 41.3 (CH2Ph) 48.0 
(NCH2CH2N), 51.0 (NCH2CH2N), 127.8, 128.2, 128.7 (3 x Ar-CH), 135.1 (Ar-Q, 183.2
77 (13%), 6 8  (37%), 65 (32%), 56 (12%); (Found: (FAB): M"+ 192.0711; CioHi2N2S 
requires Me+ 192.0721).
l-Benzyl-2-methylthio-4,5-dihydroimidazole iodide
Methyl iodide (32.0 ml; 50.0 mmol) was added to l-benzyltetrahydroimidazol-2- 
thione (2.03 g; 10 mmol) and the mixture was heated at reflux for 16 h under nitrogen. 
After allowing the mixture to cool to RT the excess Mel was removed under reduced 
pressure, the residue evaporated twice from dry methanol (2  x 1 0  ml) to afford the 
imidazolium salt as a yellow solid (1.89 g, 87%): m.p. 102-105oC; Ôh (400MHz) 2.68 (s,
182°C); Vmax. (nujol) / cm 1 3401, 2924, 1556, 1377, and 722; 5n (400MHz) 3.60 (s, 4H,
(NC=S); m/z (El) 192 (M"+, 55%), 176 (2%), 131 (10%), 104 (20%), 91 (100%), 89 (7%),
H I 
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3H, SC#,), 4.04 (t, 2H, /  = 9.2, NC#2CH2N), 4.10 (t, 211, J  = 9.2, NCH2C#2N), 4.60 (s,
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2H, C #2Ph), 7.33 (m, 5H, Ar-#); Sc (100MHz) 16.2 (SCH3), 51.9 (CH2Ph), 53.3 
(NCH2CH2N), 53.8 (NCH2CH2N), 127.6, 128.3, 128.7 (3 x Ar-CH), 137.4 (Ar-Q, 164.1 
(NC-S). A solution of the salt (1.88 g; 5.6 mmol) in dichloromethane (50 ml) was treated 
with excess K2C03 (7.7 g) and the resulting solution stirred at RT for 1 h The solution was 
filtered, extracted with dichloromethane (2 x 50 ml) and the combined organic phases dried 
(MgSC>4). The solvent was removed under reduced pressure to afford the title compound as 
a yellow solid (1.61; 8 6 %); m.p. 95-98°C; i w  (nujol) / cm"1 3128, 1587,1563, 1497,738 
and 723; 6 » (400MHz) 2.68 (s, 3H, SCI/,), 3.83 (t. 2H, J  = 9.2, NC^CHzN), 3.98 (t, 2H, J  
= 9.2, NCH2C//2N), 4.37 (s, 2H, C%Ph), 7.28 (m, 5H, Ar-fl); 5c (100MHz) 14.6 (SCH,), 
50.89 (CHaPh), 51.28 (NCH2CH2N), 51.42 (NCH2CH2N), 127.8, 128.2, 128.8 (3 x Ar- 
CH), 136.2 (Ar-Q, 163.8 (NC-S); m/z (El) 206 (M*+, 10%), 191 (17%), 116 (5%), 91 
(34%), 28 (100%); (Found: (FAB): M*+ 206.0875; C n H ^ S  requires N T  206.0877).
l-Benzyl-2-ethoxy-4^-dihydroimidazole
r
-Ph
r
-Ph
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A freshly prepared solution of NaOEt (0.38 g; 5.7 mmol) in EtOH (20 ml) was 
added to l-benzyl-2-methylthio-4,5-dihydroimidazolium iodide (0.46 g; 2.3 mmol) and the 
resulting solution heated at reflux for 24 h. Water (10 ml) was added to the solution and the
latter extracted with dichloromethane (2 x 50 ml). The combined organic phases were dried 
(MgSO*), filtered and evaporated under reduced pressure to afford the title compound as a 
white solid (0.30 g; 6 6 %): m.p. 162-165°C; 8 H (400MHz) 1.20 (t, 3H, J  = 5.2, OCH2C//3) 
3.15 (t, 2H, /  = 6 .6 , NCIfeCffzN), 3.32 (t, 2H, J  = 6 .6 , NC//2CII2N), 4.14 (s, 2H, C//2Ph), 
4.19 (q, 2H, J  = 5.2, OCI/2CH3), 7.14 (m, 5H, Ar-fl); 8c (100MHz) 14.62 (OCH2CH3), 
38.02 (CH2Ph), 48.32 (NCH2CH2N), 49.75 (NCH2CH2N), 65.11 (OCH2CH3), 127.3,
128.1, 128.6 (3 x Ar-CH), 137.6 (Ar-Q, 164.0 (NC-OEt); m/z (El) 204 (M*\ 18%), 176 
(71%), 159 (4%). 91 (100%), 77 (5%), 85 (24%), 65 (19%), 56 (11%); (Found: (FAB): M*+ 
204.1264; C u K ^ O  requires M*+ 204.1262).
l-Benzyl-2-(pyrrolidin-lyl)-4,5-dihydro-2-imidazole
!  Ph y—-Ph
SMe ----------------------- ► r M
N + N v '
H
I
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A solution of l-benzyl-2-methylthio-4,5-dihydroimidazolium iodide (0.42 g; 2.0 
mmol) in dry THF (20 ml) was taken to reflux. At that point pyrrolidine (0.20 ml; 2.0 
mmol) was added to the refluxing solution and the heating continued for 20 h. The solution 
was then allowed to cool to RT, washed with 0.1 M NaOH solution (2 x 10 ml) and 
extracted with diethyl ether (2 x 50 ml). The combined organic layers were washed with 
HgO and extracted with diethyl ether (2 x 50 ml). The final organic layer was dried
152
(MgSCU), filtered and evaporated under reduced pressure. The residue was purified by 
silica gel column chromatography using isopropylamine / chloroform (1 : 99 v/v) as eluant 
to afford the title compound as a yellow liquid (0.22 g; 47%): Vma* (film) / cm'1 2984,1487, 
1226; ôh (400MHz) 1.89 (m, 4H, NCH2C//2CH2CH2N), 3.40 (m, 2 H, NCH2Œ 2N), 3.42 
(m, 4H, NC//2CH2CH2Œ 2N), 3.72 (t, 2H, J  = 6 .8 , NC//2CH2N), 4.34 (s, 2H, Ctf2Ph), 
7.28 (m, 5H, Ar-//); ôc (100MHz) 25.5 (NCH2CH2CH2CH2N), 49.4
(NCH2CH2CH2CH2N), 50.6 (PhCH2), 52.9 (NCH2CH2N), 54.2 (N Œ 2CH2N), 126.9,
127.1, 128.6 (3 x Ar-CH), 138.5 (Ar-Q, 164.6 (NC-N); m/z (El) 229 (IVT, 54%), 200 
(41%), 186 (36%), 159 (61%), 138 (22%), 125 (37%), 110 (23%), 91 (100%), 82 (36%), 
70 (53%), 65 (30%), 55 (55%), 41 (28%), 28 (37%); (Found: (El): Me+ 229.1566; 
C14H19N3 requires M*+ 229.1578).
l-Benzyl-2-ethylamino-4,5-dihydroimidazole
A solution of ethylamine in THF (2M; 1.57 ml, 3.15 mmol) was added to a 
refluxing solution of l-benzyl-2-methylthio-4,5-dihydroimidazolium iodide (0.45 g, 2.1 
mmol) in dry THF (20 ml) and the resulting solution was left at reflux for a further 20 h. 
The residue was washed with dilute NaOH solution (0.1 M; 50 ml) and extracted with 
diethyl ether (2 x 50 ml). The organic phase was dried (MgSO,*), filtered and the remaining
-Ph
H
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solvent evaporated under reduced pressure. The residue was then purified by silica gel 
column chromatography using isopropylamine / chloroform (1 : 99 v/v) as eluant to yield 
the title compound as a yellow gum (0.40 g, 75%): Vmax (film) / cm'1 3320, 2980, 1440, 
1265; 5h (400MHz) 1.40 (t, 3H, J  = 5.7, NHCH2CH3), 3.62 (m, 4H, NCH2Œ 2N and 
NHCH2CH3), 3.76 (t, 2 H, J  = 6.9, NHC//2CH2N), 4.79 (s, 2H, C # 2Ph), 7.38 (m, 5H, Ar- 
H)\ ôc (100MHz) 15.02 (NHCH2CH3) 39.27 (NHCH2CH3), 47.42 (NCH2CH2N), 49.83 
(NCH2Œ 2N), 128.3, 128.6, 129.1 (3 x Ar-CH), 133.5 (Ar-Q, 157.5 (NCNH); (Found: 
(El) MH+ 204.1425; Ci2Hi7N3 requires MH+ 204.1422).
Methyl(l-benzyl-2-methoxycarbonylmethylthio)-4,5-dihydroimidazole
/ P h  ,— Ph
/ N  y — C02Me
C/"— •
H
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To a solution of 1 -benzyltetrahydroimidazol-2-thione (0.30 g; 1.56 mmol) in dry 
THF (25 ml) under nitrogen was added methyl bromoacetate (0.13 ml; 1.87 mmol). The 
resulting solution was heated at reflux for 18 h and then allowed to cool to RT. The solvent 
was evaporated under reduced pressure and the residue purified by silica gel column 
chromatography using ethyl acetate / hexane (45 : 55 v/v) as eluant to afford the title 
compound as a white solid (0.36 g; 87%): m.p. 111-112°C; Vmax (nujol) / cm"1 2952, 2865, 
1740, 1410, 1264; 8 h (300MHz) 3.74 (s, 3H, C 02Ctf3), 3.81 (m, 2H, NCH2CH2N), 3.94
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(m, 2H, NCH2C//2N), 4.59 (s, 2H, SCJ/2CO2CH3), 4.70 (s, 2H, Cff2Ph), 7.32 (m, 5H, Ar- 
fl); 5c (75MHz) 35.6 (CH2Ph), 44.0 (C02CH3), 49.6 (S Œ 2C 0 2CH3), 51.3 (NCH2CH2N),
53.6 (NCH2CH2N), 128.0, 128.8, 129.3 (3 x Ar-CH), 132.3 (Ar-Q, 168.4 (C02CH3); m/z 
(H) 265 (M H\ 44%), 192 (100%), 159 (10%), 104 (18%), 91 (50%); (Found: (El) MH* 
265.1014; C]3Hi«N20 2S requires MH* 265.1010).
Attempted synthesis of l-benzyl-2-methylsulfonyI-4,5-dihydroimidazole
■Ph
SMe
136 142
To a solution of Oxone® (3.12 g; 5.07 mmol) in water (25 ml) was added dropwise 
a solution of l-benzyl-2-methylthio-4,5-dihydroimidazole 136 (0.30 g; 1.45 mmol) in 
acetonitrile (10 ml). The resulting solution turned dark after the addition and allowed to stir 
at RT for 16h. The solvent was evaporated under reduced pressure, the residue extracted 
with dichloromethane (3 x 30 ml), dried over MgS0 4 , filtered and the solvent removed 
under reduced pressure. Purification of the residue by silica gel column chromatography 
using isopropylamine / chloroform (1 : 99 v/v) as eluant afforded none of the title 
compound.
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l-BenzyI-3-methoxycarbonylmethyltetrahydroimidazol-2-one
, Ph ! — Ph
XT
V
r
O
X .
N
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To a solution of 1 -benzyl-4,5-dihydroimidazol-2-one (1.03 g; 5.85 mmol) in dry 
THF (25 ml) under nitrogen at -78°C was added dropwise a solution of sec-BuLi (2.5M in 
hexanes; 7.02 mmol). The mixture was left at -78°C for 10 min and methyl bromoacetate 
(5.40 ml; 7.02 mmol) was then added dropwise. The mixture was heated at reflux for 24 h 
and then allowed to cool to RT. The solvent was removed under reduced pressure and the 
residue purified by silica gel column chromatography using ethyl acetate / hexane (4 : 6 
v/v) as eluant to afford the title compound as colourless oil (0.60 g; 41%): Vmax (film) / cm'1 
2952, 2872, 1748, 1700, 1400, 1495, 1449, 1361, 1264, 1214, 986, 937, 760, 703; Sr 
(300MHz) 3.25 (t, 2H, J  = 10.6, NCH2CH2N), 3.44 (t, 2H, J  = 10.6, NCH2CH2N), 3.75 (s, 
3H, CO2C//3), 4.03 (s, 2H, CH2CO2CH3), 4.40 (s, 2H, Ctf2Ph), 7.33 (m, 5H, Ar-#); 5c 
(75MHz) 42.0 (CH2Ph), 43.0 (CO2CH3), 45.6 (CH2CO2CH3), 48.2 (NCH2CH2N), 52.0 
(NCH2CH2N), 127.4, 128.1, 128.6 (3 x Ar-CH), 137.0 (Ar-Q, 163.0 (NC=0), 170.1 
(CO2CH3); m/z (El) 248 (M"+, 1 2 %), 189 (22%), 175 (5%), 92 (8 %), 91 (100%), 65 (9%), 
42 (9%); (Found: (El): IVT 248.1157; C13H16N2O3 requires Me+ 248.1161).
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l-Benzyl-3-methoxycarbonyImethyltetrahydroimidazol-2-thione
-Ph
143a
-Ph
143b
To a solution of the l-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-one 
(0.20 g; 0.75 mmol) in dry ozt/zo-xylene (30 ml) was added portion wise Lawesson’s 
Reagent ([2,4-bis(4-methoxyphenyl)]-l,3-dithia-2,4-diphosphetane-2,4-disulfide) (0.30 g; 
0.75 mmol). The mixture was taken to reflux for 26 h after which time it was allowed to 
cool to RT. The solvent was removed under reduced pressure and the residue purified by 
silica gel column chromatography using ethyl acetate / hexane (4 : 6  v/v) as eluant to yield 
the title compound as yellow gum (0.14 g; 6 6 %): Vmax (film) / cm"1 2950, 2874,1742,1404, 
1497, 1449, 1266, 1 2 1 1 , 983, 762; SH (300MHz) 3.45 (t, 2H, /  = 10.7, NCi^CHzN), 3.64 
(t, 2H, J  = 10.7, NCH2CZ/2N), 3.77 (s, 3H, CO2C//3), 4.44 (s, 2 H, Œ2CO2CH3), 4.91 (s, 
2H, CtfzPh); 8 c (75MHz) 45.6 (CH2Ph), 46.4 (CO2C//3), 48.8 (CH2CO2CH3), 51.8 
(NŒ2CH2N), 52.2 (NCH2Œ2N), 127.7, 128.1, 128.7 (3 x  Ar-CH), 138.2 (Ar-Q, 170.0 
(CO2CH3), 183.6 (NC=S); m/z (El) 264 (M*+, 40%), 205 (22%), 191 (8 %), 141 (10%), 1 0 2  
(8 %), 91 (100%), 72 (16%), 65 (14%), 42 (13%), 28 (27%); (Found: (El): M"+ 264.0931; 
C13H16N2O2S requires M*+ 264.0932).
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l-Benzyl-3-methoxycarbonylmethyl-2-methylthio-4,5-dihydroiimdazolium
trifluoromethanesulfonate
-Ph-Ph
—SMe 
TfO ™ 
-COîMe143b 145
To a solution of l-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-thione 
(0.30 g; 1.10 mmol) in dry dichloromethane (10 ml) under a nitrogen atmosphere, was 
added neat methyl trifluoromethanesulfonate (0.15 ml; 1.36 mmol) and the solution 
allowed to stir at RT for 1 h. The solvent was removed under reduced pressure to yield the 
title compound as a yellow gum (0.46 g; 97%); Ôh (300MHz) 2.78 (s, 3H, S Œ 3), 3.71 (t, 
2H, J  = 10.4, NCf&CHzN), 3.82 (t, 2H, J  = 10.4, NCHgC^N), 3.75 (s, 3H, CO2C//3), 4.54 
(s, 2H, C//2CO2CH3), 5.03 (s, 2H, C//2Ph); Sc (75MHz) 17.2 (SCH3), 47.1 (CH2Ph), 46.9 
(CO2Œ 3), 49.2 (CH2CO2CII3), 53.1 (NCH2CH2N), 53.6 (NCH2CH2N), 127.8, 128.4, 
128.8 (3 x Ar-CH), 140.2 (Ar-Q, 171.7 (CO2CH3), 185.1 (NC=S).
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Attempted synthesis of dimethyl 1 -benzyl-7a-methyIthiohexahydro- l//-pyrrolo [1,2-
û]imidazole-5,7-dicarboxylate
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.25ml; 2.22 
mmol) to a solution of l-benzyl-3 -methoxycarbonylmethyltetrahydroimidazol-2 -thione 
(0.49 g; 1.85 mmol) in dry THF (20 ml) under nitrogen. The solution was stirred at RT for 
1 h before methyl acrylate (0.50 ml; 5.55 mmol) was added and the resulting mixture 
heated to reflux. DBU (1,8-diazabicyclo [5.4.0]undec-7-ene) (0.32 ml; 2.22 mmol) was 
then added dropwise over a period of 4 h and heating was continued for a further 4 h. The 
solvent was evaporated under reduced pressure and the residue subjected to silica gel 
column chromatography using ethyl acetate / hexane (4: 6  v/v) as eluant but none of the 
title compound was isolated.
Attempted synthesis of dimethyl l-benzyl-7a-ethoxyhexahydro-l//-pyrrolo[l,2- 
ti]imidazole-5,7-dicarboxylate
Via a syringe was added dropwise triethyloxonium tetrafluoroborate (1.0M solution
r r
MeOzC
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in dichloromethane; 0.96 ml; 0.96 mmol) to a solution of l-benzyl-3- 
methoxycarbonylmethyltetrahydroimidazol-2-one (0.20 g; 0.8 mmol) in dry THF (20 ml) 
under nitrogen. The solution was stirred at RT for 4 h before methyl acrylate (0.22 ml; 2.4 
mmol) was added and the resulting mixture heated to reflux. DBU (0.14 ml; 0.96 mmol) 
was then added dropwise over a period of 4 h and heating was continued for a further 4 h. 
The mixture was then allowed to cool to RT, the solvent removed under reduced pressure 
and the residue subjected to silica gel column chromatography using ethyl acetate / hexane 
(4 : 6  v/v) as eluant but none of the title compound was isolated.
Attempted synthesis of methyl l-benzyl-7a-ethoxyhexahydro-l/7-pyrrolo[l,2- 
fl]imidazole-5-methoxycarbonyl-7-sulfonyl
-Ph
151bMeO
-Ph
143a
Via a syringe was added dropwise triethyloxonium tetrafluoroborate (1.0 M 
solution in dichloromethane; 2.30 ml; 2.23 mmol) to a solution of l-benzyl-3- 
methoxycarbonylmethyltetrahydroimidazol-2-one (0.47 g; 1.89 mmol) in dry THF (20 ml) 
under nitrogen. The solution was stirred at RT for 4 h before methyl vinyl sulfone (0.49 ml; 
5.67 mmol) was added and the resulting mixture heated to reflux. DBU (0.34 ml; 2.30 
mmol) was then added dropwise over a period of 4 h and heating was continued for a
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further 4 h. The mixture was then allowed to cool to RT, the solvent removed under 
reduced pressure and the residue subjected to silica gel column chromatography using ethyl 
acetate / hexane (4 : 6  v/v) as eluant but none of the title compound was isolated.
Attempted synthesis of dimethyl l-benzyl-7a-trifluoromethanesulfonyloxyhexahydrO' 
l/?-pyrrolo[l,2-a]imidazole-5,7-dicarboxylate
Via a syringe added dropwise trifluoromethane sulfonic anhydride (0.25 ml; 1.50 
mmol) to a solution of l-benzyl-3-methoxycarbonylmethyltetrahydroimidazol-2-one (0.31 
g; 1.25 mmol) in dry THF (20 ml) under nitrogen. The solution was stirred at RT for 2 h 
before methyl acrylate (0.33 ml; 3.75 mmol) was added and the resulting mixture heated to 
reflux. DBU (0.22 ml; 1.50 mmol) was added dropwise over a period of 4 h and heating 
was continued for a further 4 h. The mixture was allowed to cool to RT, the solvent 
removed under reduced pressure and the residue subjected to silica gel column 
chromatography using ethyl acetate / hexane (4 : 6  v/v) as eluant but none of the title 
compound was isolated.
x
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Attempted synthesis of dimethyl l-benzyl-5,7-bis(methoxycarbonyl)-7a-te/t-
bUtyldimethylsilyoxyhexahydro-l/f-pyiTolo[l,2-a]-imidazole-5,7-dicarboxylate
-Ph
143a
-Ph
152b
MeOzC
Via a syringe was added dropwise terf-butyldimethylsilyl trifluoromethanesulfonate 
(0.11 ml; 0.48 mmol) to a solution of l-benzyl-3-methoxycarbonylmethyltetrahydro 
imidazol-2-one (0.10 g; 0.40 mmol) in dry THF (20 ml) under nitrogen. The solution was 
stirred at RT for 2 h before methyl acrylate (0.10 ml; 1.20 mmol) was added and the 
resulting mixture heated to reflux. DBU (0.07 ml; 0.48mmol) was added dropwise over a 
period of 4 h and heating was continued for a further 4 h. The mixture was allowed to cool 
to RT, the solvent removed under reduced pressure and the residue subjected to silica gel 
column chromatography using ethyl acetate / hexane (4 : 6  v/v) as eluant but none of the 
title compound was isolated.
l-Benzyl-3-trimethylsilylmethyl-4,5-tetrahydroimidazol-2-one
-Ph-Ph
O
128
To a suspension of NaH (0.19 g; 8.29 mmol) in dry DMSO (25 ml) was added
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dropwise a solution of 1-benzyl-4,5-dihydroimidazol-2-one (1.46 g; 8.29 mmol) in dry 
DMSO (25 ml) at RT. The mixture was stirred for 30 min and then chlorotrimethylsilane 
(2.24 ml; 12.43 mmol) was added. The resulting mixture was stirred at RT for 10 h. 
Unreacted NaH residue was filtered off and the solvent removed under reduced pressure, 
The residue was purified by silica gel column chromatography using ethyl acetate / hexane 
(4 : 6  v/v) as eluant to afford the title compound as colourless oil (0.99 g; 45%): Vmax (film) 
/ cm"1 3030, 2952, 2860, 1696, 1444, 1359, 1251, 856, 756; 8 h (300MHz) 0.31 (s, 9H, 
Si(Cff3)3), 2.54 (s, 2H, Cff2Si(CH3)3), 3.25 (m, 2H, NC%CH;N), 3.41 (m, 2H, 
NCH2CH2N), 4.51 (s, 2 H, C//2Ph), 7.36 (m, 5H, Ar-fl); 5c (75MHz) - 1 .6  (Si(CH3)3), 35.4 
(CH2Si(CH3)3), 42.5 (CH2Ph), 45.5 (NCH2CH2N), 48.7 (NCH2CH2N), 127.2, 128.1, 128.5 
(3 x Ar-CH), 137.5 (Ar-Q, 161.8 (NC=0); m/z (El) 262 (M*+, 12%), 248 (5%), 247 (18%), 
189 (4%), 171 (8 %), 155 (7%), 100 (9%), 91 (100%), 73 (77%), 65 (16%), 45 (22%), 43 
(13%); (Found: (El): M*+ 262.1503; C u t^ ^ O S i requires M*+ 262.1501). Also isolated 
was l-benzyl-3-methyl-tetrahydroimidazol-2-one 154 as a colourless oil (0.44 g; 27%); 8h 
(300MHz) 2.82 (s, 3H, NCff3), 3.13 (m, 2H, NCH2CH2N), 3.18 (m, 2H, NCH2C//2N), 4.37 
(s. 2H, CH2Ph); Sc (75MHz) 31.4 (NCH3), 42.2 (CH2Ph), 44.9 (NCH2CH2N), 48.7 
(NCH2CH2N), 127.4,127.7,128.5 (3 x Ar-CH), 137.3 (Ar-Q, 161.5 (NC=0); m/z (El) 190 
(M,+, 30%), 161 (6 %), 113 (13%), 99 (34%), 92 (9%), 91 (100%), 89 (11%), 77 (23%), 65 
(34%), 56 (18%), 51 (16%), 43 (13%), 42 (44%), 39 (15%); (Found: (El) M*+ 190.1107; 
C11H14N2O requires M** 190.1106).
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l-Benzyl-3-trimethyIsilylmethyl-4,5-tetrahydroimidazol-2-thione
-Ph
153a
To a solution of the l-benzyl-3-trimethylsilylmethyltetrahydroimidazol-2-one (0.86 
g; 3.28 mmol) in dry orf&o-xylene (30 ml) was added portionwise Lawesson’s Reagent 
(1.32 g; 3.28 mmol). The mixture was heated at reflux for 26 h after which time it was 
allowed to cool to RT. The solvent was removed under reduced pressure and the residue 
purified by silica gel column chromatography using ethyl acetate / hexane (25 : 7 5  v/v) as 
eluant to afford the title compound as a yellow gum (0.63 g; 69%): Vma* (film) / 
cm"1 3030,2938,1696,1498,1445,1404,1252,1056,760,702; 8 » (300MHz) 0.20 (s, 9H, 
SiC(Ctf3)3), 3.12 (s, 2H, C%SiC(CH3)3), 3.21 (m, 2H, NCJfcCHjN) 3.25 (m, 2H, 
NCH2CH2N), 4.92 (s, 2H, CffjPh), 7.32 (m, 5H, Ar-fl); 5c (75MHz) -1.4 (Si(CH3)3), 39.3 
(CH2Ph), 45.3 (NCH2 Si(CH3)3), 48.5 (NCH2CH2N), 52.1 (NCH2CH2N), 127.5, 128.1,
128.6 (3 x Ar-CH), 136.8 (Ar-Q, 182.9 (C=S); m/z (El) 278 (M"+, 10%), 264 (5%), 263 
(21%), 92 (8 %), 91 (100%), 73 (69%), 65 (20%), 45 (23%); (Found: (El): M*+ 278.1287; 
C,4H22N2SSi requires M*+ 278.1273).
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l-Benzyl-3-trimethylsilylmethyl-2-methylthio-4,5-tetrahydroimidazolium
trifluoromethane sulfonate
r
-Ph
153b 'SiMe3
I  SMe
N+ TfO" 
158^ SiMe3
To a solution of l-benzyl-3-trimethylsilylmethyl-4,5-tetrahydroimidazol-2-thione 
(0 .1 0  g; 0.36 mmol) in dry dichloromethane ( 1 0  ml) under a nitrogen atmosphere, was 
added neat methyl trifluoromethanesulfonate (0.02 ml; 0.43 mmol) and the solution 
allowed to stir at RT for 1 h. The solvent was removed under reduced pressure to yield the 
title compound as a yellow gum (0.15 g; 94%): 5h (300MHz) 2.49 (s, 3H, SCH3), 3.14 (s, 
2H, Ctf2Si(CH3)3), 3.72 (m, 2H, NCH2CH2N), 3.76 (m, 2H, NCH2Œ /2N), 4.64 (s, 2H, 
PhŒW, 7.24 (m, 5H, Ar-H); 8 c (75MHz) -1.1 (Si(CH3)3), 17.3 (SCH3), 44.2 (CHUPh), 
49.1 (NCH2 Si(CH3)3), 54.2 (NCH2CH2N), 55.6 (NCH2CH2N), 127.4, 128.3, 128.6 (3 x 
Ar-CH), 137.7 (Ar-Q.
Attempted synthesis of methyl l-benzyl-7a-methoxyhexahydro-l//-pyrrolo[l,2- 
fl]imidazole-7-carboxylate
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.14 ml; 1.23
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mmol) to a solution of l-benzyl-3-trimethylsilylmethyltetrahydroimidazol-2-one (0.27 g;
1.03 mmol) in dry dichloromethane (10 ml) under nitrogen. The solution was stirred at RT 
for 8 h. The solvent was removed and replaced by dry glyme (45 ml). Methyl acrylate (0.28 
ml; 3.09 mmol) was added to the reaction mixture and the resulting solution stirred for 10 
min at RT and then transferred into a flask containing flamed dried caesium fluoride (0.39 
g; 2.57 mmol). The resulting mixture was the left stirring for 48 h. The solvent was 
removed under reduced pressure and residue subjected to silica gel column 
chromatography using ethyl acetate / hexane (3 : 7 v/v) as eluant but none of the title 
compound was isolated.
Attempted synthesis of methyl l-benzyl-7a-methylthiohexahydro-l/7-pyrrolo[l,2- 
a]imidazole-7-carboxylate
-Ph
,SMe
159153b'— siM*,
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.30 ml; 2.62 
mmol) to a solution of l-benzyl-3-trimethylsilylmethyltetrahydroimidazol-2-thione (0.61 g; 
2.19 mmol) in dry dichloromethane (10 ml) under nitrogen. The solution was stirred at RT 
for 8  h and the solvent removed under reduced pressure and replaced by dry glyme (45 ml). 
Methyl acrylate (0.59 ml; 6.57 mmol) was added to the reaction mixture, the resulting 
solution stirred for 10 min at RT and then transferred into a flask containing flamed dried 
caesium fluoride (0.80 g; 5.45 mmol). The resulting mixture was the left stirring for 48 h.
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The solvent was removed under reduced pressure and the residue subjected to silica gel 
column chromatography using ethyl acetate / hexane (3 : 7 v/v) as eluant but none of the 
title compound was isolated.
l ,3 -D ib e n z y lte tra h y d ro im id a zo l-2 -th io n e
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To a solution of commercial N,N/-dibenzyl-l,2-diaminoethane (0.40 g; 1.60 mmol) 
in dry THF (20 ml) under nitrogen was added a solution of l.V-thiocarbonyldiimidazole 
(0.38 g; 1.92 mmol) in dry THF (10 ml). The resulting solution was stirred at RT for 18 h 
before the solvent was evaporated under reduced pressure. The residue was washed with 
dilute hydrochloric acid (2 M; 50 ml) and extracted with dichloromethane (2 x 50 ml). The 
combined organic phases were dried (MgSCU), filtered and the solvent evaporated under 
reduced pressure to afford the title compound as a yellow solid (0.44 g; 98%): m.p. 87-
Ar-tf); ôc(100MHz) 45.69 (PhCH2), 52.09 (NCH2CH2N), 127.98, 128.49, 128.97 (3 x Ar- 
CH) 136.74 (Ar-Q, 184.82 (NC=S); m/z (El) 282 (VT, 20%), 191 (30%), 105 (9%), 91
92°C (lit. ,121 90°C); Vma, (nujol) / cm"1 2927, 2855, 1494, 1462, 1378, 1359, 1334, 1268,
1240, 731; Ôh (400M H z) 3.40 (s, 4H, NC%C%N) 4.92 (s, 4H, 2 x C//2Ph), 7.38 (m, 10H,
167
(100%), 65 (16%), 56 (5%); (Found: (El): M*+ 282.1188; C17H18N2S requires M*+ 
282.1191).
1^3-Dibenzyltetrahydroiimdazol-2-one
.Ph
L
'Ph
c  * 0 ^ 0 — - oNH N " —n
> h  ' 1
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To a solution of N,Nz-dibenzyl-1,2-diaminoethane (0.40 g; 1.6 mmol) in dry THF 
(20 ml) under nitrogen was added a solution of 1, V-carbonyldiimidazole (0.38 g; 1.92 
mmol) in dry THF (10 ml). The resulting solution was stirred at RT for 18 h before the 
solvent was evaporated under reduced pressure. The product washed with dilute 
hydrochloric acid (2 M; 50 ml) and extracted with dichloromethane (2 x 50 ml). The 
combined organic phases were dried (MgSCU), filtered and the solvent evaporated under 
reduced pressure to afford the title compound as a white solid (0.41 g; 97%): m.p. 90-91°C 
(lit. ,122 93-94°C); Vma, (nujol) / cm 1 2927, 2855, 1689, 1494, 1455, 1365, 1257, 711; 5h 
(300MHz) 3.16 (s, 4H, NCftCflaN), 4.41 (s, 4H, 2 x CH2Ph), 7.32 (m, 10H, Ar-tf); 8 c 
(75MHz) 42.2 (PhCH2), 48.6 (NCH2CH2N), 127.5, 128.3, 128.6 (3 x Ar-CH), 137.4 (Ar- 
O , 161.1 (NC=0); m/z (El) 266 (M"+, 73%), 189 (4%), 175 (71%), 132 (9%), 118 (6 %), 
105 (8 %), 91 (100%), 65 (15%); (Found: (El): M*+ 266.1414; CnHigl^O requires M*+
168
266.1419).
l^-Dibenzyl-2-methylthio-4,5-dihydroimidazolmium trifluoromethanesulfonate
161b 162
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.09 ml; 0.85 
mmol) to a solution of 1,3-dibenzyltetrahydroimidazol-2-thione (0.20 g; 0.71 mmol) in dry 
dichloromethane (10 ml). The solution was stirred at RT for 1 h. The solvent was then 
removed under reduced pressure to afford the title compound as a yellow oil (0.32 g; 
100%): Vmwt (film) / cm"1 3034, 2944, 1591,1574, 1499, 1455, 1357, 1262 (br), 1225 (br), 
1157 (br), 1031, 756, 738, 703; Sh (300MHz) 2.86 (s, 3H, SC#,), 3.90 (s, 4H, 2 x 
NCJ/2CH2N), 4.92 (s, 4H, 2 x C%Ph), 7.29 (m, 5H, Ar-#), 7.37 (m, 5H, Ar-#); 5c 
(75MHz) 16.47 (SCH3), 47.8 (2  x CHiPh), 53.3 (2 x NCH2), 127.6, 127.9, 128.5 (6  x Ar- 
CH), 132.4 (2 x Ar-Q, 167.2 (NCS); (Found: (ES, M-CF3SO3 ): M*+ 297.1422; 
C19H21F3N2O3S2 requires M*+ 297.1425).
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l^-Dibenzyl-2-methyliminotetrahydroimidazole
r
-Ph
161b V _ph
o le
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.13 ml; 1.10 
mmol) to a solution of 1 ,3-dibenzyltetrahydroimidazol-2-thione (0.26 g; 0.92 mmol) in dry 
dichloromethane (10 ml) under a nitrogen atmosphere and the solution stirred at RT for 1 
h. Methyl amine (2M solution in THF; 0.69 ml; 1.38 mmol) was added and the resulting 
solution heated at reflux for 18 h. The solvent was removed under reduced pressure and the 
residue purified by silica gel column chromatography using isopropylamine / chloroform (2  
: 98 v/v) as solvent system to afford the title compound as a yellow gum (0.10 g; 40%): 
vma* (film) / cm 1 2870, 1490, 1226, 1220; Sh (300MHz) 3.01 (s, 3H, NC#3), 3.44 (s, 4H, 
N Œ 2CH2), 4.53 (s, 4H, 2 x Ctf2Ph), 7.26 (m, 6 H, Ar-#), 7.30 (m, 4H, Ar-#); Sc (75MHz) 
30.9 (2 x N=CH3), 46.7 (2 x CHgPh), 50.7 (2 x NCH2CH2N), 127.5, 128.4, 129.1 (3 x Ar- 
CH), 133.8 (Ar-Q, 158.5 (NC=NCH3); m/z (El) 279 (M*+, 24%), 250 (10%), 207 (16%), 
125 (19%), 111 (35%), 97 (58%), 91 (23%), 83 (57%), 69 (77%), 57 (100%), 49 (27%), 43
(76%), 39 (15%), 29 (26%); (Found: (El): IVflT 280.1738; Ci7H2iN3 requires MH* 
280.1735).
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Attempted synthesis of l^-dibenzyl-2-[bis(ethoxycarbonylmethyl)imino]
tetrahydroimidazolinium trifluoromethanesulfonate
*N x— C02Et
^ P h  Tfd"
y — C02Et
161b Ph 165
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.09 ml; 0.84 
mmol) to a solution of 1,3-dibenzyltetrahydroimidazol-2-thione (0.20 g; 0.70 mmol) in dry 
dichloromethane (10 ml) under a nitrogen atmosphere and the solution stirred at RT for 1 
hour. The solvent was removed under reduced pressure, dry toluene (20 ml) was injected 
into the reaction flask and the solution treated with diethyl imino-diacetate (0.15 ml; 0.84 
mmol). The resulting mixture was heated at reflux for 72 h. The solvent was removed 
under reduced pressure and the residue subjected to NMR analysis. Only starting material 
161b peaks could be observed.
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l,3-Dibenzyl-2-(tetramethyleneimino)tetrahydroimidazoIinium trifluoromethane 
sulfonate
161b rn
r-P h
Ph TfO
164
Via a syringe was added dropwise methyl trifluoromethanesulfonate (0.12 ml; 1.0 mmol) 
to a solution of 1,3-dibenzyltetrahydroimidazol-2-thione (0.25 g; 0.88 mmol) in dry 
dichloromethane (15 ml) under nitrogen, and the solution stirred at RT for 1 hour. The 
solvent was removed under reduced pressure, dry THF (25 ml) was added under nitrogen 
to the residue and the resulting solution treated with pyrrolidine (0.09 ml; 1.0 mmol). The 
resulting solution was heated to reflux for 26 h and then allowed to cool to RT. The solvent 
was removed under reduced pressure to afford the title compound as a brown oil (0.32 g;
7.39 (m, 4H, Ar-//); ôc (75MHz) 25.5 (CH2CH2), 49.4 (NCH2), 50.8 (2 x CH2Ph), 53.4 
(CH2N), 126.3, 128.2, 129.3 (3 x Ar-CH), 134.8 (Ar-Q, 162.4 (NC=N).
77%): ÔH (300MHz) 1.86 (t, 4H, /  = 6 .6 , CH2CH2 pyrrolidine), 3.61 (t, 4H, J = 6 .6 , NCH2
pyrrolidine), 3.84 (s, 4H, PhNC/^C/^NPh), 4.76 (s, 4H, 2 x CZ/2Ph), 7.26 (m, 6 H, Ar-Q,
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Attempted synthesis of l-(l,3-dibenzyltetrahydroimidazole-2-ylidene)-2- 
methoxycarbonyl-pyrrolidium trifluoromethanesulfonate
Ph yMeC^C TfO 
Ph 166161b
Prepared as for l,3-dibenzyl-2-(tetramethyleneimino)tetrahydroimidazolium 
trifluoromethane sulfonate 164 but using 1,3-dibenzyltetrahydroimidazol-2-thione (0.20 g; 
0.71 mmol), methyl trifluoromethanesulfonate (0.09 ml; 0.85 mmol) and proline methyl 
ester (0.08 g; 0.85 mmol) in place of pyrrolidine. The crude residue was analysed by NMR 
where the expected peaks for the formation of the title compound were not observable.
Attempted synthesis of methyl l-benzyl-7a-methylthio-5-phenylhexahydro-lZf- 
pyrrolo[lv2-a]imidazole-7-carboxylate
Methyl trifluoromethanesulfonate (0.10 ml; 0.93 mmol) was added to a solution of
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1,3-dibenzyltetrahydroimidazol-2-thione (0.22 g; 0.78 mmol) in dry THF under nitrogen at 
RT and the solution stirred for 1 h. The solution was then cooled to -78°C before the 
dropwise addition of sec-BuIi (1.3M solution in hexanes; 0.72 ml; 0.93 mmol) followed 
by the addition of methyl acrylate (0,21 ml; 2.34 mmol). The resulting solution was then 
warmed to RT and then heated at reflux for 12 h. Removal of the solvent under reduced 
pressure and subjection of the crude residue to silica gel column chromatography afforded 
none of the title compound.
Attempted synthesis of l-benzyl-5-phenyl-7-methoxycarbonyl-7a-(pyrrolidin-l- 
yl)hexahydro-lH-pyrrolo[l,2-a]imidazole
To a solution of l,3-dibenzyl-2-(tetramethyleneimino)tetrahydroimidazolinium 
trifluoromethane sulfonate 164 (0.40 g; 0.85 mmol) in dry THF (20 ml) at -78°C was 
added sec-BuLi (1.3M solution in hexanes; 0.78 ml; 1.0 mmol). The solution was kept at 
-78°C for 20 min and treated with excess methyl acrylate (0.23 ml; 2.55 mmol). The 
resulting solution was allowed to warm up to RT and heated at reflux for 8 h. The solvent 
was removed under reduced pressure and the residue subjected to silica gel column 
chromatography using ethyl acetate / hexane (3 : 7 v/v) as eluant but none of the title
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compound was isolated.
Attempted synthesis of methyl l-benzyl-5-phenyl-7a-(trimethylsiloxy)hexahydro-l/7- 
pyrrolo[l, 2^z]imidazole-7-carboxylate
To a solution of 1,3-dibenzyltetrahydroimidazol-2-one (0.42 g; 1.58 mmol) in dry 
THF (15 ml) at RT and under nitrogen, was added trimethylsilyltrifluoromethane sulfonate 
(0.36 ml; 1.89 mmol). The solution was stirred for 30 min at RT and then cooled to -78°C. 
sec-BuLi (1.3M solution in hexanes; 1.45 ml; 1.89 mmol) was added dropwise followed by 
the addition of methyl acrylate (0.43 ml; 4.74 mmol). The reaction mixture was allowed to 
warm up to RT and heated at reflux for a further 8  h. Subjection of the residue to column 
chromatography using ethyl acetate / hexane (4 : 6  v/v) as eluant afforded none of the title 
compound.
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Attempted synthesis of methyl l-benzyl-5-phenyl-7a-(ter?-butyldimethylsiloxy)
hexahydro - 1/f-pyrrolo [ 1,2-a] imidazole-7 - carboxy late
To a solution of l,3-dibenzyltetrahydroimidazol-2-one (0.47 g; 1.76 mmol) in dry 
THF (15 ml) at RT and under nitrogen, was added tert-butyldimethylsilyl 
trifluoromethanesulfonate (0.48 ml; 2.11 mmol). The solution was stirred for 30 min and 
then cooled to -78°C. sec-BuLi (1.3M solution in hexanes; 1.63 ml; 2.11 mmol) was added 
dropwise followed by the addition of methyl acrylate (0.48 ml; 5.28 mmol). The reaction 
mixture was allowed to warm up to RT and then heated at reflux for a further 8 h. 
Subjection of the residue to silica gel column chromatography using ethyl acetate / hexane 
(4 : 6  v/v) as eluant afforded none of the title compound.
ITBDMS
/C 0 2Me
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Attempted synthesis of methyl l-benzyl-5-phenyl-7a-(trifluoromethanesulfonyloxy)
hexahydro-l/f-pyrrolo[l,2-a]imidazole-7-carboxylate
To a solution of l,3-dibenzyltetrahydroimidazol-2-one (0.25 g; 0.94 mmol) in dry 
THF (20 ml) under nitrogen, was added (in a glove box) trifluoromethane sulfonic 
anhydride (0.19 ml; 1.13 mmol) and the resulting solution allowed to stir at RT for 2 h 
before methyl acrylate (0.25 ml; 2.82 mmol) was added. The mixture was heated at reflux 
and sec-BuIi (1.3 M solution in hexanes; 0.86 ml; 1.13 mmol) was added over a period of 
4 h. Reflux was continued for a further 4 h and the mixture was allowed to cool to RT. 
Subjection of the residue to by silica gel column chromatography using ethyl acetate / 
hexane (4 : 6  v/v) as eluant afforded none of the title compound.
Ethyl glyoxalate95
Ethyl diethoxyacetate (12.90 g; 73 mmol), glyoxylic acid monohydrate (6  50 g;
p-TsOH
187 188
o
186
177
70.0 mmol) and p-toluenesulphonic acid (200.0 mg; 1.0 mmol) were combined and the 
resulting mixture refluxed for 27 h using an air condenser. The resultant clear 
homogeneous syrup was cooled (ice-methanol), stirred vigorously while phosphorous 
pentoxide (8.00 g; 28.0 mmol) was added portionwise and the subsequent mixture heated 
at 90-100°C for a further 2 h. Distillation under reduced pressure afforded the title 
compound as a viscous and colourless liquid (7.14 g; 89%): b.p. 72-78°C / 25mmHg 
(Lit.,95 49°C /  35 mmHg); V™, (film) /  cm 1 3450, 3168, 1590, 1586, 1290; 8h (400MHz)
Sc (100MHz) 13.90 (CO2CH2CH3), 63.11 (CO2CH2CH3), 159.44 (CO2CH2CH3), 183.91 
(CHO); m/z 103 (El) (M*+, 54%), 85 (25%), 83 (33%), 75 (100%), 57 (34%).
N-(2-Benzylaminoethyl)-2,2-diethoxyethanamide
Ethyl diethoxyacetate (1.06 g; 6.0 mmol) was added to a stirred solution of 1- 
benzyl-diaminoethane (1.00 g; 6.0 mmol) in diethyl ether (70 ml) and the resulting solution 
stirred at RT for 24 h. The solution was then washed with water (20 ml) and extracted with 
diethyl ether (2 x 30 ml). The combined organic extracts were dried (MgSCX) and the 
solvent evaporated under reduced pressure. The residue was then purified by silica gel 
column chromatography using chloroform / methanol (10 : 90 v/v) as eluant to afford the
1.46 (t, 3H, 7 = 7.1, CO2CH2Œ 3) 4.47 (q, 2 H, 7 = 7.1, CO2Œ 2CH3), 9.47 (s, 1H, CHO); 
-Ph -Ph
126 187
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title compound as a colourless oil (0.80 g; 47%): 8h (400MHz) 1.26 (t, 6 H, J  = 6.9, 2 x 
OCH2C//3), 2.79 (t, 2 H, /  = 6.0, NHC//2CH2N), 3.39 (t, 2 H, J  = 6.0, NHCH2C//2N), 3.58 
(m, 4H, 2 x O Œ 2CH3), 3.73 (s, 2H, CH2Ph), 4.75 (s, 1H, COC//(OEt)2), 7.22 (m, 5H, Ar-
H)\ 5c (1 0 0 MHz) 15.1 (2  x OCH2CH3), 38.6 (CH2Ph), 47.7 (NHCH2CH2N), 53.33 
(NHCH2CH2N), 62.5 (2  x OCH2CH3), 98.6 (COCH(OEt)2), 127.0, 128.00, 128.3 (3 x Ar- 
CH), 136.1 (Ar-Q, 162.9 (NC=0); m/z (El) 281 (MH4-, 20%), 205 (35%), 189 (65%), 133 
(38%), 120 (57%), 106 (22%), 103 (49%), 91 (100%), 75 (28%), 65 (10%).
l-Benzyl-2-formyl-4,5-dihydroimidazole
 -Ph
J
OEt
O 190
/ /
"N H
191
A solution of N-(2-benzylaminoethyl)-2,2-diethoxyethanamide 190 (0.30 g; 1.1 
mmol) in ethanol (20 ml) was stirred at RT for 14 h and then quenched with a solution of 
sodium thiosulfate (2.79 g) in H2O (50 ml). Stirring was continued for 1 h then the solution 
extracted with dichloromethane (2 x 50 ml). The organic phase was dried (MgSO^ and 
evaporated under reduced pressure to afford the title compound as a yellow gum (0 .12 g; 
60%): Vma, (film) / cm-1 3171 (br), 3030, 1641, 1524, 1456, 1379, 1297, 1203, 919, 731; 
Sh (400MHz) 3.74 (t, 3H, J  = 6.4, NCH2CH2N), 3.97 (t, 3H, J  = 6.4, NCH2CH2N), 4.80 (s, 
2H, Cff2Ph), 7.29 (m, 5H, Ai-H), 8.94 (s, 1H, CHO); Sc (100MHz) 40.3 (CH2Ph), 51.7
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(NCHzCHjN), 52.7 (NCH2CH2N), 127.3, 128.1, 128.4 (3 x Ar-CH), 136.1 (Ar-Q, 161.2 
(N=CCHO), 200.1 (CHO); m/z (El) 189 (MH+, 13%), 161 (60%), 91 (100%), 81 (25%), 69 
(30%), 57 (27%), 41 (19%), 28 (20%); (Found: (El): MH+ 189.1028; CnHizNzO requires 
MET 189,1028)
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3.2 Intramolecular approach experimental
2-(3-Ethoxycarbonyl-4-oxopentyl)dioxalanc105
203
OEt -------------------■
201
The title compound was prepared using a slight variation of a literature 
procedure.105 To an ice-cold suspension of Natt (3.31 g; 144 mmol) in dry THF (300 ml) 
and was added dropwise ethyl acetoacetate 201(14.68 ml; 120.0 mmol). The resulting 
mixture was refluxed and of commercial 2-(2-bromoethyl)-1,3-dioxolane 203 (16.25 ml; 
144.0 mmol) was added dropwise over a period of 30 min. Heating was continued for a 
further 36 h. The reaction mixture was then allowed to cool down to RT and filtered and 
the solvent removed under reduced pressure. The residue was purified by column 
chromatography using ethyl acetate / hexane (25 : 75 v/v) as eluant to afford the title 
compound as an orange oil (11.92 g; 45%): Vmax (film) / cm'1 2981, 2888, 1741, 1717, 
1144,1030; SH (300MHz) 1 .2 2  (t, 3H, 7 = 7.1, CO2CH2CH3), 1.59 (m, 2 H, OCHCH2), 1.94 
(q, 2H, J  = 7.7, OCHCH2CH2), 2.18 (s, 3H, CH3CO), 3.43 (t, 1H, J  = 7.5, COCtfC02Et), 
3.75 (m, 2H, OCH2CH2O), 3.82 (ni, 2H, 0CH2CH20), 4.11 (q, 2H, J  = 7.1, CO2CH2CH3), 
4.79 (t, 1H, J  = 4.4, OCH2CH2OCHCH2); Sc (75MHz) 14.1 (CO2CH2CH3), 22.3 
(OCHCH2CH2), 28.9 (CH3CO), 31.2 (OCHCH2), 59.2 (COCHC0 2Et), 61.4 
(C02CH2CH3), 64.9 (2 x OCH2), 103.8 (OCHO), 169.6 (C02Et), 201.9 (CH3COCH).
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Attempted synthesis of 2-(5-chloro-3-ethoxycarbonyl-4-oxopentyl)dioxalane
c
OEt Cl
208 c ° 2Et 209
To an ice-cold suspension of NaH (0.34 g; 14.4 mmol) in dry THF (40 ml) was 
added dropwise ethyl 4-chloroacetoacetate 208 (1.64 ml; 12.0 mmol). The resulting 
mixture was refluxed then 2-(2-bromoethyl)-l,3-dioxolane 202 (1.57 ml; 13.3 mmol) was 
added dropwise over a period of 30 min. The solution was unchanged by TLC analysis 
after 16 h reflux and after work-up afforded the starting material 208.
2-(4-Oxopentyl)dioxalane105
A mixture of 2-(3-ethoxycarbonyl-4-oxopentyl)dioxolane 203 (0.56 g; 2.43 mmol) 
and 5% aqueous sodium hydroxide solution (5.82 ml; 7.29 mmol) was stirred under reflux 
for 16 h. After cooling, the reaction mixture was extracted with diethyl ether (3 x 25 ml), 
the combined organic extracts dried (MgSC^) and the solvent evaporated under reduced 
pressure to afford the crude keto-acetal. Purification by column chromatography using 
ethyl acetate / hexane (25 : 75 v/v) as eluant afforded the title compound as a brown oil
902; ÔH (300MHz) 1.71 (m, 4H, CH2CH and C772CH2CH), 2.16 (s, 3H, CH3CÔ), 2.49 (t,
205
(0.34 g; 89%): v^,, (film) / cm"1 2956, 2886, 1714, 1412, 1363, 1227, 1141, 1030, 970,
2H, J  = 6.9, CH3COCH2), 3.88 (m, 2 H, OCH2CH2O), 3.95 (m, 2 H, OCH2CH2O), 4.83 (t.
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1H, J  = 4.2Hz, OCHO); ôc (75MHz) 18.2 (COCH2CH2), 29.9 (CH2CH2CH), 33.0 
(CH3CO), 43.3 (CH3COCH2), 64.8 (OCH2CH2O), 104.2 (OCHO), 208.6 (CH3COCH2); 
m/z (El) 159 (MH+, 54%), 115 (82%), 84 (21%), 73 (100%), 51 (12%), 49 (41%), 43 
(22%); (Found: (El) MHf 159.1021; CgHnOj requires MH+ 159.1021)
5-Oxo-hexanal105
206205
To a cooled solution of the keto-acetal 205 (6.4 g; 40.0 mmol) in THF (100 ml) was 
added, dropwise with stirring, 1 M hydrochloric acid (120.0 ml; 120.0 mmol). The solution 
was heated at 50°C for 5 h and then allowed to cool to RT. After neutralisation with 
NaHCOg (10.08 g; 120.0 mmol) the product was extracted with dichloromethane. The 
organic phase was dried (MgSCU) and evaporated under reduced pressure to afford the 
crude title compound as a colourless liquid, but which was used directly without further 
purification: 5H (300MHz) 1.80 (m, 2H, COCH2CH2CH2CO), 2.16 (s, 3H, Œ 3CO), 2.55 
(m, 4H, COCH2CH2CH2CO), 9.70 (s, 1H, CH2CHO).
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Methyl (triphenylphosphoranylidene)acetate106
PPh3 + BrCH2C0 2Me ----------    PhgPCHCOgMe
210
Using a slight variation of literature methodology, 106 a solution of 
triphenylphosphine (25 g; 0.095 mol) in dry toluene (150 ml) was added dropwise methyl 
bromoacetate (9.90 ml; 0.10 mol). The resulting solution was refluxed for 2 h and then 
cooled to RT. The white solid was filtered, washed with hexane and then dissolved in cold 
water (1.5 1) and dichloromethane (1.0 1) was added to the solution. The resulting two 
phase mixture was stirred vigorously whilst excess NaOH (1 M; 50 ml) was added 
dropwise. When the solution was alkaline, the organic phase was separated and the 
aqueous solution extracted with dichloromethane (3 x 400 ml). The combined organic 
extracts were dried (MgSCX), filtered and the solvent the removed under reduced pressure 
until the initial formation of a precipitate could be observed. Hexane (30 ml) was then 
added, the flask sonic and the resulting solid was filtered and washed with hexane to afford 
the title compound as a white solid (28 g; 8 8 %): m.p. 160-161°C (lit. ,123 162-163°C); 6h 
(300Mhz) 2.94 (d, 1H, J  = 21.7 PhgPC# ), 3.58 (s, 3H, C 0 2CH3\  7.40-7.65 (m, 15H, Ar- 
H ) .
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Methyl Z?-7-oxooct-2-enoate and methyl Z-7-oxooct-2-enoate105
,  ^   ^ ^ 0 2M e
H  ^  v  v  ^
206 E-207a and Z-207b
A solution of methyl (triphenylphosphoranylidene)acetate 210 (17.72 g; 23.1 
mmol) in dichloromethane (50 ml) was added dropwise with stirring to a solution of the 
crude 5-oxo-hexanal 206 (2.44 g; 21.0 mmol). The reaction mixture was stirred overnight 
at RT. After removal of the solvent under reduced pressure, the residue was purified by 
silica gel column chromatography using ethyl acetate / hexane (2  : 8 v/v) as eluant to afford 
the title compound separable mixture of E- and Z- isomers (8:1 E  : Z) and as a colourless 
oil (3.25 g; 90%): Vma, (film) / cm"1 2980, 1716,1650,1443,1367,1273, 1190,1047, 984, 
708; (E-isomer) 8 H (300MHz) 1.74 (quin, 2H, / =  7.3, CH2CH2CH2), 2.11 (s, 3H, CH3CO), 
2.23 (m, 2H, Cff2CH=CH), 2.43 (t, 2H, J  = 7.3, CH3COCH2), 3.70 (s. 3H, CO2C#,), 5.79 
(dt, 1H, J  = 1.6, 15.8, CH=CtfC02Me), 6.90 (dt, 1H, J  = 6.9, 15.8, C//=CHC02Me); 5c 
(75MHz) 21.6 (CH2CH2CH2), 30.8 (CH2CH=CH), 32.3 (CH3CO), 41.1 (CH3COCH2), 51.7 
(CO2CH3), 122.2 (CH=CHC02Me), 147.6 (CH=CHCC>2Me), 166.4 (CO2CH3), 208.3 
(CH3COCH2); (Z-isomer) 5H (300MHz) 1.79 (quin, 2H, J  = 7.3, CH2CH2CH2), 2.21 (s, 3H, 
C//3CO), 2.67 (dq, 2H, 7 = 1.6, 7.5, C7/2CH=CH), 2.70 (t, 2H, J  = 7.3, CH3COC//2), 3.70 
(s. 3H, CO2W 3), 5.82 (dt, 1H,7= 1.6,11,5, CH=CffCC>2Me), 6.19 (dt, 1H, J = 7.7,11.5, 
C//=CHC02Me); Sc (75MHz) 21.9 (CH2Œ 2CH2), 27.6 (CH2CH=CH), 38.7
(CH3COCH2), 51.6 (CO2CH3), 120.2 (CH=CHC02Me), 147.9 (CH=CHC02Me), 167.3 
(CO2CH3), 202.1 (CH3COCH2); m/z (El) 171 (MET, 1 2 %), 160 (15%), 158 (100%), 138 
(8 %), 113 (10%), 95 (13%), 8 6  (25%), 84 (41%), 81 (15%), 6 8  (12%), 51 (31%), 49 
(98%), 43 (100%); (Found: (El): MH+ 171.1021; C9H14O3 requires MH+ 171.1021).
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Methyl E-8-bromo-7-oxooct-2-enoate
o
!02Me B :02Me
E -207a E- 196a
All glassware used for this reaction was flame dried and all reagents were freshly 
distilled. A solution of methyl £-7-oxooct-2-enoate (1.63 g; 9.58 mmol) in dry THF (10 
ml) at -78°C was added dropwise to a freshly prepared solution of IDA (1.2 eq; 11.5 
mmol), prepared from n-BuLi (2.5M solution in hexanes; 4.60 ml; 11.5 mmol) and 
diisopropylamine (1.74 ml; 12.4 mmol), in dry THF (10 ml) at -78°C. The resulting 
mixture was allowed to stir at -78°C for 20 min before a solution of chlorotrimethylsilane 
(6.07 ml; 47.9 mmol) in dry THF (5 ml) also at -78°C was added. After stirring for 5 min, 
triethylamine (6.67 ml; 4.84 g) was added and the mixture allowed to warm to RT. 
Saturated sodium hydrogen carbonate (3 ml) was added and the mixture extracted with 
diethyl ether (3 x 30 ml). The organic phase was dried (MgSCW and the solvent removed 
under reduced pressure to afford the crude silyl enol ether moiety, which was used directly' 
without further purification, as a colourless liquid (1.85 g; 79%). A solution of the silyl 
enol ether (1.85 g; 7.60 mmol) in dry THF (10 ml) at -78°C was treated with solid 
NaHCOg (1.12 g; 13.41 mmol), and the mixture allowed to stir at that temperature for 10 
min. N-Bromosuccinimide (2 .2 1  g; 12.45 mmol) was then added portionwise and the 
resulting mixture stirred for 4 h at -78°C. The mixture was then warmed to RT and 
subsequently heated at 80°C for 2 h. The solvent was evaporated under reduced pressure 
and the residue purified by column chromatography using ethyl acetate / hexane (15 : 85 
v/v) as eluant to afford the title compound as a dark liquid (0.85 g; 4 5 %): v^ax (film) / cm*1
2951, 1719, 1646, 1439, 1408, 1369, 1174, 1092, 1039; Ôh  (300MHz) 1.80 (quin, 2 H ,/ =
186
7.1, CH2CH2CH2), 2.23 (m, 2H, C//2CH=CH), 2.67 (t, 2H, 7 =  7.1, COCff2), 3.79 (s, 3H, 
CO2CH3), 3.91 (s, 2H, BrCH2CO), 5.82 (dt, 1H, 7 =  1.6, 15.6, CH=ClïC02Me), 6.87 (dt, 
1H, 7 = 6.9, 15.6, C7/=CHC02Me); 5c (75MHz) 21.9 (CH2CH2CH2), 31.1 (CH2CH=CH),
34.1 (BrCH2CO), 38.7 (COCH2), 51.5 (CO2CH3), 121.8 (CH=ŒC0 2 Me), 147.9 
(CH=CHC02Me), 166.8 (CO2CH3), 201.4 (BrOfeCOO^); m/z (CI) 266 (MNH/), 
100%), 258 (14%), 244 (23%), 214 (8 %), 202 (9%), 188 (93%), 171 (5%); (Found: (CC) 
MNH4+ 266.0392; C9H13B1O3 requires MNH,4- 266.0392).
Methyl Z-8-bromo-7-oxooct-2-enoate
OoMe
Z- 207b
C02Me
Z- 196b
Prepared as for methyl E-8-bromo-7-oxooct-2-enoate 196a, but using methyl Z-7- 
oxooct-2-enoate 207b (0.90 g; 5.30 mmol), LDA (1.2 eq; 6.30 mmol),
chlorotrimethylsilane (3.36 ml; 26.5 mmol), triethylamine (3.69 ml; 26.5 mmol), NaHCOg 
(0.62 g; 7.42 mmol) and N-bromosuccinimide (1.22 g; 6.89 mmol). Purification of the 
crude residue by column chromatography using ethyl acetate / hexane (15 : 85 v/v) as 
eluant afforded the title compound as a dark liquid (0.60 g; 45%): v^ax (film) / cm"1 2954, 
1717, 1643, 1434, 1410, 1370, 1171, 1092, 1039; Ôh (300MHz) 1.76 (quin, 2H, /  = 7.3, 
CH2C//2CH2), 2.23 (s, 3H, C H 3 C O ) ,  2.66 (dq, 2 H , / =  1.6, 7.5, Ctf2CH=CH), 2.72 (t, 2H, 
J = 7.3, C O C H 2 ) ,  3.70 (s, 3H, CO2Œ 3), 3.75 (s, 2H, BrCtf2CO), 5.84 (dt, 1H, J = 1.6,
11.5, CH=C//C02Me), 6.23 (dt, 1H, J  = 7.7, 11.5, CH=CHC02Me); ôc (75MHz) 22.8 
(CH2CH2CH2), 27.9 (CH2CH=CH), 34.3 (BrCH2COCH2), 38.9 (CH3COCH2), 51.1
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(CO2CH3), 120.4 (CH=CHC02Me), 148.9 (CH=CHC02Me), 167.2 (C02CH3), 202.3 
(CH3COCH2).
Methyl l-benzyl-2,3,7,8,9,9a-hexahydro-l^-pyrrolo[l,2,3-<fe]quinoxaline-6-
carboxylate
217Ph'
-Ph
+
To a solution of 1-benzyl-4,5-dihydroimidazole (0.15 g; 0.98 mmol) in dry THF (15 
ml) under an atmosphere of nitrogen was added a solution of methyl E-8-bromo-7-oxooct- 
2-enoate (0.27 g;T.08 mmol) in dry THF (5 ml). The resulting solution was refluxed for 2 
h. DBU (0.17 ml; 1.17 mmol) was added dropwise over 4 h. The reaction was kept at 
reflux for a further 4 h. After cooling the reaction to RT and evaporating the solvent under 
reduced pressure, the residue was purified by silica gel column chromatography using ethyl 
acetate / hexane (3 : 7 v/v) as eluant to afford the title compound às a white solid (0.095 g; 
31 %): m.p. 120-123°C; (nujol) / cm"1 2881, 2944, 1735, 1697, 1524, 1463, 1390, 
1248, 1172, 1098, 1051, 916, 732; Sh (300MHz) 1.45 (dtd, 1H, J  = 2.5, 11.6, 13.5, 9- 
CflH), 1.76 (dddt, 1H, J = 2.1, 6.0, 11.6, 13.7, 8 -CHfl), 2.12 (m, 1H, 8 -CflH), 2.29 (m,
IH, 9-CHfl), 2.49 (ddd, 1H, J  = 7.5, 10.0, 12.5, 2-CHH), 2.66 (dddd, 1H, J  = 2.1, 5.8,
II.2 ,16 .8 ,7-CHH), 2.85 (dd, 1H, .7=6.4,16.8,7-C77H), 3.02 (ddd, 1H, 7=  2.3, 3.9, 12.5, 
2-CHH), 3.13 (d, 1H, J  = 13.2, PhC7/2), 3.28 (br. d, 1H, J  = 10.6, 9a-C77), 3.76 (s, 3H, 
COzCffs), 3.85 (m, 2H, 3-Cff2), 4,25 (d, 1H, J  = 13.2, PhC/ft), 7.12 (s. 1H, 5-Cfl), 7.23-
188.
7.37 (m, 5H, Ar-tf); Sc (75MHz) 22.4, 22.5 (C-8  and C-7), 27.9 (C-9), 44.9 (C-2), 49.7 (C- 
3), 50.6 (CO2CH3), 57.3 (PhCHa), 59.7 (C-9a), 113.8 (C-6 a), 117.0 (C-6 ), 124.3 (C-5), 
127.2, 128.4, 129.0 (3 x Ar-CH), 130.2 (C-9b), 138.4 (Ar-Q, 165.9 (CO2CH3); m/z (El) 
311 (MIT, 10%), 283 (10%), 282 (41%), 191 (39%), 161 (6 %), 91 (100%), 49 (21%), 43 
(17%); (Found: (El): MET 311.1763; C19H22N2O2 requires MH1" 311.1759). The title 
compound 217 is also obtained (20% yield) using methyl Z-8-bromo-7-oxooct-2-enoate 
196b.
Ethyl £-2-methyl-7-oxooct-2-enoate
222206
To a solution of 5-oxohexanal (5.07 g; 43.8 mmol) in dry dichloromethane (50 ml) 
was added dropwise a solution of ethyl 2 -(triphenylphosphoranylidene) propionate109 2 2 1  
in dry dichloromethane (100 ml). The resulting solution was stirred for 8 h, the solvent 
removed under reduced pressure and the residue purified by silica gel column 
chromatography using ethyl acetate / hexane ( 1 : 9  v/v) as eluant to afford the title 
compound as a colourless oil (2.8 g; 32%): Vmax (film) / cm'1 2983, 1713, 1650, 1446, 
1389, 1261, 1163, 1123, 1088; 5» (300MHz) 1.29 (t, 3H, /  -  7.1, C O ^C ^C H ^  1.73 
(quin, 2H, J  = 7.3, CH2C7/2CH2), 1.82 (br. s, 3H, CH=C(Œ 3)C0 2CH3), 2.14 (s, 3H, 
Œ3COCH2), 2 .2 0  (q, 2 H, J = 7.3, C^2CH=C(CH3)), 2.45 (t, 2 H, J = 7.3, CH3COŒ2), 
4.18 (q, 2H, /  = 7.1, CO2Œ2CH3), 6.71 (t, 1H, J  = 7.5, CH2C//=C(CH3)C0 2 CH3); Sc 
(75MHz) 12.4 (CO2CH2CH3), 14.3 (CH=C(CH3)C0 2 CH3), 22.5 (CH2CH2CH2), 27.8
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(CHjCOCH;,), 29.9 (CH2CH=CH(CH3)), 42.8 (CH3COŒ2), 60.5 (CO2CH2CH3), 129.2 
(CH=C(CH3)C02CH3), 140.9 (CH=C(CH3)C02CH3), 167.1 (CO2CH3), 206.2
(CH3COCH2); m/z (El) 199 (MH", 13%), 172 (16%), 152 (51%), 125(15%), 109 (42%), 95 
(41%), 84 (71%), 67 (25%), 51 (38%); (Found: (El) MIT 199.1330; C„H,g0 3  requires 
MET 199.1334).
Ethyl £-8-bromo-2-methyl-7-oxooct-2-enoate
£-222 £-224
Prepared as for methyl £-8-bromo-3-methyl-7-oxooct-2-enoate 196a, but using 
ethyl £-2-methyl-7-oxooct-2-enoate 222 (1.86 g; 9.39 mmol), IDA (1.2 eq.; 1.12 mmol), 
chlorotrimethylsilane (5.96 ml; 46.9 mmol), triethylamine (4.74 ml; 46.9 mmol), NaHC0 3  
(1.10 g; 13.14 mmol) and N-bromosuccinimide (2.17 g; 12.20 mmol). The solvent was 
removed under reduced pressure and the residue purified by silica gêl column 
chromatography using ethyl acetate / hexane (1 : 9 v/v) as eluant to afford the title 
compound as a brown oil (1.16 g; 44%): v^» (film) / cm"1 2982, 1713, 1650, 1446, 1393, 
1368, 1262, 1184, 1124, 1088; 8 h (300MHz) 1.29 (t, 3H, J  = 7.1, CO2CH2C//3), 1.78 
(quin, 2H, J  = 7.2, CH2CH2CH2); 1.83 (d, 3H, J  ~ 1.3, CH=C(Ctf3)C0 2Et), 2.21 (q, 2H, J  
= 7.5, CH2CH2CH=CH), 2.60 (t, 2H, / =  7.1, COCH2CH2), 3.87 (s. 2 H, BrCH2CO), 4.19 
(q, 2H, J  = 7.1, CO2CH2CH3), 6.70 (tq, 1H, J  = 1.3, 6.1, CH2CH=CH(CH3)); 5c (75MHz) 
12.4 (CO2CH2CH3), 14.3 (CH=CH(CH3)C0 2 Et), 22.6 (CH2CH2CH2), 27.6 
(CH2CH=CH(CH3); 34.1 (BrCH2CO), 38.9 (CO Œ 2CH2), 60.5 (CO2CH2CH3), 128.9 
(CH=CH(CH3)C0 2Et), 140.4 (CH2CH=CH(CH3)), 160.3 (CO2CH2CH3), 201.6
(CH2COCH2); m/z (CI) 294 (MNH4+, 100%), 277 (5%), 254 (12%), 216 (98%); (El) 203 
(28%), 197 (22%), 169 (62%), 151 (27%), 123 (31%), 112 (30%), 95 (62%), 83 (4%), 82 
(27%), 81 (39%), 79 (24%), 67 (33%), 43 (100%); (Found: (CI): MNH/- 294.0705; 
C11H17B1O3 requires MNH*"" 294.0705).
Attempted synthesis of ethyl l-benzyl-9-methyl-5-oxo-decahydro-l//-imidazo[l,2- 
fl]indo!e-9-carboxylate
-Ph
+
N
29 225
Methyl £,-8-bromo-2-methyl-7-oxooct-2-enoate (0.78 g; 2.83 mmol) in dry THF (5 
ml) was added to a solution of 1 -benzyl-4,5-dihydroimidazole (0.38 g; 2.36 mmol) in dry 
THF (15 ml). The solution was refluxed for 2 h and DBU (0.42 ml; 2.83 mmol) was then 
added dropwise over 4 h. The mixture was refluxed for a further 4h, the reaction flask 
cooled to RT, thé solvent was removed under reduced pressure and the residue subjected to 
silica gel column chromatography using ethyl acetate / hexane (10 : 9 v/v) as eluant but 
none of the title compound was isolated. The data of the isolated product is as follows: Vmax 
(film) / cm’1 2979, 1715, 1693, 1455, 1365, 1335, 1262, 1218, 1161, 1116; 8 » (300MHz) 
1.29 (t, 3H, / =  7.3, CO2CH2C//3), 1.52 (m, 1H), 1.76 (m, 1H), 1.82 (s, 3H, CH=C(Cff3)), 
1.91 (m, 1H), 2.03 (m, 1H), 2.12 (m, 2H), 2.54 (m, 1H), 3.10 (m, 1H), 3.29 (t, 1H, J  = 5.0), 
3.42 (m, 1H), 3.45 (d, 1H, J  = 13.4, PhCHH), 3.76 (m, 1H), 3.96 (d, 1H, /  = 13.4, 
PhCHH), 4.18 (q, 2H, 7=7.3, CO2C//2CH3), 6.73 (tq, 1H, 7=  1.3, 6.1, C#=C(CH3)), 7.26
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(m, 5H, Ar-fl), 9.47 (s, 1H); ôc (75MHz) 12.4, 14.3, 24.0, 28.4, 29.9, 39.8, 44.9, 58.1,
60.5, 65.4, (128.3, 128.6, 128.7 (3 x Ar-CH)), 137.2 (Ar-Q, 141.2, 162.4, 168.1, 173.3; 
m/z (CI) 373 (MET, 30%), 345 (MUT- CO); (Found: (CI): MUT 373.2127; C21H28N2O2 
requires MtT 373.2126).
l-Benzyl-4-formyl-2-(4-mtrophenyI)-l,4,5,6-tetrahydropyrazine
+
Ph' NO
-Phr
+
230
anti-232
Prepared as methyl 1 -benzyl-2,3,6a,7,9,9a,9b-octahydro- lH-pyrrolo[ 1,2,3-
de]quinoxaline-6-carboxylate 217 but using 1 -benzyl-4,5-dihydroimidazole (0.40 g; 2.50 
mmol), commercial 2-bromo-4/-nitroacetophenone 230 (0.67 g; 2.75 mmol) and DBU 
(0.44 ml; 3.0 mmol). The solvent was removed under reduced pressure and the residue 
subjected to silica gel column chromatography using ethyl acetate / hexane (8 : 92 v/v) as 
eluant to afford the title compound as a mixture of rotamers and an orange oil (0.70 g; 87 
%): Vma, (film ) /  cm"1 2349, 1683, 1628, 1589, 1515, 1415, 1395, 1343, 1191; 8h 
(300MHz) 3.06 (m, 2H, 6 -CH2 of syn rotamer), 3.15 (m, 2H, 6 -CH2 of anti rotamer), 3.30 
(m, 2H, 5-CH2 of anti rotamer), 3.42 (m, 2H, 5-CH2 of syn rotamer), 3.81 (s, 2H, PhCH2), 
3.84 (s, 2 H, PhCH2 for other rotamer), 6.48 (s, 1H, 3-CH of syn rotamer), 6.98 (s, 1H, 3- 
CH of anti rotamer), 7.21-7.32 (m, 9H, Ar-H), 7,66 (m, 2H, ArN02-H), 7.90 (s, 1H, 
N=COH of anti rotamer), 8.17 (m, 2H, ArN02-H for other rotamer), 8.27 (s,lH, N=COH
of syn rotamer); Sc (75MHz) 35.2 (C-5), 40.2 (C-6 ), 45.2 (C-5 for other rotamer), 46.2 (C- 
6  for other rotamer), 56.3 (PhCH]), 56.6 (PhCHa for other rotamer), 108.6 (C-3 of anti 
rotamer), 112.2 (C-3 of syn rotamer), 124.0 (ArNOz-CH), 124.1 (ArNOa-CH), 126.7 
(ArNOz-CH), 127.1 (ArN02 CH), 127.7, 127.9, 128.8 (3 x Ar-CH)), 137.1 (Ar-Q, 142.2 
(ArNOz-Q, 143.1 (C- 2  of anti rotamer), 147.3 (C- 2  of syn rotamer), 147.5 (ArNOz-Q,
159.3 (N=CHO of anti rotamer), 159.9 (N=CHO of syn rotamer ); m/z (El) 324 (MET1", 6 %), 
293 (8 %), 174 (8 %), 118 (12%), 91 (100%), 65 (28%), 51 (9%); (Found: (El): M*+ 
323.1268; CigHnNgOg requires M*+ 323.1270).
w
l-bromoheptan-2 -one124
241 239
Prepared as for methyl £-8-bromo-7-oxooct-2-enoate 196a but using commercial 
heptan-2-one (4.0 g; 35.0 mmol), LDA (42.0 mmol), prepared from n-BuLi (1.6M solution 
in hexanes; 26.27 ml; 42.0 mmol) and diisopropylamine (6.37 ml; 45.5 mmol), 
chlorotrimethylsilane (22.21 ml; 175.0 mmol), triethylamine (24.39 ml; 175.0 mmol), 
NaHCOs (4.11 g; 49.0 mmol) and N-bromosuccinimide (8.09 g; 45.5 mmol). The solvent 
was removed under reduced pressure and the residue purified by silica gel column 
chromatography using ethyl acetate / hexane (7 : 93 v/v) as eluant to afford the title 
compound as a brown oil (2.80 g; 41%): Vmax (film) / cm'1 2958, 2932, 1718, 1466, 1405; 
Sh (300MHz) 0.89 (t, 3H, 7=6.8, C^(CHz)^CO), 1.31 (m, 4H, Œ L 3 C H 2 C H 2 ), 1.62 (quin, 
2H, /  = 7.1, COCII2CZ/2CII2), 2.64 (t, 2H, J  = 7.3, BrCOCHzCHz), 3.88 (s, 2H,
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BrC#2COCH2); ôc (75MHz) 13.8 (CH3(CH2)4), 22.4 (CH3CH2CH2CH2), 23.5 
(CH3CH2CH2CH2), 31.2 (CH3CH2CH2CH2), 34.3 (BrCH2COCH2), 39.8 (BrCH2COCH2),
202.3 (BrCH2COCH2).
Attempted synthesis of -benzyl-4-formyl-2-(4-pentane)-l,4,5,6-tetrahydropyrazine
Ph
Cf *
29 239 240
Prepared as l-benzyl-4-formyl-2-(4-nitrophenyl)-l,4,5,6-tetrahydropyrazine 232 but 
using 1-benzyl-4,5-dihydroimidazole (0.30 g; 1.89 mmol), l-bromo-heptan-2-one (0.40 g; 
2.08 mmol) and DBU (0.33 ml; 2.26 mmol). The solvent was removed under reduced 
pressure and the residue subjected to silica gel column chromatography using ethyl acetate 
/ hexane (1 : 9 v/v) as eluant to afford a compound isolated an oil (0.89 g) and which 
spectroscopic data is as follows: Vmax (film) / cm*1 1725, 1695, 1228, 1174; Ôh (300MHz) 
0.81 (t, 3H, J  = 6 .8 ), 1.22 (m, 7H), 1.50 (br. s, 6 H), 1.81 (m, 1H), 1.94 (m, 1H), 2.40 (m, 
1H), 2.98 (m, 1H), 3.21 (t, 1H, / =  5.0), 3.32 (m, 2H), 3.69 (m, 1H), 3.88 (d, 1H, / =  13.3, 
PhCflH), 7.23-7.28 (m, 5H, Ar-tf), 9.40 (s, 1H); ôc (75MHz) 14.0, 22.5, 24.7, 30.2, 31.7, 
39.87, 44.9, 58.0, 65.6, (127.56, 128.5, 128.7 (3 x Ar-CH)), 137.4 (Ar-Q, 162.5, 173.6; 
m/z (Cl) 289 (MNH/, 87%), 261 (96%), 106 (100%).
194
tert-Butyl 2-acetyl-S-oxohexanoate112
According to the published method, 112 to a mixture of cerium (ID) chloride 
heptahydrate (0.94 g; 2.52 mmol) and sodium iodide (0.19 g; 1.26 mmol) was added tert- 
butyl acetoacetate 246 (2.09 ml; 12.6 mmol) followed by but-l-en-3-one 247 (0.93 ml;
13.6 mmol). The resulting mixture was stirred at RT for 8 h until all the starting material 
was consumed. Dichloromethane (20 ml) was added and the mixture filtered and the 
residue rinsed with dichloromethane. The combined filtrates were concentrated under 
reduced pressure and the crude product was purified by silica gel chromatography using 
ethyl acetate / hexane (4 : 6  v/v) as eluant to afford the title compound a pale yellow oil 
(2.79 g; 97%): Vnw* (film) / cm"1 2979, 1713, 1643, 1422, 1394, 1370, 1254, 1146, 962, 
846; Sh (300MHz) 1.46 (s, 9H, C0 2C(CHih\ 2.03 (m, 2 H, CH3COCH2CH2CH), 2.13 (s, 
3H, ŒfcCOCHCOz'Bu), 2.26 (s, 3H, C//3COCH2CH2), 2.48 (t, 2H, J  = 6.9, 
CH3COCH2CH2), 3.37 (t, 1H, J  = 7.1, CH3COCH2CH2ŒO; Sc (75MHz) 22.1 
(CH3COCH2CH2CH), 27.8 (C02C(CH3)3), 28.5 (CH3CO), 29.6 (CH3CO), 40.1 
(CH3COCH2CH2CH), 58.9 (CH3COCH2CH2CH), 81.6 (C02C(CH3)3), 168.3
(C0 2 C(CH3)3), 202.7 (CH3CO), 207.3 (CH3CO); m/z (Cl) 246 (MNH/, 50%), 242 (13%), 
225 (5%), 191 (12%), 190 (100%), 176 (14%), 158 (7%), 148 (27%), 146 (62%), 128 
(18%), 77 (15%), 61 (8 %), 58 (17%); (Found: (CI): M N H / 246.1698; C12H20O4 requires 
M N îV  246.1705).
195
2,6-heptanedione
fgrf-Butyl 2-acetyl-5-oxohexanoate 248 (0.66 g; 2.89 mmol) was treated with 
excess neat trifluoroacetic acid (30 ml) and the resulting red solution was stirred for 30 min 
at RT. The excess acid was removed under reduced pressure and the residue distilled under 
reduced pressure to afford the title compound as a colourless oil (0.35 g; 98%): b.p. 92°C / 
1U mmHg (lit. ,125 Z 12 mmHg); Vm„  (film) / cm'1 2942, 1714, 1428, 1360, 1171; Ôh 
(300MHz) 1.86 (quin, 2H, J  = 7.1, COCHzCtfzCHzCO), 2.14 (s, 6 H, 2 x CH3COCH2), 
2.46 (t, 4H, 7=7 .1 , 2  x COCff2); 6 c (75MHz) 17.6 (COCH2CH2CH2CO), 29.9 (CH3CO),
42.4 (CH3COCH2), 209.1 (2 x CH3COÇH2).
E- and Z-Methyl-3-methyl-7-oxooct-2-enoate
0 2Me
249 E- and Z-250
A solution of commercial trimethyl phosphonaeetate (3.70 ml; 23 mmol) in dry 
THF (10 ml) was added dropwise with cooling (ice / water bath) to a suspension of NaH 
(0.60 g; 25 mmol) in dry THF (30 ml) under nitrogen. The water bath was removed and the 
mixture stirred at RT for a further 30 min. A solution of 2,6-heptanedione 249 (2.6 g; 20.9 
mmol) in dry THF (10 ml) was then added dropwise, and the reaction stirred at RT for a 
further 10 h. The solvent was removed under reduced pressure and the residue purified by
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silica gel column chromatography using ethyl acetate / hexane (7.5 : 92.5 v/v) as eluant to 
afford the title compound as a yellow oil (1.55 g; 40%), that was an inseparable (50 : 50) 
mixture of E- and Z-isomers: Vmax (film) / cm*1 2951, 1718, 1651, 1436, 1363, 1227, 1151, 
1085, 1028, 921, 8 6 6 ; 5h (300MHz) 1.77 (m, 2H, CH2CH2CH2CH), 1.89 (d, 1.5H, / =  1.3, 
CH2C(C#3)=CH for Z-isomer), 2.14 (s, 3H, CH3COCH2 for both Z- and E-isomers), 2.16 
(d, 1.5H, J  = 1.3, CH2C (Œ 3)=CH for E-isomer), 2.20 (t, 1H, /  = 7.5, C #2C(CH3)=CH for 
E-isomer), 2.44 (t, 1H, 7 = 7.1, CH3COC/ / 2  for E- or Z-isomer), 2.49 (t, 1H, 7 = 7.1, 
CH3C O Œ 2 for E- or Z-isomer), 2.62 (t, 1H, 7 = 7.5, C7 f2C(CH3)=CH for Z-isomer), 3.67 
(s, 1.5H, CO2C/ /3  for Z-isomer), 3.69 (s, 1.5H, CO2C/ /3  for E-isomer), 5.66 (sext, 0.5H, 7 
= 1.3, C(CH3)=C//C0 2CH3 for Z-isomer), 5.68 (br m, 0.5H, C(CH3)=C//C0 2CH3 for E- 
isomer); 5c (75MHz) 21.1, 21.9 (CH2CH2CH2 for E- and Z-isomers), 24.9, 27.9 
(C(CH3)=CHC0 2 Me for E- and Z-isomers), 29.9, 30.0 (CH3CO for E- and Z-isomers),
32.4 (CH3COCH2 for E- and Z-isomers), 42.5,43.1 ( Œ 2C(CH3)=CHC0 2Me for E- and Z- 
isomers), 50.8, 50.9 (CO2CH3 for E- and Z-isomers), 115.7, 116.2 (C(CH3)=CHC0 2 CH3 
for E- and Z-isomers), 159.2, 160.0 (C(CH3)^CHC0 2Me for E- and Z-isomers), 166.7,
167.1 (CO2CH3 for E- and Z-isomers), 208.2, 208.7 (CH3COCH2 for E- and Z-isomers); 
m/z (Cl) 2 0 2  (MNH/, 1 0 0 %), 185 (1 1 %), 172 (13%), 152 (18%), 127 (14%), 109 (38%), 
95 (53%), 82 (24%), 79 (7%), 67 (32%), 59 (8 %), 55 (20%), 49 (39%), 43 (100%); 
(Found: (Cl): M N H /202.1489; CioH^Os requires M N H / 202.1443).
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Methyl £-8-bromo-7-oxo-3-methyl-oct-2-enoate
B ^  .C 02Me
E- and Z-250 £-245
Prepared as for methyl £’-8-bromo-7-oxooct-2-enoate 196a, using a mixture of E- 
and Z-methyl-3-methyl-7-oxooct-2-enoate 250 (0.74 g; 4.02 mmol), LDA (1.2 eq.; 4.8 
mmol), chlorotrimethylsilane (2.55 ml; 20.1 mmol), triethylamine (2.80 ml; 20.1 mmol), 
NaHCOg (0.47 g; 5.6 mmol) and N-bromosuccinimide (0.93 g; 5.22 mmol). The solvent 
was removed under reduced pressure and the residue purified by silica gel column 
chromatography using ethyl acetate / hexane ( 1 : 9  v/v) as eluant to afford the title 
compound as a single isomer and as a brown oil (0.30 g; 30%): Vmax (film) / cm'1 2950, 
1713, 1651, 1436, 1379, 1228, 1155, 1087, 921, 857; Ôh (300MHz) 1.70 (quin, 2H, / =  7.6, 
CH2C7 / 2CH2), 1.78 (d, 3H, J = 1.4, C(Ctf3)=CHC02Me), 2.49 (br. t, 2H, J  = 6.6, 
C£2C(CH3)=CH), 2.59 (t, 2H, J  = 7.3, C O Œ 2CH2), 3.56 (s, 3H, C 0 2CH3\  3.79 (s, 2H, 
BrCi/2CO), 5.59 (br s, 1H, CHzCfCHg^CffCOzMe); 8C (75MHz) 22.1 (CH2Œ 2CH2),
25.1 (C(CH3)=CH), 32.3 (CH2CH=CH(CH3)C02Me), 34.4 (BrCH2CO), 39.3
(CO Œ 2CH2), 51.1 (CO2CH3), 116.7 (C(CH3)=CHC0 2 Me), 159.7
(CH2C(CH3)=CHC0 2Me), 166.9 (CO2CH3), 202.0 (CH2COCH2); m/z (Cl) 280 (MNH/, 
100%), 263 (11%), 258 (13%), 232 (14%), 216 (11%), 203 (12%), 202 (100%), 200 (5%), 
185 (16%), 172 (11%); (El) 151 (42%), 109 (57%), 95 (100%), 82 (44%), 81 (63%), 79 
(40%), 67 (6 8 %), 43 (100%); (Found: (CI): MNH4+ 280.0551; CioHisBrOg requires 
MNH4+ 280.0548)
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Attempted synthesis of ethyl l-benzyl-8a-methyl-5-oxo-decahydroimidazo[l,2-
û]indole-9-carboxylate
r
-Ph
^  /C 0 2Me
:02Me
29 E- 245 243
Methyl £-8-bromo-3-methyl-7-oxooct-2-enoate (0.10 g; 0.38 mmol) in dry THF (5 
ml) was added to a solution of 1-benzyl-4,5-dihydroimidazole (0.06 g; 0.38 mmol) in dry 
THF (15 ml). The solution was refluxed for 2 h then DBU (0.07 ml; 0.45 mmol) was added 
dropwise over 4 h. The mixture was refluxed for a further 4 h, the reaction flask was 
allowed to cool to RT, the solvent was removed under reduced pressure and the residue 
subjected to silica gel column chromatography using ethyl acetate / hexane (5 : 95 v/v) as 
eluant but none of the title compound was isolated.
Ethyl f?-10-bromo-9-oxodec-2-enoate126
Prepared as for methyl 2s-8-bromo-7-oxooct-2-enoate 196a but using ethyl E-9- 
oxodec-2-enoate 251113 (4.0 g; 18.8 mmol), LDA (22.6 mmol), chlorotrimethylsilane 
(11.93 ml; 94.0 mmol), triethylamine (13.10 ml; 94.0 mmol), NaHCO] (2.21 g; 26.32 
mmol) and N-bromosuccinimide (4.35 g; 24.4 mmol). The solvent was removed under 
reduced pressure and the residue purified by silica gel column chromatography using ethyl
O O
^ X 0 2Et Br < ^ , C 0 2Et
251 E- 253
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acetate / hexane (8 : 92 v/v) as eluant to afford the title compound as a brown oil (2.0 g; 
36%): Vm, (film) / cm"1 2981, 2937, 1713, 1655, 1463, 1393, 1368, 1310, 1269, 1184, 
1044, 983; Sh (300MHz) 1.28 (t, 3H, J = 7.1, CO2CH2CH3), 1.34 (quin, 2H, J  = 7.2, 
Cff2CH2CH2CH-CHC02Et), 1.48 (quin, 2H, J  = 7.2, C%CHzCH=CH), 1.62 (quin, 2H, J  
= 7.4, COCH2C//2CH2), 2.20 (m, 2H, CH2Cff2CH=CH), 2.66 (t, 2H, J  = 7.3, COCH2CH2), 
3.87 (s, 2H, B1CH2CO), 4.18 (q, 2H, /  = 7.1, CO2CH2CH3), 5.81 (dt, 1H, /  = 1.6, 15.5, 
CH=CflC0 2 Et), 6.94 (dt, 1H, J  = 6.9, 15.5, C//=CHC02Et); Sc (75MHz) 14.3 
(CO2CH2CH3), 23.5 (CH2CH2CH2CH=CH), 27.7 (CH2CH2CH=CH), 28.4 
(COCH2CH2CH2), 31.9 (CTfeCTMH), 34.2 (BrCH2CO), 39.6 (C O Œ 2CH2), 60.2 
(CO2CH2CH3), 121.5 (CH=CHC0 2 Et), 148.8(CH=CHCC>2Et), 166.7 (CO2CH2CH3), 202.0 
(CH2COCH2); m/z (Cl) 308 (MNH4+, 100%), 213 (10%), 202 (8 %); (El) 244 (100%), 217 
(21%), 197 (43%), 165 (10%), 137 (17%), 123 (23%), 95 (50%), 81 (54%), 67 (23%), 55 
(61%), 43 (1 0 0 %); (Found: (Cl): MNHt+ 308.0858; C12H19B1O3 requires M N H/ 
308.0861).
Attempted synthesis Ethyl 5-benzyl-4,5,5a,<>,7,8,9,10-octahydro-3/7-2a,5-diaza- 
cycloocta[cd]mdene-l-carboxylate
r
p
29
V7 X+
255
Prepared as for methyl 1-benzyl-2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-
de]quinoxaline-6 -carboxylate 217 but using 1-benzyl-4,5-dihydroimidazole (0.22 g; 1.36
200
mmol), ethyl E1- 10-bromo-9-oxodec-2-enoate (0.43 g; 1.50 mmol) and DBU (0.25 ml; 1.64 
mmol). The solvent was removed under reduced pressure and the subjected to silica gel 
column chromatography using ethyl acetate / hexane ( 1 : 9  v/v) but none of the title 
compound was isolated. The compound isolated was an oil (0.12 g) which spectroscopic 
data is as follows: (film) / cm 2935, 1720, 1689, 1266, 1217, 909, 733; Sh (300
MHz) 1.28 (t, 3H, J = 7.3, CO2CH2C//3), 1.46 (t, 2H, 7=7.3), 1.58 (m, 2H), 1.89 (m, 1H),
2.03 (m, 1H), 2.17 (m, 2H), 2.47 (m, 1H), 3.05 (m, 1H), 3.27 (t, 1H, 7=  5.0), 3.36 (m, 1H), 
3.40 (d, 1H, 7 = 13.4, PhCflH), 3.76 (m, 1H), 3.94 (d, 1H, 7 = 13.4, PhCHH), 4.18 (q, 2H, 
7 = 7.3, CO2CH2CH3), 5.80 (dt, 1H, 7 = 1.6, 15.6, CH=C7/C02Et), 6.94 (dt, 1H, 7 = 6.9,
15.6, Cff=CHC02Et), 7.32 (m, 5H, Ar-fl), 9.47 (s, 1H); Sc (75MHz) 14.3, 24.8,27.8,28.9,
30.0, 32.0, 39.8, 44.9, 58.1, 60.1, 65.4, 121.4, (127.6, 128.6, 128.7 (3 x Ar-CH)), 137.3 
(Ar-Q, 149.0, 162.4, 166.7, 173.5; m/z (Cl) 387 (MH*, 60%), 359 (MH*- CO, 90%); 
(Found: (CI): MH* 387.2287; C22H30N2O2 requires MH+387.2284).
4-Oxopentanal
256 257
To an ice-cold suspension of pyridinium chlorochromate (PCC) (31.68 g; 147.0 
mmol) in dry dichloromethane (80 ml) and silica (8  g) was added a solution of 5 - 
hydroxypentan-2-one 256 (10.0 g; 98.0 mmol) in dry dichloromethane (50 ml). The 
resulting mixture was stirred at RT for 2 h then the brown solution was decanted from the
201
black residues which were then washed using diethyl ether (4 x 300 ml). The combined 
organic solutions were concentrated by removing the solvent under reduced pressure. The 
residue was extracted with hexane (3 x 200 ml), the hexane extracts concentrated under 
reduced pressure and finally distilled to afford the title compound as a colourless oil (1 .0  g; 
10%): b.p. 86-89°C / 20 mmHg (lit. ,127 64-65°C / 11 torr); Vm» (film) / cm'1 3505, 2912, 
2844, 1713, 1411, 1369, 1171, 1081, 1030, 968, 880; 5» (300MHz) 2.19 (s, 3H, 
CH3COCH2), 2.76 (s, 4H, CH3COCH2CH2CHO), 9.75 (s, 1H, CM)); ôc (75MHz) 29.8 
(CH3COCH2), 35.5 (COCH2CH2CHO), 37.4 (COCH2CH2CHO), 200.4 (CHO), 206.4 
(CH3COCH2).
Methyl Z?-6-oxo-hept-2-enoate128
O
M
0 2M e
£-258
O
257
Prepared as for methyl E -l-oxooct-2-enoate 196a but using 4-oxopentanal 257 
(0.36 g; 3.56 mmol) and methyl (triphenylphosphoranylidene)acetate106 210 (1.31 g; 3.90 
mmol). The solvent was removed under reduced pressure and the residue purified by silica 
gel column chromatography using ethyl acetate / hexane (5 : 95 v/v) as eluant to afford the 
title compound as a colourless oil (0.40 g; 72%): Vmax (film) / cm"1 2847, 1723, 1713, 1659, 
1462, 1368,1318, 1276, 1203, 1161, 1097, 1041, 924, 849, 719; Ôh (300MHz) 2.14 (s, 3H, 
CH3COCH2), 2.45 (m, 2H, CH2CH2CH=CH), 2.58 (t, 2 H, J  = 6 .8 , CH3COCH2), 3.69 (s, 
3H, CO2CH3), 5.80 (dt, 1H, J = 1.6, 15.6, CH=CHC02Me), 6.90 (dt, 1H, J  = 6 .8 , 15.6, 
CH=CHC02Me); ôc (75MHz) 25.9 (CH2CH=CHC0 2 Me), 29.9 (CH3COCH2), 41.4
202
(CH3COCH2), 51.4 (CO2CH3), 121.6 (CH=ŒC0 2 Me), 147.4 (O fcC H O W e), 166.8 
(CO2CH3), 206.6 (CH3 COCH2); m/z (El) 156 (M**, 98%), 149 (78%), 141 (79%), 135 
(34%), 133 (49%), 113 (21%), 81 (39%), 43 (100%); (Found: (El): MH1" 157.0863; 
CgHnOs requires MH* 157.0864).
Methyl E-7-bromo-6-oxohept-2-enoate
Br>
Prepared as for methyl £-8-bromo-7-oxooct-2-enoate 196a but using methyl E-6 - 
oxohept-2-enoate (0.35 g; 2.24 mmol), LDA (2.69 mmol), chlorotrimethylsilane (1.42 ml;
11.2 mmol), prepared from n-BuLi (2.5M solution in hexanes; 1.07 ml; 2.69 mmol), 
triethylamine (1.56 ml; 11.2 mmol), NaHCOg (0.22 g; 2.64 mmol) and N- 
bromosuccinimide (0.44 g; 2.44 mmol). The solvent was removed under reduced pressure 
and the residue purified by silica gel column chromatography using ethyl acetate / hexane 
(7.5 : 92.5 v/v) as eluant to afford the title compound as a brown oil (0.18 g; 34%): Vma* 
(film)/cm"1 2840,1721,1716,1665,1457,1369,1312,1276,1164,1091, 1040,923, 844, 
716; 5h (300MHz) 2.38 (m, 2H, CH2CH=CHC02Me), 2.70 (t, 2H, J  = 7.3, 
BrCH2COCtf2CH2), 3.56 (s, 3H, CO2CH3), 3.74 (s, 2H, BiO^COCHz), 5.71 (dt, 1H, 7 =
1.5,15.6, CH=C//C02Me), 6.77 (dt, 1H, J  = 6.8, 15.6, Cfl=CHC02Me); 8c (75MHz) 25.6 
(CH2CH=CHCC>2Me), 32.9 (BrC^COCH;), 37.6 (B1CH2COCH2), 51.4 (CO2CH3), 121.9 
(CH=CHC02Me), 146.5 (CH=CHC02Me), 166.6 (CO2CH3), 200.3 (BrCH2COCH2); m/z
203
(CI) 174 (MNH4+, 100%), (El) 156 (100%), 149 (75%), 141 (75%), 133 (48%), 81 (34%), 
43 (100%); (Found: (El): M N H/ 252.0232; CgHnOg requires MNH4+ 252.0235).
Attempted synthesis of methyl l-benzyl-5-oxo-decahydro-l,4-diazacyclopenta[l,2- 
fl]pentalene-8 -carboxylate
Prepared as for methyl 1-benzyl-2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-
tik]quinoxaline-6 -carboxylate 217 but using 1-benzyl-4,5-dihydroimidazole (0.07 g; 0.43 
mmol), methyl E -l-bromo-6-oxohept-2-enoate (0.11 g; 0.47 mmol) and DBU (0.08 ml; 
0.51 mmol). The solvent was removed under reduced pressure and the residue subjected to 
silica gel column chromatography using ethyl acetate / hexane (1 :9  v/v) as eluant but none 
of the title compound was isolated.
Methyl 6-benzyl-5-phenyl-2r3,7,8,9,9a-hexahydro-l/f-pyrrolo[l,2r3-de] 
qumoxaline-6 -carboxylate
O
To a solution of 1 -benzyl-2-phenyl-4,5-dihydroimidazole (0.23 g; 1.0 mmol) in dry 
THF (15 ml) under an atmosphere of nitrogen was added a solution of methyl E-8 -bromo-
204
7-oxooct-2-enoate (0.27 g; 1.1 mmol) in dry THF (5 ml). The resulting solution was 
refluxed for 2 h. DBU (0.15 ml; 1.2 mmol) was added dropwise over 4 h. The reaction was 
kept at reflux for a further 4 h, cooled, the solvent evaporated under reduced pressure and 
the residue purified by silica gel column chromatography using ethyl acetate / hexane (3 : 7 
v/v) as eluant to afford the title compound as a white solid (0.13 g; 33%). Recrystallisation 
from methanol / hexane gave white needles for X-ray crystallographic analysis: m.p. 148- 
150°C; Vm,, (nujol) / cm"1 2932, 2857, 1694, 1489, 1466, 1382, 1348, 1264, 1193, 1170, 
1086, 911, 736, 701; Sh (300MHz) 1.55 (did, 1H, 7=2.5 , 11.6, 13.5, 9-CHH), 1.80 (dddt, 
1H, J  = 2.1, 6.0, 11.6, 13.7, 8 -CflH), 2.14 (m, 1H, 8 -CHff), 2.33 (m, 1H, 9-CHH), 2.45 
(ddd, 1H, J  = 7.5, 10.0, 12.5, 2-CflH), 2.72 (dddd, 1H, J  = 2 .1 , 5.8, 11.2, 16.8, 7-CHH), 
2.94 (m, 2H, 7-CHff and 2-CHH), 3.12 (d, 1H, 7 =  13.3, PhCff2), 3.34 (br. d, 1H, 7 =  10.6, 
9a-Cfl), 3.52 (m, 2H, 3-C#2), 3.60 (s, 3H, C0 2CH3), 4.26 (d, 1H, 7 = 13.3, PhC#2), 7.26- 
7.32 (m, 10H, Ar-fl); Sc (75MHz) 22.5, 23.0 (C-8  and C-7), 28.0 (C-9), 44.2 (C-2), 49.9 
(C-3), 50.4 (C02CH3), 57.3 (PhCH2), 59.7 (C-9a), 111.2 (C-6 a), 117.5 (C-6 ), 127.1,127.8,
127.9, 128.3, 128.5, 128.9 (6  x Ar-CH), 130.4 (C-9b), 132.0 (C-5), 136.7, 138.3 (2 x Ar- 
O , 165.9 (C02CH3); m/z (ED 387 (MH*, 21%), 359 (26%), 358 (98%), 267 (54%), 237 
(22%), 207 (11%), 180 (12%), 167 (8 %), 91 (100%), 65 (8 %), 49 (4%); (Found: (ED: MH* 
387.2077; C25H26N20 2 requires MH* 387.2072)
Methyl (3K,9S)-l-benzy]-3-phcnyl-2r3,7,8,9,9a-hcxahydro-l/7-pyrrolo[l,2,3-de] 
quinoxaline-6 -carboxylate
!OoMeB
264bPh'
-Ph
205
To a solution of (/?)-1 -benzyl-4-phenyl-4,5-dihydroimidazole (0.20 g; 0.88 mmol) 85 
in dry THF (15 ml) under an atmosphere of nitrogen was added a solution of methyl £-8 - 
bromo-7-oxooct-2-enoate (0.24 g; 0.96 mmol) in dry THF (5 ml). The resulting solution 
was refluxed for 2 h. DBU (0.15 ml; 0.10 mmol) was added dropwise over 4 h. The 
reaction was kept at reflux for a further 4, cooled, the solvent evaporated under reduced 
pressure and the residue purified by silica gel column chromatography using ethyl acetate / 
hexane (7.5 : 92.5 v/v) as eluant to afford the title compound as a white solid (0.10 g; 
30%). Recrystallisation from methanol / hexane gave white needles for X-ray 
crystallographic analysis: m.p. 176-176°C; ( [ ocJd 20 = +32.01; c = 0.345; DCM); Vma* (nujol) 
/ c m 1 2945, 1704, 1631, 1518, 1495, 1454, 1358, 1334, 1243, 1208, 1092, 892, 737, 701; 
Ôh (300MHz) 1.53 (dtd, 1H, 7=2.5, 11.6, 13.5, 9-CflH), 1.82 (dddt, 1H, 7=2.1, 6.0, 11.6, 
13.7, 8 -CtfH), 2.15 (m, 1H, 8 -CHfl), 2.35 (m, 1H, 9-CHH), 2.40 (dd, 1H, 7 = 4.9, 12.4, 2- 
CHH), 2.71 (dddd, 1H, 7 = 2.1, 5.8, 11.2, 16.8, 7-CHH), 2.92 (dd, 1H, 7 = 6.4, 16.8, 7- 
CHH), 3.08 (dd, 1H, 7=  4.9, 12.4, 2 -CHH), 3.12 (d, 1H, 7=  13.3, PhCtf2), 3.45 (br. d, 1H, 
7 = 1 0 .6 , 9a-CH), 3.72 (s, 3H, CO2CH3), 4.24 (d, 1H, 7 = 13.3, PhCtf2), 4.90 (dd, 1H, 7 =
4.9, 12.4, 3-Ctf), 6 .8 6  (s, 1H, 5-Ctf), 7.28-7.31 (m, 10H, Ar-tf); 5c (75MHz) 22.3, 22.6 
(C-8  and C-7), 28.1 (C-9), 50.6 (CO2CH3), 57.1 (PhCH2), 59.1 (C-2), 59.5 (C-9a), 60.3 (C- 
3), 114.1 (C-6 a), 117.1 (C-6 ), 124.3 (C-5), 127.2, 127.7, 128.4, 128.5, 128.7, 128.9 (6  x 
Ar-CH), 130.2 (C-9b), 138.2, 138.6 (2 x Ar-Q, 165.8 (C02CH3); m/z (El) 387 (MH% 
20%), 359 (27%), 358 (92%), 268 (20%), 267 (100%), 238 (7%), 206 (8 %), 91 (100%), 65 
(6 %); (Found: C, 76.87; H, 6 .6 6 ; N, 7.00%; El): MH+ 387.2069; C23H2^ H2O2.O.25 MeOH 
requires C, 76.88; H, 6.90; N, 7.10%; MH+ 387.2072).
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Attempted synthesis of methyl 2,3,7,8,9,9a-hexahydro-l-oxa-3a-aza-5-
phenylacenaphthylene-6-carboxylate
266
^O^Me -------
265 E 1 9 6 a
Prepared as for methyl 1 -benzyl-2,3,7,8,9,9a-hexahydro- l//-pyrrolo[ 1,2,3- 
de]quinoxaline-6-carboxylate 217 but using 2-phenyl-2-oxazoline 265 (0.10 g; 0.72 mmol), 
methyl E-8-bromo-7-oxooct-2-enoate (0.19 g; 0.79 mmol) and DBU (0.12 ml; 0.79 mmol). 
The solvent was removed under reduced pressure and the residue subjected to silica gel 
column chromatography using ethyl acetate / hexane (2 : 8 v/v) as eluant but none of the 
title compound was isolated. Both starting materials, 2-phenyl-2-oxazoline 265 and methyl 
£-8-bromo-7-oxooct-2-enoate 196a were recovered in 85% and 15%, respectively.
C y a n o (m e th y le n e tr ip h e n y l)p h o sp h o ra n e 103
+  -
PPh3 + BrCH2CN ----------------  Ph3PCHCN
267
Prepared as for methyl (triphenylphosphoranylidene)acetate 210, using triphenyl 
phosphine (20 g; 76.0 mmol) and chloroacetonitrile (9.70 ml; 152.0 mmol) to afford the 
title compound as a white solid (20.1 g; 88%): m.p. 248-250°C (lit.,129 246°C).
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E-7-oxo-oct-2-ene-nitrile130
206
.CN
E-26S
Prepared as for methyl £-7-oxooct-2-enoate 196a, using crude 5-oxohexanal (4.72 
g; 41 mmol) and cyano(methylenetriphenyl)phosphorane (14.9 g; 49.6 mmol) 267. The 
residue was purified by silica gel column chromatography using ethyl acetate / hexane (15 : 
85 v/v) as eluant to afford the title compound as a colourless oil (3.0 g; 53%): Vmax (film) / 
cm*1 2943, 2223, 1714, 1633, 1414, 1369, 1161, 975, 736; Ôh (300MHz) 1.72 (quin, 2H, J  
= 7.1, CH2C//2CH2), 2.13 (s, 3H, C//3CO), 2.22 (m, 2H, Ctf2CH=CHCN), 2.38 (t, 2H, J  =
7.4, COCH2), 5.40 (dt, 1H, J  = 1.5, 15.6, CH=C#CN), 6.78 (dt, 1H, /  = 6.8, 15.6, 
CH=CHCN); 5c (75MHz) 21.9 (CH2CH2CH2), 30.1 (Œ3COCH2), 31.2
(CH2CH2CH=CH), 42.2 (CH3COŒ2), 100.4 (CH=CHCN), 117.3 (CH=CHCN), 154.1 
(CH=CHCN), 207.5 (CH3COCH2); m/z (Cl) 155 (MNH/, 100%), 132 (4%), 94 (12%), 84 
(3%), 80 (19%), 73 (6%), 67 (17%), 58 (53%), 49 (6%), 43 (100%); (Found: (Cl): M NH/ 
155.1183; CgHnNO requires MNH4" 155.1184).
Attempted synthesis of E-8-bromo-7-oxo-oct-2-ene-mtrile
 X :
£-268
Prepared as for methyl £-8-bromo-7-oxooct-2-enoate 196a, using £-7-oxooct-2- 
enenitrile (1.40 g; 10.2 mmol), freshly prepared LDA (1.20 eq.; 12.16 mmol), prepared 
from n-BuIi (1.6M solution in hexanes; 7.66 ml; 12.26 mmol) and diisopropylamine (1.85
208
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ml; 13.2 mmol), chlorotrimethylsilane (6.47 ml; 51.0 mmol), triethylamine (7.10 ml; 51.0 
mmol), NaHCOg (1.19 g; 11.3 mmol) and N-bromosuccinimide (2.36 g; 13.26 mmol). The 
solvent was removed under reduced pressure and the residue subjected to silica gel column 
chromatography using ethyl acetate / hexane (15 : 85 v/v) but the none of the title 
compound was isolated. The compound 2s-2,8-dibromo-7-oxo-oct-2-ene-nitrile 271 was 
isolated as a brown oil (0.35 g; 12%): Vmax (film) / cm'1 2958, 2202, 1718, 1589, 1409, 
1369, 1254, 846, 763, 699, 666; Ôh (300MHz) 1.47 (quin, 2H, J = 7.8, COCH2Œ 2CH2),
2.07 (q, 2H, J  = 7.8, CH2CH2CH), 2.42 (t, 2H, J  = 7.0, BrCHzCOC#), 3.58 (s, 2H, 
BrC//2CO), 6.75 (t, 1H, J = 7.8, CH2CH2Œ ); ôc (75MHz) 22.7 (COCH2CH2CH2), 31.7 
(CH2CH2CH), 34.5 (BrCH2CO), 39.1 (BrCHzCOC#), 116.5 (C=N), 121.4
(CH=C(Br)CN), 165.0 (CH=C(Br)CN), 201.8 (BrCH2CO). The low and high-resolution 
mass spectroscopic analysis did not show the presence of either M*+ or MH* for 271.
Attempted synthesis of l-benzyl-6a-bromo-2r3,7,8,9,9a-hexahydro-lH-pyrrolo[1^2,3- 
de]quinoxaline-6-cyanate
r
THF:n+ DBU, A
27229
Prepared as for methyl 1-benzyl-2,3,7,8,9,9a-hexahydro-lH-pyrrolo[l,2,3- 
de]quinoxaline-6-carboxylate 217 but using 1-benzyl-4,5-dihydroimidazole 29 (0.04 g; 
0.27 mmol), E-2,8-dibromo-7-oxo-oct-2-ene-nitrile 271 (0.09 g; 0.32 mmol) and DBU 
(0.04 ml; 0.32 mmol). The solvent was removed under reduced pressure and the residue
209
subjected to silica gel column chromatography using ethyl acetate / hexane (2  : 8 v/v) as 
eluant but none of the title compound was isolated. Only unchanged starting material 29 
was isolated in virtually quantitative yield.
Ethyl (triphenylphosphoranylidene)acetate103
p p h 3 + BrCH2C02Et ----------------   Ph3PCHC02Et
274
Prepared as for methyl (triphenylphosphoranylidene)acetate 210, using triphenyl 
phosphine (25 g; 95.3 mmol) and ethyl bromoacetate (11.62 ml; 104.8 mmol) to afford the 
title compound as a white solid (28 g; 84%): m.p. 118-118°C (lit. ,123 116-117°C).
Ethyl E-7-oxooct-2-enoate131
206
Prepared as for methyl £-7-oxooet-2-enoate 196a, but using 5-oxo-hexanal (6.65 g;
58.3 mmol) and ethyl (triphenylphosphoranylidene)acetate (22.31 g; 64.1 mmol) 274. The 
residue was purified by silica gel column chromatography using ethyl acetate / hexane (8  : 
92 v/v) as eluant to afford the title compound as a colourless oil (6.40 g; 59%): Vmax (film) / 
cm"1 2982, 1718, 1655,1447, 1368, 1270, 1191,1045, 985; 8 h (300MHz) 1.28 (t, 3H, J  =
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7.1, C O 2C H 2C H 3), 1.75 (quin, 2 H, J  = 7.3, C H 2 C H 2 C H C H ) ,  2.14 (s, 3H, C //3 C O ) , 2.20 
(m, 2H, C //2 C H = C H C 0 2E t) , 2.46 (t, 2H, J  = 7.3, C H 3 C O C H 2 ), 4.19 (q, 2H, J  = 7.1, 
C O 2C H 2C H 3), 5.82 (d t, 1H, /  = 1.6, 15.5, C H = C f lC 02E t) ,  6.92 (d t , 1H, J  = 6.9, 15.5, 
C7f = C H C 02E t); Sc (75MHz) 14.2 (C O 2C H 2C H 3), 21.8 (C H 2 C H 2C H 2C H = C H ), 29.9 
(C H 3 C O C H 2 ), 31.2 (C H 2C H 2 C H = C H ), 42.5 (C H 3 C O C H 2 ), 60.2 (C O 2C H 2C H 3), 122.0 
(C H = C H C 0 2 E t) ,  147.9 ( C H = C H C 0 2 E t) ,  166.4 (C O 2C H 2C H 3), 208.1 (C H 3 C O C H 2 ); m/z 
(Cl) 2 0 2  (MNH/, 100%), 185 (10%), 158 (1 2 %); (El) 185 (MH*, 10%), 139 (44%), 138 
(70%), 127 (23%), 114 (42%), 110 (28%), 99 (93%), 95 (71%), 8 6  (38%), 81 (75%), 6 8  
(53%), 58 (49%), 43 (100%); (Found: (Cl): MNH,* 202.1443, C ,o H 160 3 requires MNHt* 
202.1443).
Ethyl E-8-bromo-7-oxooct-2-enoate
0 2Et -------------------►
£-275 £-273
Prepared as for methyl £-8 -bromo-7-oxooct-2-enoate 196a but using ethyl £-7- 
oxooct-2-enoate (3.85 g; 20.9 mmol), LDA (19.42 ml; 25 mmol), prepared from n-BuLi 
(1.6M solution in hexanes; 15.62 ml; 25 mmol) and diisopropylamine (3.81 ml; 27 mmol), 
chlorotrimethylsilane (13.26 ml; 104.5 mmol), triethylamine (14.56 ml; 104.5 mmol), 
NaHCOg (2.45 g; 29.2 mmol) and N-bromosuccinimide (4.83 g; 27.2 mmol). The residue 
was purified by silica gel column chromatography using ethyl acetate / hexane (9 : 91 v/v) 
as eluant to afford the title compound as a brown oil (2.30 g; 41%): (film) / cm*1 2980,
1714, 1655, 1394, 1271, 1186, 1096, 1042, 981, 843; SH (300MHz) 1.19 (t, 3H, 7= 7 .1 , 
CO2CH2CH3), 1.70 (quin, 2H, J = 7.2, CEfeCi^CHzCI^CH), 2.23 (m, 2H, CH2CH=CH),
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2.54 (t, 2 H, J = 7.3, CHgCOCtfz), 3.76 (s, 2H, BrCH2CO), 4.08 (q, 2H, J  = 7.1, 
CO2C//2CH3), 5.73 (dt, 1H, J  = 1.6, 15.6, CHfcCffCOjEt), 6.80 (dt, 1H, 7 = 6.9,
15.6,Cff=CHC02Et); 5c (75MHz) 14.5 (C02CH2CH3), 22.1 (CH2CH2CH2), 31.5 
(CH2CH2CH=CH), 34.2 (BrCH2CO); 38.9 (COCH2CH2), 60.5 (C02CH2CH3), 122.5 
(CH=CHC0 2 Et), 148.2 (CH=CHC02Et), 166.6 (C02CH2CH3), 201.6 (BiCH2CO); m/z 
(CI) 280 (MNH4+, 100%), 266 (23%), 254 (31%), 242 (18%), 240 (32%), 237 (26%), 204 
(19%), 202 (100%), 158 (28%); (El) 263 (MH*, 12%), 191 (7%), 169 (5%), 137 (38%), 
123 (24%), 109 (18%), 99 (31%), 95 (55%), 85 (46%), 6 8  (33%), 55 (61%), 43 (100%); 
(Found: (CI): M N H /280.0550; CioHi5Br03 requires MNH,* 280.0548).
Ethyl 1 -benzyl-2,3,7,8 ,9,9a-hexahydro-lf/-pyrrolo[l^,3-de]quinoxaline-6-carboxylate
277a
-Ph
0,Et+
To a solution of 1 -benzyl-4,5-dihydroimidazole (0.16 g; 1.03 mmol) in dry THF (15 
ml) under an atmosphere of nitrogen was added a solution of ethyl £-8-bromo-7-oxboct-2- 
enoate (0.30 g; 1.14 mmol) in dry THF (5 ml). The resulting solution was lefluxcd for 2 h. 
DBU (0.186 ml; 1.12 mmol) was added dropwise over 4 h. The reaction was kept at reflux 
for a further 4  h, cooled, the solvent removed under reduced pressure and the residue 
purified by silica gel column chromatography using ethyl acetate / hexane ( 1 : 9  v/v) as 
eluant to afford the title compound as a white solid (0.10 g; 30%). Recrystallisation from
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methanol / hexane gave white needles for X-ray crystallographic analysis: m.p. 122-123°C; 
Vmax (nujol) / cm"1 2942, 2880, 1730, 1698, 1530, 1662, 1175, 1098, 1054, 918, 730; 6 h 
(300MHz) 1.19 (t, 3H, J  = 7.1, CO2CH2C//3), 1.35 (dtd, 1H, J  = 2.5, 11.6, 13.5, 9-CflH), 
1.65 (dddt, 1H, 7  = 2 .1 , 6.0, 11.6, 13.7, 8  CHH), 2.02 (m, 1H, 8 -CHH), 2.17 (m, 1H, 9 
CHfl), 2.36 (ddd, 1H ,7= 7 .5 ,1 0 .0 ,12 .5 ,2 -CflH), 2.54 (dddd, 1H ,7= 2 .1 ,5.8,11.2,16.8, 
7-CflH), 2.75 (dd, 1H, 7 = 6.4, 16.8, 7-CHH), 2.90 (ddd, 1H, 7 = 2.3, 3.9, 12.5, 2-CHff),
3 .0 1  (d, 1H, 7 = 13.2, PhCHH), 3.16 (br. d, 1H, 7 = 10.6, 9a-Cfl). 3.72 (m, 2 H, 3-C#2), 
4.12 (m, 3H , CO2C//2CH3 and PhCHH), 7.02 (s, 1H, 5-Cfl), 7.18-7.25 (m, 5H, Ar-fT); 5c 
(75MHz) 14.6 (CO2CH2CH3), 22.5,22.6 (C-8  and C-7), 27.9 (C-9), 45.0 (C-2), 49.8 (C-3),
57.3 (PhCHj), 59.2 (CO2CH2CH3), 59.7 (C-9a), 114.2 (C-6 a), 117.0 (C-6 ), 124.3 (C-5),
127.3, 128.4, 129.0 (3 x Ar-CH), 129.3 (C-9b), 138.5 (Ar-Q, 165.6 (CO2CH2CH3); m/z 
(El) 325 (MH*, 100%), 235 (15%), 233 (12%), 106 (7%), 91 (100%), 65 (18%), 52 (38%); 
(Found: C, 73.18; H, 7.35; N, 8.18%; (El): MH* 325.1921, C20H24N2O2.O.2 5  MeOH 
requires C, 73.16; H, 7.58; N, 8.43%; MH* 325.1916).
Ethyl 6-benzyl-5-phenyl-2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-de] 
quinoxaline-6 -carboxylate
Ph + OoEt
:o2EtPh.
277b£-273
To a solution of l-benzyl-2-phenyl-4,5-dihydroimidazole (0,20 g; 0.86 mmol) 
in dry THF (15 ml) under an atmosphere of nitrogen was added a solution of ethyl £-8 -
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bromo-7-oxooct-2-enoate (0.25 g; 0.95 mmol) in dry THF (5 ml). The resulting solution 
was taken and kept at reflux for 2 h. DBU (0.15 ml; 1.03 mmol) was added dropwise over 
4 h and the reaction kept at reflux for a further 4 h. The reaction was cooled, the solvent 
removed under residue and the residue purified by silica gel column chromatography using 
ethyl acetate / hexane (7.5 : 92.5 v/v) as eluant to afford the title compound as a white solid 
(0.11 g; 31%): m.p. 124-125°C; (nujol) / cm"1 2932, 2857, 1694, 1489, 1414, 1382, 
1348, 1264, 1170, 1148,1067, 773, 736; 5h (300MHz) 1.08 (t, 3H, 7 = 7.1, CO2CH2C//3), 
1.50 (dtd, 1H, 7 = 2.5, 1 1 .6 , 13.5, 9-CHH), 1.78 (dddt, 1H, 7 = 2.1, 6.0, 11.6, 13.7, 8 - 
CHH), 2.17 (m, 1H, 8 -CHH), 2.32 (m, 1H, 9-CHfl), 2.45 (ddd, 1H, 7 =  7.5,10.0,12.5, 2- 
CflH), 2.73 (dddd, 1H, 7 = 2.1, 5.8, 11.2, 16.8, 7-CtiH), 2.94 (m, 2H , 7-CHff and 2- 
CHH), 3.12 (d, 1H, 7=  13.3, PhCff2), 3.34 (br. d, 1H, 7=  10.6, 9a-CH), 3.53 (ddd, 1H, 7 =
7.5, 10.0, 12.5, 3-CHH), 3.63 (ddd, 1H, 7 = 2.3, 3.9, 12.5, 3-CHfl), 4.07 (q, 2H, 7 = 1.29,
7.1, CO2C//2CH3), 4.26 (d, 1H, 7 =  13.3, PhC%), 7.28-7.31 (m, 10H, Ar-fl); 5c (75MHz)
14.1 (CO2CH2CH3), 22.5, 22.9 (C-8  and C-7), 28.0 (C-9), 44.2 (C-2 ), 49.9 (C-3), 57.3 
(PhCHz), 58.9 (CO2CH2CII3), 59.7 (C-9a), 112.8 (C-6 a), 117.5 (C-6 ), 127.1, 127.7, 17.8,
128.3, 128.5, 128.9 ( 6  x Ar-CH), 130.5 (C-9b), 132.1 (C-5), 138.4 (2 x Ar-Q, 165.4 
(CO2CH2CH3); m/z (El) 401 (MIT, 25%), 373 (2 2 %), 372 (100%), 299 (23%), 281 (23%), 
253 (34%), 237 (31%), 207 (31%), 178 (28%), 91 (100%), 55 (35%), 43 (6 8 %); (Found: 
(El): MIT 401.2234; CzsHasNaOz requires MIT 401.2229).
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Ethyl (3/?,9S)-l-beiizyl-3-phenyl-2,3,7,8,9,9a-hexahydro-lïf-pyrrolo[l,2,3-de]
quinoxaline-6-carboxylate
Ph,
277cPh'
-Ph
+
To a solution of (/?)-!-benzyl-4-phenyl-4,5-dihydroimidazole (0.20 g; 0.86 mmol) 
in dry THF (15 ml) under an atmosphere of nitrogen was added a solution of ethyl E-8 - 
bromo-7-oxooct-2-enoate (0.25 g; 0.95 mmol) in dry THF (5 ml). The resulting solution 
was refluxed for 2 h. DBU (0.15 ml; 0.10 mmol) was added dropwise over 4 h and the 
reaction kept at reflux for a further 4 h. The reaction was cooled, the solvent removed 
under reduced pressure and the residue purified by silica gel column chromatography using 
ethyl acetate / hexane (7.5 : 92.5 v/v) as eluant to afford the title compound as a yellow oil 
(0.10 g; 30%): ([a] D20 = + 47.12; c = 2; DCM); Vms, (film) / cm"1 2858, 2362, 2341, 1716, 
1699,1577, 1419,1359,1334,1244,1197,1186,1094,1064, 853,701; 8 » (300MHz) 1.26 
(t, 3H, J  = 7.0, CO2CH2C7/3), 1.49 (dtd, 1H, 7=2.5, 11.6,13.5, 9-CflH), 1.82 (dddt, 1H, J  
= 2.1, 6.0,11.6,13.7, 8 -CHH), 2.13 (m, 1H, 8 -CHH), 2.37 (m, 1H, 9-CHH), 2.42 (dd, 1H, 
7 = 4.9,12.4, 2-CflH), 2.72 (dddd, 1H ,7=2.1, 5.8, 11.2, 16.8, 7-CflH), 2.94 (dd, 1H,7 = 
6.4, 16.8, 7-CHfl), 3.09 (dd, 1H, 7 = 4.9, 12.4, 2-CHfl), 3.16 (d, 1H, 7 = 13.2, PhCflH),
3.45 (br. d, 1H, 7 10.6, 9a-CH), 4.15-4.27 (q, 2H, 7 = 7.0, CO2CH2CH3 and d, 1H, 7 = 
13.2, PhCHH), 488 (dd, 1H, 7 = 4.9, 12.4, 3-Cfl), 6.87 (s, 1H, 5-Cfl), 7.31-7.35 (m, 10H, 
Ar-fl); 8 c (75MHz) 14.5 (CO2CH2CH3), 22.3, 22.5 (C-8  and C-7), 29.5 (C-9), 52.7 (C-2),
57.0 (PhCH2), 59.2 (CO2CH2CH3), 59.5 (C-9a), 60.3 (C-3), 114.7 (C-6 a), 117.2 (C-6 ),
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124.2 (C-5), 127.1, 127.6, 128.3, 128.4, 128.7, 128.9 (6  x Ar-CH), 130.6 (C-9b), 138.2, 
128.62 (2 x A r - 0 ,168.5 (CO2CH2CH3); m/z (ET) 401 (MH\ 23%), 372 (8 8 %), 300 (41%), 
281 (100%), 252 (60%), 208 (36%), 206 (44%), 180 (34%), 149 (53%), 91 (100%), 55 
(30%), 43 (59%); (Found: (El): NOT 401.2229; C zA iA O z requires MH* 401.2229).
tert-Butyl (triphenylphosphoranylidene) acetate106
PPh3 + BrCH2C0 2 tBu ----------------   PhgPCHCO^'Bu
279
Prepared as for methyl (triphenylphosphoranylidene)acetate 210, using triphenyl 
phosphine (25 g; 95.3 mmol) and terf-butyl bromoacetate (18.59 ml; 114.0 mmol) to afford 
the title compound as a white solid (32 g; 89%): m.p. 156-157°C (ht. ,132 154-155°C); Vma* 
(nujol) / cm"1 3000, 2980, 1605, 1436, 1363, 1161; 5h (300MHz) 1.26 (s, 9H, 
C02C(CH3)3), 2.78 (d, 1H, J = 21.5, PhgPCtf), 7.20-7.46 (m, 15H, Ai-H).
tert-Butyl £'-7-oxooct-2-enoate
206
Prepared as for methyl E-7-oxooct-2-enoate 196a, but using 5-oxohexanal (4.83 g;
42.0 mmol) and rezt-butyl (triphenylphosphoranylidene)acetate (17.54 g; 46.6 mmol) 279. 
The solvent was removed under reduced pressure and the residue purified by silica gel 
column chromatography using ethyl acetate / hexane (8  : 92 v/v) as eluant to afford the title
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compound as a colourless oil (5.2 g; 58%): Vm, (film) / cm"1 2979, 1713, 1654, 1478, 
1393, 1368, 1317, 1293, 1257, 1223, 1162, 984; 8 h (300MHz) 1.48 (s, 9H, C0 2(.CHih), 
1.73 (quin, 2H, J  = 7.3, CH2C//2CH2), 2.14 (s. 3H, Cff3CO), 2.20 (m, 2H, Ctf2CH=CH),
2.45 (t, 2H, J ~ 7.3, CH3COCJÏ2), 5.74 (dt, 1H, J = 1.5, 15.5, CH2CH=CffC0 2 tBu), 6.80 
(dt, 1H, J  = 7.0, 15.5, CH2Cff=CHC0 2 tBu); Sc (75MHz) 21.9 (CH2CH2CH2), 28.1 
(CH=CHC0 2 C (Œ 3)3), 29.9 ( Œ 2CH=CHC0 2 tBu), 31.1 (OfeCOCIfe), 42.6
(COCH2CH2), 80.2 (CH=CHC02C(CH3)3), 123.7 (CH=CHC02tBu), 146.7
(CH=CHC02tBu), 167.1 (C02,Bu), 206.4 (CH3COCH2); m/z (Cl) 230 (MNH/, 6 8 %), 174 
(100%); (El) 156 (8 %), 139 (8 %), 138 (22%), 120 (3%), 111 (11%), 95 (16%), 84 (7%), 81 
(18%), 6 8  (18%), 57 (80%), 43 (100%); (Found: (Cl): M N H /230.1752; C,2H2o0 3 requires 
MNH4* 230.1756).
tert-Butyl E-8-bromo-7-oxooct-2-enoate
Prepared as for methyl Zs-8-bromo-7-oxooct-2-enoate 196a, but using tert-butyl E- 
7-oxooct-2-enoate (4 g; 18.8 mmol), LDA (22.6 mmol), chlorotrimethylsilane (11.93 ml; 
94 mmol), triethylamine (13.10 ml; 94 mmol), NaHCOg (2.21 g; 26.3 mmol) and N-bromo 
succinimide (4.35 g; 24.4 mmol). The solvent was removed under reduced pressure and the 
residue purified by silica gel column chromatography using ethyl acetate / hexane (7 : 93 
v/v) as eluant to afford the title compound as a brown oil (2.20 g; 40%): (film) / cm'1
2978, 1713, 1654, 1477, 1393, 1368, 1318, 1295, 1155, 982, 890; 0H (300MHz) 1.48 (s, 
9H, C0 2C(Ci/3)3), 1.79 (quin, 2 H, J  = 7.3, CH2Œ 2CH2), 2 .2 1  (m, 2 H,
Ctf2CH=CH), 2.68 (t, 2H, J  = 7.3, COŒ^CHz), 3.71 (BrC^CO), 5.76 (dt, 1H, /  = 1.6,
15.5, CH2CH=C//C0 2 tBu), 6.80 (dt, 1H, J = 6.7, 15.5, CH2C//=CHC02tBu); 5c (75MHz)
22.0 (CH2CH2CH2), 28.1 (C0 2C(CH3)3), 30.9 (CH2CH=CHC02'Bu), 34.1 (BrCH2CO),
38.7 (COCH2CH2), 80.3 (CH=CHC0 2C(CH3)3), 123.9 (CH2CH=CHC0 2tBu), 146.2 
(CH2CH=CHC02tBu), 165.8 (CO^Bu), 201.4 (CH2COCH2); m/z (Cl) 308 (M NH/, 7%), 
230 (49%), 175 (10%), 174 (100%), 158 (13%), 52 (21%); (El) 137 (6 %), 95 (7%), 81 
(8 %), 6 8  (19%), 57 (100%), 41 (67%); (Found: (Cl): M N lV  308.0856; Ci2Hi9Br0 3 
requires MNHV" 308.0861).
to/t-Butyl l-benzyl-2,3,7,8,9,9a-hexahydro-l//-pyrrolo[l,2,3-de]quinoxaline-6-
carboxylate
-Ph
282aPh'
"N
29
To a solution of 1-benzyl-4,5-dihydroimidazole (0.19 g; 1.21 mmol) in dry THF (15 
ml) under an atmosphere of nitrogen was added a solution of terf-butyl £,-8-bromo-7- 
oxooct-2-enoate (0.39 g; 1.34 mmol) in dry THF (5 ml). The resulting solution was 
refluxed for 2 h. DBU (0.22 ml; 1.45 mmol) was added dropwise over 4 h and the reaction 
kept at reflux for a further 4 h. The solvent was removed under reduced pressure and the 
residue purified by silica gel column chromatography using ethyl acetate / hexane (15 : 85 
v/v) as eluant to afford the title compound as a yellow oil (0.14 g; 33%): Vma* (film) / cm"1 
2983,1736, 1698,1524,1466, 1374, 1246, 1174,1096, 1048, 914, 735; 5h (300MHz) 1.47
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(dtd, 1H, /  = 2.5, 11.6, 13.5, 9-C#H), 1.52 (s, 9H, C0 2 C(CH3)3), 1.74 (dddt, 1H, / =  2.1,
6.0, 11.6, 13.7, 8 -CflH), 2.08 (m, 1H, 8 -CHH), 2.27 (m, 1H, 9-CHH), 2.47 (ddd, 1H, /  =
7.5, 10.0, 12.5, 2-CHH), 2.63 (dddd, 1H, / =  2.1, 5.8, 11.2, 16.8, 7-CHH), 2.85 (dd, 1H, J  
= 6.4, 16.8, 7-CHH), 3.00 (ddd, 1H, /  = 2.3, 3.9, 12.5, 2-CHH), 3.12 (d, 1H, J  = 13.2, 
PhCtf2), 3.27 (br. d, 1H, /  = 10.6, 9a-CH), 3.82 (m, 2H, 3-CH2), 4.22 (d, 1H, J  = 13.2, 
PhC#2), 7.07 (s, 1H, 5-CH), 7-28-7.32 (m, 5H, Ar-H); 5c (75MHz) 22.0, 22.6 (C-8  and C- 
7), 27.8 (C-9), 28.3 (CO2C(CH^). 44.9 (C-2 ), 49.7 (C-3), 57.1 (PhCH2), 59.6 (C-9a), 79.1 
(C0 2C(CH3)3), 115.7 (C-6 a), 116.6 (C-6 ), 124.1 (C-5), 128.1, 128.3, 128.9 (3 x Ar-CH), 
130.5 (C-9b), 138.5 (Ar-Q, 165.0 (C0 2C(CH3)3); m/z (El) 353 (MH+, 28%), 324 (2 1 %), 
268 (38%), 177 (32%), 91 (100%), 65 (15%), 57 (50%), 41 (33%); (Found: (El): MH+ 
353.2228; C22H28N20 2requires MH+ 353.2229).
to/t-Butyl 6-benzyl-5-phenyl-2^3,7,8,9,9a-hexahydro-lH-pyrrolo[l,2,3-</e] 
quinoxaline-6-carboxylate
-Ph
// 
"N
263
Ph,
+
282b
To a solution of l-benzyl-2-phenyl-4,5-dihydroimidazole (0.22 g; 0.94 mmol) in 
dry THF (15 ml) under an atmosphere of nitrogen was added a solution of terf-butyl £-8 - 
bromo-7-oxooct-2-enoate (0.30 g; 1.03 mmol) in dry THF (5 ml). The resulting solution 
was refluxed for 2 h. DBU (0.17 ml; 1.12 mmol) was added dropwise over 4 h and the 
reaction kept at reflux for a further 4 h. The reaction was cooled, the solvent was removed
219
under reduced pressure residue purified by silica gel column chromatography using ethyl 
acetate / hexane (7.5 : 92.5 v/v) as eluant to afford the title compound as a white solid 
(0.14 g; 34%): m.p. 52-54°C; V™, (nujol) / cm"1 2927, 2855, 1687, 1460, 1377, 1164, 
1148; 8h (300MHz) 1.27 (s, 9H, C0 2C(C//3)3), 1.51 (dtd, 1H, .7=2.5,11.6,13.5, 9-CHH), 
1.81 (dddt, 1H, J  = 2.1, 6.0, 11.6, 13.7, 8 -CHH), 2.15 (m, 1H, 8 -CHH), 2.30 (m, 1H, 9- 
CHH), 2.42 (ddd, 1H, 7 = 7.5,10.0,12.5,2-CHH), 2.74 (dddd, 1H, 7=  2.1, 5.8,11.2,16.8, 
7-CHH), 2.93 (m, 2H, 7-CHH and 2-CHH), 3.09 (d, 1H, 7 = 13.4, PhCH2), 3.32 (br. d, 1H, 
7 = 10.6, 9a-CH), 3.46 (ddd, 1H, 7 = 7.5, 10.0, 12.5, 3-CflH), 3.57 (ddd, 1H, 7 = 2.3, 3.9, 
12.5,3-CHH), 4.23 (d, 1H, 7 = 13.4, PhCH2), 7.26-7.30 (m, 10H, Ar-H); 8 c (75MHz) 22.5,
22.8 (C-8  and C-7), 27.9 (C-9), 28.1 (CO2C(CH2)2), 44.0 (C-2), 49.9 (C-3), 57.1 (PhCH2),
59.6 (C-9a), 78.7 (CO2C(CH2)2), 112.9 (C-6 a), 117.3 (C-6 ), 126.9, 127.6, 127.7, 128.2,
128.3, 128.8 (6  x Ar-CH), 130.4 (C-9b), 132.4 (C-5), 136.8, 138.4 (2 x Ar-Q, 164.5 
(C0 2C(CH3)3); m/z (El) 429 (MH+, 12%), 401 (21%), 400 (77%), 371 (9%), 355 (7%), 345 
(13%), 344 (100%), 253 (8 %), 91 (100%), 65 (8 %), 57 (43%); (Found: C, 77.70; H, 7.48; 
N, 6.32%; (El): MH* 429.2546; e 28H32N2O2.0.25 MeOH requires C, 77.72; H, 7.62; N, 
6.42%; MH1" 429.2542).
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fert-Butyl (3/?,4a/?,8aS,9S,9a/?)-l-benzyl-5-oxo-3-phenyldecahydro-lJ7-imidazo[l,2-
fl]indole-9-carboxylate
-Ph
/>  +
CO^Bu
£-278
0 2lBu
To a solution of (£)-1 -benzyl-4-phenyl-4,5-dihydroimidazole (0.26 g; 1.12 mmol) 
in dry THF (15 ml) under an atmosphere of nitrogen was added a solution of tert-butyl £-8 - 
bromo-7-oxooct-2-enoate (0.36 g; 1.23 mmol) in dry THF (5 ml). The resulting solution 
was refluxed for 2 h. DBU (0.20 ml; 1.35 mmol) was added dropwise over 4 h and the 
reaction kept at reflux for a further 4 h. The reaction was cooled, the solvent was removed 
under reduced pressure and the residue purified by silica gel column chromatography using 
ethyl acetate / hexane ( 1 : 9  v/v) as eluant to afford the title compound as a white solid 
(0.15 g; 31%). Recrystallisation from methanol / hexane gave white needles for X-ray 
crystallographic analysis: m.p. 169-171°C; ([ajo20 = +14.25; c = 2; DCM); v™* (nujol) / 
cm"1 2926, 2855, 1715, 1490, 1379, 1219, 1147; 5h (300MHz) 1.45 (s, 9H, C0 2C{CH&\ 
1.80-1.82 (m, 2H, 8 -CHH and 7-CHH), 1.90-1.92 (m, 2H, 8 -CHH and 7-CHH), 2.14 (m, 
1H, 6 -CHH), 2.32 (dd, 1H, J  = 9.2, 10.0, 2-CHH), 2.50 (m, 1H, 6 -CHH), 2.83 (t, 1H, J  =
6.9, 9-CH), 3.17 (m, 1H, 8 a-CH), 3.22 (d, lH ,/=  12.9, CH2Ph), 3.25 (dd, 1H, / =  5.5, 9.2,
2-CHH), 3.62 (d, 1H, 7 = 6 .6 ,4a-CH), 4.09 (dd, 1H, J  = 5.5, 10.0, 3-CH), 4.11 (d, lH , /  =
12.9, CH2Ph), 4.58 (d, 1H, J  = 6.9, 9a-CH), 7.28-7.32 (m, 10H, Ar-H); Sc (75MHz) 24.2 
(C-8 ), 26.2 (C-7),. 28.3 (C0 2C(CH3)3), 39.3 (C-6 ), 45.5 (C-8 a), 53.5 (C-9), 58.6 (CH2Ph),
63.0 (C-2 ), 6 8 .1  (C-3), 73.0 (C-4a), 81.2 (C0 2C(CH3)3), 86.7 (C-9a), 126.6, 126.9, 127.2,
128.1, 128.2, 128.9 ( 6  x Ar-CH), 138.1 and 141.2 (2 x Ar-Q, 170.3 (C02C(CH3)3), 210.3
221
(C-5); m/z (El) 447 (MH+, 28%), 389 (90%), 373 (63%), 369 (22%), 345 (38%), 299 
(61%), 291 (100%), 250 (46%), 249 (52%), 91 (100%), 57 (70%), 43 (16%), 41 (33%); 
(Found: (El): MH1" 447.2646; C28H34N2O2 requires MH1" 447.2647).
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Addendum
The reaction of a-bromomethylketones 224, 239 and 253 with 1-benzyl-4,5- 
dihydroimidazole 29 gives rise to products of structures A1-A3.
Ph'
R
A l, R  = (CH2)3CH=C(M 6)C02E t
A2,R = (CH2)4CH3
A3, R  = (CH 2)5CH =CH C02Et
Moreover, reaction of chloroacetone A5 under analogous conditions gives rise to 
compound A4.
M e
A4
This structure is entirely consistent with the spectroscopical data, for example, in 
compounds A2 and A4 (which lack the conjugated ester functionality) the infra-red spectra 
exhibit two carbonyl stretches at 1695 and 1725 cm*1 that are the symmetric and 
asymmetric vibrations characteristic of an N-formylimide involving a six-membered ring 
lactam.81'83 Furthermore, the ^  NMR signal of the formyl proton in such structures is
235
found in the region Ô 9.2-9.5, as observed for our compounds. In the 13C NMR spectra the 
signals at Ô 162 and 6 173 can be attributed to the formyl and lactam carbonyl carbons. 
Finally, the mass spectra exhibited molecular ions consistent with the above formulation 
and also an M-28 fragment that can be accounted for the by the loss of CO as shown in 
Scheme Al.
+ •
Ph' Ph'
Scheme Al
The formation of compounds A l A4 probably follows a similar pathway as the formation 
of compound 232 involving hydrolytic ring-opening of the 1,3-dipole followed by 
recyclisation to form the piperizine ring (Scheme A2). However, the formation of A1-A4 
formally requires the rehydration and oxidation of the tetrahydropiperizine ring. It is 
unclear why these latter two reactions should take place.
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-Ph
Phf Ph"
Oxid.
Phf
Scheme A2
Additional Experimental
4-benzyl-l-formyl-3-methyl-piperizine-2-one
-Ph
XT
29 AS
Ph
I A4
Prepared as for 1 -benzyl-4-formyl-2-(4-nitrophenyl)-1,4,5,6-tetrahydropyrazine 
232 but using 1 -benzyl-4,5-dihydroimidazole 29 (0.66 g; 4.12 mmol) and commercial 
chloroacetone (0.40 ml; 4.95 mmol). After purification of the residue by silica gel column 
chromatography using ethyl acetate / hexane (1 :9  v/v) the title compound was isolated as
237
a orange oil (0.45 g; 47%): ( film) / cm"1 1725,1695,1455,1470,1250; 8h (300 MHz)
1.52 (d, 3H, J  = 4.8 Hz, PhNCHCH3), 2.5 (m, 1H, 5-C%), 3.0 (m, 1H, 5-CH2), 3.35 (q, 
1H, J  = 4.8 Hz, 3-CH), 3.38 (d, 1H, J  = 10.6 Hz, Ctf2Ph), 3.42 (m, 1H, 6 -CH2), 3.67 (m, 
1H, 6 -CH2), 3.94 (d, 1H, J  = 10.6 Hz, PhCH2), 7.28-7.32 (m, 5H, Ar fl), 9.44 (s, 1H, 
NCffO); 8c (75 MHz) 15.3 (PhNCHCH3), 40.7 (C-5), 44.9 (CH2Ph), 57.9 (C-6), 61.1 (C- 
3), 127.6,128.4, 128.7 (3 x Ar-CH), 137.1 (Ar-Q, 162.6 (NCHO), 173.7 (NCOCHN); m/z 
(Cl) 233 (MH*", 100%), 205 (MET-CO, 100%); (Found: (Cl)MH*232.1292;C,3H,6N202 
requires M*+ 232.1290)
Additional References
al. J. C. Gramain and R. Remuson, Synth., Commun., 1982, 264.
a2. N. Murugesan and M. Shamma, Tetrahedron. Lett., 1979,47,4521.
a3. J-C. Gramain, R. Remuson and Y. Train, Tetrahedron, 1979, 35, 759.
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Table 1. Crystal data and structure refinement for 264a.
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F(000)
Crystal 
Crystal size
0  range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to 0 = 27.48° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2,
Final R indices [F2  > 2o(Fa)] 
R indices (all data) 
Extinction coefficient 
Largest diff. peak and hole
ct= 86.50(3)° 
j3= 87.96(3)° 
Y = 77.45(3)°
C 2 5 H 2 6 N 2 O 2
386.48 
150(2) K 
0.71073 Â 
Triclinic 
P - l
a = 11.448(2) Â 
6 = 11.905(2) Â 
c = 15.067(3) Â 
2000.1(7) Â3 
4
1.283 M g/m 3 
0.082 mm""1 
824
Block; colourless 
0.14x0.12x0.12 mm3 
3.08 -  27.48°
-12 < Zi < 13, -15 <k<  15, -18 < Z< 18 
17728
7744 [Ri„t = 0.1722]
84.4 %
Semi-empirical from equivalents 
0.9903 and 0.9887 
Full-matrix least-squares on F2  
7744/0 /526 
0.867
R1 = 0.0682, wR2 = 0.1036 
R1 = 0.2781, wR2 = 0.1613 
0.0014(3)
0.237 and-0.237 eÂ"3
Diffractometer: Enraf Nonius KappaCCD area detector (0 scans and (û scans to fill Ewald 
sphere). Data collection and cell
refinement: Denzo (Z. Otwinowski & W. Minor, Methods in Enzymology (1997) Vol. 276: 
Macromolecular Crystallography,
part A, pp. 307-326; C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption 
correction: SORTAV (R. H. Blessing,
Acta Cryst. A51 (1995) 33-37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 421-426). 
SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) A46 467-473). Program used to refine 
structure: SHELXL97 (G. M. Sheldrick (1997 ) , U n iv e r s i ty  o f  G o t t in g e n , 
G erm any).
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Table 2. Crystal data and structure refinement for 264b.
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F(000)
Crystal 
Crystal size
0  range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to 6 = 27.48° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2  
Final R indices [F2  > 2o(Fa)] 
R indices (all data)
Absolute structure parameter 
Extinction coefficient 
Largest diff. peak and hole
C 2 5 H 2 6 N 2 O 2
386.48 
150(2) K 
0.71073 Â 
Monoclinic 
P 2 i
a = 10.559(2) Â a  =90°
b = 9.6567(19) Â 0 = 1 12.47(3)'
c=  11.052(2) Â y = 90°
1041.5(4) Â3 
2
1.232 M g/m 3 
0.078 nun-1 
412
Block; colourless 
0.25 x 0.25 x 0.10 mm3 
1.99-27.48°
-13 < A < 13, -12 < * < 12, -13 < ! < 14 
12212
4640% ,, = 0.0362]
99.6 %
Semi-empirical from equivalents 
0.9922 and 0.9807 
Full-matrix least-squares on F2  
4640 / 1 / 264 
1.043
R1 = 0.0373, wR2 = 0.0836 
R1 = 0.0507, wR2 = 0.0897 
0 .6(10)
0.031(3)
0.172 and-0.147 eÂ"3
Diffractometer: Enraf Nonius KappaCCD area detector (0 scans and co scans to fill Ewald 
sphere). Data collection and cell
refinement: Denzo (Z. Otwinowski & W. Minor, Methods in Enzymology (1997) Vol. 276: 
Macromolecular Crystallography,
part A, pp. 307-326; C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption 
correction: SORTAV (R. H. Blessing,
Acta Cryst. A51 (1995) 33-37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 421-426).
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Table 3. Crystal data and structure refinement for 277a.
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F(000)
Crystal 
Crystal size
0  range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to 0= 27.43° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F 2 
Final R indices [F2 > 2o(F2)] 
R indices (all data) 
Extinction coefficient 
Largest diff. peak and hole
a  =81.91(3)° 
j8= 87.82(3)° 
y = 88.80(3)°
C 2 0 H 2 4 N 2 O 2  
324.41 
150(2) K 
0.71073 Â 
Triclinic 
P -l
a = 5.3447(11) Â 
6 =  10.854(2) Â 
c=  14.722(3) Â 
844.8(3) A 3 
2
1.275 M g/m 3 
0.083 mm-1 
348
Needle; colourless 
0.30 x 0.05 x 0.02 mm3 
1.90 -  27.43°
- 6 < h < 6 , - 1 4 < fc< 14, -19 < Z< 19 
12313
3729% * = 0.1814]
97.4 %
Semi-empirical from equivalents 
0.9983 and 0.9756 
Full-matrix least-squares on F2 
3729/0/219 
0.944
R1 = 0.0566, wR2 = 0.1034 
R1 = 0.1507, wR2 = 0.1318 
0.017(4)
0.239 and-0.261 e Â '3
Diffractometer: Enraf Nonius KappaCCD area detector (0 scans and (û scans to fill Ewald 
sphere). Data collection and cell
refinement: Denzo (Z. Otwinowski & W. Minor, Methods in Enzymology (1997) Vol. 276: 
Macromolecular Crystallography,
part A, pp. 307-326; C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption 
correction: SORTAV (R. H. Blessing,
Acta Cryst. A51 (1995) 33-37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 421-426). Program 
used to solve structure:
SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) A46 467-473).
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Table 4. Crystal data and structure refinement for 283.
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F(000)
Crystal 
Crystal size
0  range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to 0= 24.71° 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on F2 
Final R indices [F2 > 2o(F2)] 
R indices (all data)
Absolute structure parameter 
Extinction coefficient 
Largest diff. peak and hole
C 2 8 H 3 4 N 2 O 3
446.57 
150(2) K 
0.71073 Â 
Monoclinic 
P2i
a = 5.8566(4) Â
b = 22.8548(18) Â 92.913(6)'
c = 9.1424(7) À 
1222.14(16) Â3 
2
1.214 M g/m 3 
0.079 mm-1 
480
Colourless block 
0.20 x 0.20 x 0.10 mm3 
3.48-24.71°
-6 < h < 6 , -26 < fc<24, - 1 0 < / < 1 0  
6900
33461%, = 0.0585]
94.0 %
0.9922 and 0.9845 
Full-matrix least-squares on F2 
3346/1/299 
1.014
R1 = 0.0500, wR2 = 0.0957 
R1 = 0.0842, wR2 = 0.1075 
Not reliably determined 
0.028(3)
0.181 and-0.178 e Â '3
Diffractometer: Enraf Nonius KappaCCD area detector (0 scans and œ scans to fill Ewald 
sphere). Data collection and cell refinement: Denzo (Z. Otwinowski & W. Minor, Methods 
in Enzymology (1997) Vol. 276: Macromolecular Crystallography, part A, pp. 307-326; C. 
W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption correction: SORTAV (R. 
H. Blessing, Acta Cryst. A51 (1995) 33-37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 
421-426). Program used to solve structure: SHELXS97 (G. M. Sheldrick, Acta Cryst.
(1990) A46 467-473), Program used to refine structure; SHELKL97 (G. M. Sheldrick 
(1997), University of Gdttingen, Germany).
Special details: All hydrogen atoms were placed in idealised positions and refined using a 
riding model.Relative chirality C l = S, C6 = R, C13 = R, CIS = R, C16 = S
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